
<html lang="en"     class="pb-page"  data-request-id="00d5d975-14b1-40a0-96fa-0d3284f94fbb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b00186;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-16;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy" /></meta><meta name="dc.Creator" content="Michael M.  Miller" /></meta><meta name="dc.Creator" content="Jacques  Banville" /></meta><meta name="dc.Creator" content="Todd J.  Friends" /></meta><meta name="dc.Creator" content="Mark  Gagnon" /></meta><meta name="dc.Creator" content="Jon J.  Hangeland" /></meta><meta name="dc.Creator" content="Jean-François  Lavallée" /></meta><meta name="dc.Creator" content="Alain  Martel" /></meta><meta name="dc.Creator" content="Harold  O’Grady" /></meta><meta name="dc.Creator" content="Roger  Rémillard" /></meta><meta name="dc.Creator" content="Edward  Ruediger" /></meta><meta name="dc.Creator" content="François  Tremblay" /></meta><meta name="dc.Creator" content="Shana L.  Posy" /></meta><meta name="dc.Creator" content="Nick J.  Allegretto" /></meta><meta name="dc.Creator" content="Victor R.  Guarino" /></meta><meta name="dc.Creator" content="David G.  Harden" /></meta><meta name="dc.Creator" content="Timothy W.  Harper" /></meta><meta name="dc.Creator" content="Karen  Hartl" /></meta><meta name="dc.Creator" content="Jonathan  Josephs" /></meta><meta name="dc.Creator" content="Sarah  Malmstrom" /></meta><meta name="dc.Creator" content="Carol  Watson" /></meta><meta name="dc.Creator" content="Yanou  Yang" /></meta><meta name="dc.Creator" content="Ge  Zhang" /></meta><meta name="dc.Creator" content="Pancras  Wong" /></meta><meta name="dc.Creator" content="Jing  Yang" /></meta><meta name="dc.Creator" content="Michel  Bouvier" /></meta><meta name="dc.Creator" content="Dietmar A.  Seiffert" /></meta><meta name="dc.Creator" content="Ruth R.  Wexler" /></meta><meta name="dc.Creator" content="R. Michael  Lawrence" /></meta><meta name="dc.Creator" content="E. Scott  Priestley" /></meta><meta name="dc.Creator" content="Anne  Marinier" /></meta><meta name="dc.Description" content="In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, UDM-001651, in a monkey thrombosis..." /></meta><meta name="Description" content="In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, UDM-001651, in a monkey thrombosis..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 27, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00186" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00186" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00186" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00186" /></link>
        
    
    

<title>Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00186" /></meta><meta property="og:title" content="Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0015.jpeg" /></meta><meta property="og:description" content="In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, UDM-001651, in a monkey thrombosis model. Beginning with a high-throughput screening hit, we identified an imidazothiadiazole-based PAR4 antagonist chemotype. Detailed structure–activity relationship studies enabled optimization to a potent, selective, and orally bioavailable PAR4 antagonist, UDM-001651. UDM-001651 was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation of kidney bleeding time. This combination of excellent efficacy and safety margin strongly validates PAR4 antagonism as a promising antithrombotic mechanism." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00186"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00186">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00186&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00186&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00186&amp;href=/doi/10.1021/acs.jmedchem.9b00186" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 7400-7416</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00030" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00360" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Michael M. Miller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael M. Miller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+M.++Miller">Michael M. Miller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jacques Banville</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jacques Banville</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jacques++Banville">Jacques Banville</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Todd J. Friends</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Todd J. Friends</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Todd+J.++Friends">Todd J. Friends</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Gagnon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Gagnon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Gagnon">Mark Gagnon</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jon J. Hangeland</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jon J. Hangeland</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jon+J.++Hangeland">Jon J. Hangeland</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8234-8857" title="Orcid link">http://orcid.org/0000-0002-8234-8857</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jean-François Lavallée</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jean-François Lavallée</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Fran%C3%A7ois++Lavall%C3%A9e">Jean-François Lavallée</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alain Martel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alain Martel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alain++Martel">Alain Martel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Harold O’Grady</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Harold O’Grady</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Harold++O%E2%80%99Grady">Harold O’Grady</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roger Rémillard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roger Rémillard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roger++R%C3%A9millard">Roger Rémillard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Edward Ruediger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edward Ruediger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edward++Ruediger">Edward Ruediger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">François Tremblay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">François Tremblay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fran%C3%A7ois++Tremblay">François Tremblay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shana L. Posy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shana L. Posy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 3551 Lawrenceville Road, Princeton, New Jersey 08540, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shana+L.++Posy">Shana L. Posy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nick J. Allegretto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nick J. Allegretto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nick+J.++Allegretto">Nick J. Allegretto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Victor R. Guarino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Victor R. Guarino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Victor+R.++Guarino">Victor R. Guarino</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David G. Harden</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David G. Harden</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+G.++Harden">David G. Harden</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy W. Harper</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy W. Harper</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+W.++Harper">Timothy W. Harper</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen Hartl</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen Hartl</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Hartl">Karen Hartl</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jonathan Josephs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonathan Josephs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan++Josephs">Jonathan Josephs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah Malmstrom</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah Malmstrom</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah++Malmstrom">Sarah Malmstrom</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carol Watson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carol Watson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carol++Watson">Carol Watson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanou Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanou Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanou++Yang">Yanou Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ge Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ge Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ge++Zhang">Ge Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pancras Wong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pancras Wong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pancras++Wong">Pancras Wong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jing Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Yang">Jing Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michel Bouvier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michel Bouvier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</div><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Québec H3C 3J7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michel++Bouvier">Michel Bouvier</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1128-0100" title="Orcid link">http://orcid.org/0000-0003-1128-0100</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dietmar A. Seiffert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dietmar A. Seiffert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dietmar+A.++Seiffert">Dietmar A. Seiffert</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ruth R. Wexler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ruth R. Wexler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ruth+R.++Wexler">Ruth R. Wexler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">R. Michael Lawrence</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">R. Michael Lawrence</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=R.+Michael++Lawrence">R. Michael Lawrence</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">E. Scott Priestley</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">E. Scott Priestley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#a5d6c6cad1d18bd5d7ccc0d6d1c9c0dce5c7c8d68bc6cac8"><span class="__cf_email__" data-cfemail="0a7969657e7e247a78636f797e666f734a68677924696567">[email protected]</span></a>. Phone: 609-466-5069 (E.S.P.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=E.+Scott++Priestley">E. Scott Priestley</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8390-1143" title="Orcid link">http://orcid.org/0000-0001-8390-1143</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Anne Marinier</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anne Marinier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Research in Immunology and Cancer, Université de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#f2939c9c97dc9f93809b9c9b9780b2919a9b9f9b97dc9b809b91dc9193"><span class="__cf_email__" data-cfemail="2647484843084b47544f484f435466454e4f4b4f43084f544f45084547">[email protected]</span></a>. Phone: 514-343-6111. Ext. 17351 (A.M.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anne++Marinier">Anne Marinier</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00186&amp;href=/doi/10.1021%2Facs.jmedchem.9b00186" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 7400–7416</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 27, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 January 2019</li><li><span class="item_label"><b>Published</b> online</span>27 June 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 August 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00186" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00186</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7400%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMichael%2BM.%2BMiller%252C%2BJacques%2BBanville%252C%2BTodd%2BJ.%2BFriends%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D16%26contentID%3Dacs.jmedchem.9b00186%26title%3DDiscovery%2Bof%2BPotent%2BProtease-Activated%2BReceptor%2B4%2BAntagonists%2Bwith%2Bin%2BVivo%2BAntithrombotic%2BEfficacy%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7416%26publicationDate%3DAugust%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00186"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1957</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00186" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;M. Miller&quot;},{&quot;first_name&quot;:&quot;Jacques&quot;,&quot;last_name&quot;:&quot;Banville&quot;},{&quot;first_name&quot;:&quot;Todd&quot;,&quot;last_name&quot;:&quot;J. Friends&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Gagnon&quot;},{&quot;first_name&quot;:&quot;Jon&quot;,&quot;last_name&quot;:&quot;J. Hangeland&quot;},{&quot;first_name&quot;:&quot;Jean-François&quot;,&quot;last_name&quot;:&quot;Lavallée&quot;},{&quot;first_name&quot;:&quot;Alain&quot;,&quot;last_name&quot;:&quot;Martel&quot;},{&quot;first_name&quot;:&quot;Harold&quot;,&quot;last_name&quot;:&quot;O’Grady&quot;},{&quot;first_name&quot;:&quot;Roger&quot;,&quot;last_name&quot;:&quot;Rémillard&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;Ruediger&quot;},{&quot;first_name&quot;:&quot;François&quot;,&quot;last_name&quot;:&quot;Tremblay&quot;},{&quot;first_name&quot;:&quot;Shana&quot;,&quot;last_name&quot;:&quot;L. Posy&quot;},{&quot;first_name&quot;:&quot;Nick&quot;,&quot;last_name&quot;:&quot;J. Allegretto&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;R. Guarino&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;G. Harden&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;W. Harper&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Hartl&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;Josephs&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;Malmstrom&quot;},{&quot;first_name&quot;:&quot;Carol&quot;,&quot;last_name&quot;:&quot;Watson&quot;},{&quot;first_name&quot;:&quot;Yanou&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Ge&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Pancras&quot;,&quot;last_name&quot;:&quot;Wong&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Michel&quot;,&quot;last_name&quot;:&quot;Bouvier&quot;},{&quot;first_name&quot;:&quot;Dietmar&quot;,&quot;last_name&quot;:&quot;A. Seiffert&quot;},{&quot;first_name&quot;:&quot;Ruth&quot;,&quot;last_name&quot;:&quot;R. Wexler&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Michael Lawrence&quot;},{&quot;first_name&quot;:&quot;E.&quot;,&quot;last_name&quot;:&quot;Scott Priestley&quot;},{&quot;first_name&quot;:&quot;Anne&quot;,&quot;last_name&quot;:&quot;Marinier&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;7400-7416&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00186&quot;},&quot;abstract&quot;:&quot;In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, UDM-001651, in a monkey thrombosis model. Beginning with a high-throughput screening hit, we identified an imidazothiadiazole-based PAR4 antagonist chemotype. Detailed structure–activity relationship studies enabled optimization to a potent, selective, and orally bioavailable PAR4 antagonist, UDM-001651. UDM-001651 was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation of kidney bleeding time. This combination of excellent efficacy and safety margin strongly validates PAR4 antagonism as a promising antithrombotic mechanism.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00186&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00186" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00186&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00186" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00186&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00186" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00186&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00186&amp;href=/doi/10.1021/acs.jmedchem.9b00186" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00186" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00186" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00186%26sid%3Dliteratum%253Aachs%26pmid%3D31246024%26genre%3Darticle%26aulast%3DMiller%26date%3D2019%26atitle%3DDiscovery%2Bof%2BPotent%2BProtease-Activated%2BReceptor%2B4%2BAntagonists%2Bwith%2Bin%2BVivo%2BAntithrombotic%2BEfficacy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D16%26spage%3D7400%26epage%3D7416%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/jmcmar.2019.62.issue-16/20190822/jmcmar.2019.62.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, <b>UDM-001651</b>, in a monkey thrombosis model. Beginning with a high-throughput screening hit, we identified an imidazothiadiazole-based PAR4 antagonist chemotype. Detailed structure–activity relationship studies enabled optimization to a potent, selective, and orally bioavailable PAR4 antagonist, <b>UDM-001651</b>. <b>UDM-001651</b> was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation of kidney bleeding time. This combination of excellent efficacy and safety margin strongly validates PAR4 antagonism as a promising antithrombotic mechanism.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Atherothrombotic cardiovascular and cerebrovascular diseases are the leading cause of morbidity and mortality in developed countries and claim more lives each year than cancer in the United States.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Atherothrombotic diseases, such as acute coronary syndrome and stroke, originate with a gradual buildup of plaque in the arterial wall. The eventual rupture of an atherosclerotic plaque exposes a prothrombotic milieu to the blood and activates platelets at the site of the injury, leading to the formation of a potentially occlusive thrombus and subsequent ischemia. Antiplatelet agents, such as aspirin and clopidogrel, inhibit thrombus formation and significantly reduce ischemic events; thus, they are cornerstone therapies for the medical management of atherothrombotic diseases.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Recently, more potent and efficacious platelet P2Y<sub>12</sub> receptor antagonists, such as prasugrel and ticagrelor, have been studied extensively and found to be associated with increased bleeding risks, limiting their utility to improve clinical outcomes.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3−7)</a> A significant unmet medical need remains, and novel antiplatelet agents with better efficacy and reduced bleeding risk are an important research goal.</div><div class="NLM_p">Thrombin, the central enzyme in the coagulation cascade, activates platelets with subnanomolar potency. It binds to two G-protein-coupled receptors on human platelets,<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> the protease-activated receptor 1 (PAR1) and protease-activated receptor 4 (PAR4),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and cleaves at a specific site within the N-terminal sequence of each receptor. The newly exposed, shortened N-termini serve as tethered ligands that activate their respective receptors through intramolecular interactions. Synthetic peptide analogues based on the thrombin-cleaved N-terminal sequence can also activate the corresponding receptors in the absence of proteolytic activation.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Targeting PAR1 or PAR4 with an antagonist is expected to reduce platelet activation without inhibiting the other coagulation functions of thrombin.</div><div class="NLM_p">PAR1 has generated widespread interest as an antithrombotic target, as evidenced by preclinical research activity and the development of two PAR1 antagonist clinical candidates, vorapaxar (<b>1</b>) and atopaxar (<b>2</b>), <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. Phase III clinical studies of vorapaxar in combination with aspirin and clopidogrel demonstrated incremental reduction of ischemic events at the price of a significant increase in intracranial bleeding.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> In 2014, the U.S. Food and Drug Administration approved the use of vorapaxar to reduce thrombotic cardiovascular events in patients with prior myocardial infarction or peripheral arterial disease. The drug is contraindicated for patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage because of bleeding risk.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Atopaxar has completed phase II clinical trials in acute coronary syndromes and coronary artery disease and demonstrated reductions in ischemia and numerical increases in major bleeding. Liver enzyme elevations and QT interval prolongation were also noted in atopaxar-treated patients.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Further development of atopaxar has not been reported and is presumed to have been discontinued.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of PAR1 and PAR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is hypothesized that improved separation between effects on thrombosis and hemostasis may be achieved by selectively targeting the late stage of thrombus formation and vessel occlusion.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> PAR1 is proteolytically activated at low concentrations of thrombin and induces a rapid and transient calcium signal, whereas PAR4 is cleaved at relatively high concentrations of thrombin and induces a sustained calcium signal with a slower onset.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20−22)</a> Based on these signaling differences, it appears that PAR1 is important for triggering platelet activation, while PAR4 is required for sustaining platelet activation. Thus, inhibiting PAR4, while maintaining thrombin signaling through PAR1, could potentially inhibit occlusive thrombosis while preserving hemostasis. Selective PAR4 antagonism may comprise a novel antiplatelet mechanism with a lower risk of bleeding than existing antiplatelet therapies. We have recently disclosed preclinical studies<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> that demonstrate an outstanding efficacy and bleeding profile for Bristol-Myers Squibb (BMS)-986120, a PAR4 antagonist clinical candidate. The early stages of the medicinal chemistry effort that led to BMS-986120 are described in this manuscript. Further optimization culminating in BMS-986120 will be reported subsequently.</div><div class="NLM_p">In contrast to the vigorous investigation of PAR1 as an antithrombotic target, there were very few reported PAR4 antagonists at the outset of this work. Only a single chemical class of indazoles, typified by the compound <b>YD-3</b> (<b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) had been reported.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a><b>YD-3</b> was shown to possess modest activity as judged by the inhibition observed in a GYPGKF-induced platelet aggregation assay (IC<sub>50</sub> 130 nM).<a onclick="showRef(event, 'ref26 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref28">(26,28)</a> Recent work on the <b>YD-3</b> lead led to a nitroindole, <b>ML354</b>, with 70 nM IC<sub>50</sub> in a GYPGKF-induced platelet aggregation assay, low in vitro metabolic stability, and 70-fold selectivity versus PAR1.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Further optimization of this indole chemotype has not yet led to compounds with activity against platelet aggregation in whole blood or in vivo antithrombotic efficacy.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a></div><div class="NLM_p last">In this report, we describe the identification and optimization of PAR4 antagonists with potent activity in platelet-rich plasma (PRP) from an imidazothiadiazole high-throughput screening (HTS) lead. We also demonstrate in vivo antithrombotic efficacy and low bleeding liability in a cynomolgus (cyno) monkey electrolytic carotid artery thrombosis (ECAT) model, confirming the therapeutic potential of PAR4 antagonism as a novel antiplatelet approach.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Like the rest of the PAR family, PAR4 couples to the G-protein Gq, which upon receptor activation induces intracellular-signaling events resulting in an increase in cytosolic calcium.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> To screen for molecules possessing PAR4 antagonist activity, a calcium mobilization assay (PAR4 fluorescent imaging plate reader (FLIPR)) was developed using a HEK293-PAR4 cell line, an aequorin reporter,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and a PAR4 agonist peptide AYPGKF.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> YD-3 showed inhibitory activity in this assay (PAR4 FLIPR IC<sub>50</sub> 410 nM). From a screening campaign of the BMS compound collection, 199 compounds were identified, which inhibited PAR4 agonist peptide-induced calcium signaling and did not elicit agonist activity when tested in the absence of an added PAR4 agonist. The PAR4-dependent antiplatelet effects of these compounds were then evaluated in a γ-thrombin-induced washed platelet (γ-Thr WP) aggregation assay. γ-Thrombin is a proteolytic fragment of thrombin, which specifically activates PAR4.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The imidazo[2,1-<i>b</i>][1,3,4]-thiadiazole (IDT)-based compound <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was one of the most potent hits identified by the high-throughput screen (HTS) (PAR4 FLIPR IC<sub>50</sub> 11 nM, γ-Thr WP IC<sub>50</sub> 270 nM).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structure of the PAR4 antagonist HTS hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lead profiling of <b>4</b> demonstrated poor in vitro liver microsomal stability across species and no significant activity in cytochrome P450 (CYP), human ether-à-go-go-related gene (hERG), or pregnane X receptor (PXR) assays. Biotransformation studies indicated that the methylthio group was oxidized to the sulfoxide and sulfone. Both metabolites, but not the parent methyl thioether, react rapidly with glutathione and <i>N</i>-acetylcysteine. In addition, oxidative metabolites of the benzofuran ring were detected (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_001.pdf" class="ext-link">Supporting Information</a>). Early structure–activity relationship (SAR) exploration was directed at improving potency in the PAR4 FLIPR and platelet aggregation assays and improving metabolic stability.</div><div class="NLM_p">Initial SAR optimization of the IDT scaffold was conducted using the synthetic approach shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. IDT <b>4</b> was obtained by the condensation of 5-(methylthio)-1,3,4-thiadiazol-2-amine <b>5</b> with bromoketone <b>6</b>. Activation of the thiomethyl group with <i>meta</i>-chloroperoxybenzoic acid (<i>m</i>-CPBA) gave sulfone <b>7</b>, which was converted to a series of methylthio replacements upon treatment with various nucleophiles (thiols, amines, alcohols) in the presence of a base. The regiochemistry of the cycloaddition was verified by an X-ray crystal structure of compound <b>4</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route for Imidazothiadiazoles with 2-Position Modifications<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH, microwave (μwave): 150 °C, 5 min; (b) <i>m</i>-CPBA, tetrahydrofuran (THF); (c) XSH, MeOH, 70 °C; (d) CH<sub>3</sub>NH<sub>2</sub>, dimethylformamide (DMF), μwave: 70 °C, 10 min; (e) NaOMe, MeOH, room temperature (rt) or XOH, K<sub>2</sub>CO<sub>3</sub>, DMF, rt.</p></p></figure><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> summarizes SAR for the 2-position of the IDT scaffold generated by this synthetic approach. Incorporation of increased polarity as in sulfone <b>7</b> or steric bulk as in the ethylthio and phenylthio analogues <b>8</b> and <b>9</b>, respectively, decreased potency by 74–260-fold, relative to the parent methylthio compound <b>4</b>. Importantly, the methoxy analogue <b>10</b> retained the potent activity of <b>4</b> in both the PAR4 FLIPR and γ-Thr WP assays and possessed improved human liver microsome metabolic stability based on the percent of parent remaining at 10 min. Follow-up in a five time-point kinetic assay, however, showed no improvement in human liver microsome <i>t</i><sub>1/2</sub> (compound <b>4</b>, <i>t</i><sub>1/2</sub> = 5.4 min vs compound <b>10</b>, <i>t</i><sub>1/2</sub> = 6.9 min). As observed for the thioethers, larger ether substituents had successively lower potency (<b>10</b> vs <b>11</b> and <b>12</b>). The methylamine analogue <b>13</b> also had modest activity, especially in the platelet aggregation assay, suggesting that amines are not favored.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Imidazothiadiazole 2-Position Structure–Activity Relationships</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0009.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">cpd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">PAR4 FLIPR IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">γ-Thr WP IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">liver microsome stability (% remaining, H, R)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>4</b></td><td class="colsep0 rowsep0" align="left">MeS</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">270</td><td class="colsep0 rowsep0" align="left">25, 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="left">MeSO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">820</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="left">EtS</td><td class="colsep0 rowsep0" align="left">2900</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">45, 35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>9</b></td><td class="colsep0 rowsep0" align="left">PhS</td><td class="colsep0 rowsep0" align="left">1900</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="left">MeO</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">240</td><td class="colsep0 rowsep0" align="left">80, 31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>11</b></td><td class="colsep0 rowsep0" align="left">EtO</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">2100</td><td class="colsep0 rowsep0" align="left">57, 37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>12</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-PrO</td><td class="colsep0 rowsep0" align="left">760</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="left">MeNH</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">65, 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>14</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">20, 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>15</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">2400</td><td class="colsep0 rowsep0" align="left">30, 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>16</b></td><td class="colsep0 rowsep0" align="left"><i>c</i>-Pr</td><td class="colsep0 rowsep0" align="left">530</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">62, 53</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Reported IC<sub>50</sub> values are typically the mean of at least two experiments. ND = not determined.</p></div></div></div><div class="NLM_p">Results from the exploration of carbon-based replacements for sulfur are also shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Methyl analogue <b>14</b> shows at least 3-fold reduced potency relative to <b>4</b> and <b>10</b>. Increasing the size of the alkyl group to ethyl (compound <b>15</b>) maintained potency, with continued poor metabolic stability, while the cyclopropyl analogue <b>16</b> lost 14-fold potency. A detailed biotransformation analysis on <b>15</b> identified the ethyl group as the principal site of metabolism (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_001.pdf" class="ext-link">\Supporting Information</a>). While metabolic stability can be improved with substitution on the ethyl moiety, both the putative hydroxy metabolites and bulkier alkyl alternatives were found to possess weak PAR4 inhibitory activity.</div><div class="NLM_p">To improve potency by gaining additional binding interactions and to modulate the benzofuran metabolism, we next explored substitution on the benzofuran ring. Analogues with benzofuran substitution were synthesized according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. The substituted benzofurans were obtained by condensing appropriately substituted 2-hydroxy-benzaldehydes <b>17</b> with chloroacetone, followed by bromination of the resulting 2-acetylbenzofurans <b>18</b>. Reaction of 2-amino-5-bromo-1,3,4-thiadiazole with the resulting α-bromomethylketones <b>19</b> provided the bromo-IDT derivatives <b>20</b>. Displacement of the bromide with sodium methoxide gave the methoxy-IDT derivatives <b>21</b>–<b>29</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Route for the Preparation of Benzofuranyl Imidazothiadiazoles with Benzofuran Modifications<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 22 °C, 18 h; (b) <i>p</i>-TsOH, 0.1 equiv, THF, rt, 1 h; (c) lithium bis(trimethylsilyl)amide (LiHMDS), trimethylsilyl chloride, THF, −78 °C; (d) <i>N</i>-bromosuccinimide (NBS), −25 to 0 °C, 1.5 h; (e) isopropyl alcohol (IPA), 88 °C, 19 h; (f) 150 °C, 30 min, μwave; (g) NaOMe, MeOH, dichloromethane (DCM), rt, 1 h; (h) diisopropyl azodicarboxylate (DIAD), Ph<sub>3</sub>P, MeOH, THF, rt; (i) BnBr, K<sub>2</sub>CO<sub>3</sub>, DMF; (j) diisobutylaluminum hydride (DIBAL), −78 °C, CH<sub>2</sub>Cl<sub>2</sub>; (k) MeOH, HCl; (l) BCl<sub>3</sub>, pentamethylbenzene, −78 °C, DCM; (m) ArCH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (n) ArCH<sub>2</sub>OH, Bu<sub>3</sub>P, 1,1’-(azodicarbonyl)dipiperidine, THF, rt.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Benzofuran Substituent Structure–Activity Relationships</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0010.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">cpd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">PAR4 FLIPR IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">γ-Thr WP IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">γ-Thr PRP IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">liver microsome stability (% remaining, H, R)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>10</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">240</td><td class="colsep0 rowsep0" align="left">15 000</td><td class="colsep0 rowsep0" align="left">80, 31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>21</b></td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">350</td><td class="colsep0 rowsep0" align="left">1300</td><td class="colsep0 rowsep0" align="left">40, 42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>22</b></td><td class="colsep0 rowsep0" align="left">4-OBn</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">3100</td><td class="colsep0 rowsep0" align="left">4100</td><td class="colsep0 rowsep0" align="left">85, 75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>23</b></td><td class="colsep0 rowsep0" align="left">5-OMe</td><td class="colsep0 rowsep0" align="left">220</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">30, 38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>24</b></td><td class="colsep0 rowsep0" align="left">6-OMe</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">480</td><td class="colsep0 rowsep0" align="left">57, 55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>25</b></td><td class="colsep0 rowsep0" align="left">6-OBn</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">1800</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">94, 68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>26</b></td><td class="colsep0 rowsep0" align="left">7-OMe</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">240</td><td class="colsep0 rowsep0" align="left">3500</td><td class="colsep0 rowsep0" align="left">25, 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>27</b></td><td class="colsep0 rowsep0" align="left">6-OMe, 7-OMe</td><td class="colsep0 rowsep0" align="left">1800</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="left">20, 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>28</b></td><td class="colsep0 rowsep0" align="left">4-OMe, 7-OMe</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">2100</td><td class="colsep0 rowsep0" align="left">10 000</td><td class="colsep0 rowsep0" align="left">55, 28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>29</b></td><td class="colsep0 rowsep0" align="left">4-OMe, 6-OMe</td><td class="colsep0 rowsep0" align="left">0.99</td><td class="colsep0 rowsep0" align="left">74</td><td class="colsep0 rowsep0" align="left">530</td><td class="colsep0 rowsep0" align="left">86, 70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>34</b></td><td class="colsep0 rowsep0" align="left">4-OBn, 6-OMe</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">1000</td><td class="colsep0 rowsep0" align="left">1600</td><td class="colsep0 rowsep0" align="left">100, 77</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Reported IC<sub>50</sub> values are typically the mean of at least two experiments.</p></div></div></div><div class="NLM_p">To prepare benzofuran analogues bearing alkoxy substituents at the 4- and 6-positions, acetonide <b>30</b> was regioselectively derivatized at the <i>p</i>-phenol with the desired alcohol using a Mitsunobu reaction, as described by Kamisuki et al.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Subsequent alkylation at the remaining phenol with an appropriate bromide provided the bis-alkoxy intermediate <b>32</b>, which was reduced with DIBAL and hydrolyzed to afford the desired 2-hydroxy-4,6-dialkoxy-benzaldehydes <b>33</b>. These benzaldehydes were then reacted as shown for intermediate <b>17</b> to give analogues <b>34</b>–<b>38</b>. Alternatively, analogues <b>39</b>–<b>58</b> were prepared from analogue <b>34</b> after benzyl deprotection and alkylation or Mitsunobu reaction of the resulting phenol <b>35</b>. In the benzyl deprotection step, the use of BCl<sub>3</sub> with pentamethylbenzene as cation scavenger was crucial for high yields.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">As the potency of our PAR4 antagonists improved, we began to measure antiplatelet activity with a γ-thrombin-induced platelet-rich plasma (γ-Thr PRP) aggregation assay, enabling the evaluation of antiplatelet effects in the presence of plasma proteins. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the addition of methoxy substituents at the 4-, 6-, and 7-positions of the benzofuran ring maintains a single-digit nanomolar potency in the PAR4 FLIPR assay and importantly improves inhibitory potency 4- to 30-fold in the γ-Thr PRP assay (compounds <b>21</b>, <b>24</b>, and <b>26</b>). However, a methoxy group is not tolerated at the 5-position (compound <b>23</b>). Increasing the size of the substitution, as with benzyloxy groups, was detrimental to potency but beneficial for improving microsomal stability (compounds <b>22</b> and <b>25</b>).</div><div class="NLM_p">Exploration of several disubstitution patterns (compounds <b>27</b>–<b>29</b> and <b>34</b>) showed that 4,6-disubstitution provided the best antagonist activity. The 4,6-dimethoxy and 4-benzyloxy-6-methoxy analogues <b>29</b> and <b>34</b> were noteworthy, in that, they possess low micromolar γ-Thr PRP activity with significantly improved metabolic stability relative to unsubstituted <b>10</b>.</div><div class="NLM_p">In light of their combination of antiplatelet potency and microsomal stability, the pharmacokinetic profiles of compounds <b>29</b> and <b>34</b> were assessed in rat, as summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. The 4,6-dimethoxy analogue <b>29</b> demonstrated high clearance and poor oral bioavailability. Compound <b>34</b>, bearing a bulky benzyloxy substituent at the benzofuran 4-position, showed a promising pharmacokinetic profile with low clearance, long half-life, and appreciable bioavailability.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Metabolic Stability and Pharmacokinetic Data<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> for Compounds <b>29</b> and <b>34</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0011.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center"><b>29</b></th><th class="colsep0 rowsep0" align="center"><b>34</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver microsome <i>t</i><sub>1/2</sub>, min (H, R)</td><td class="colsep0 rowsep0" align="left">17, 22</td><td class="colsep0 rowsep0" align="left">>120, 40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat CL, mL/(min kg)</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub>, h</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i>, %</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">27</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Intravenous (iv) dose 0.5 mpk, iv vehicle 25/75 propylene glycol/poly(ethylene glycol) (PEG)400 at 2 mL/kg, 10 min infusion; per os (po) dose 2 mpk, po vehicle 5/5/90 EtOH/<span class="smallcaps smallerCapital">d</span>-α-tocopheryl polyethylene glycol succinate (TPGS)/PEG300 at 5 mL/kg.</p></div></div></div><div class="NLM_p">With a promising combination of γ-Thr PRP potency and favorable pharmacokinetic properties established for compound <b>34</b>, a series of extended aryl analogues were prepared in an attempt to further drive potency (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, compounds <b>36</b>–<b>38</b>). Although the γ-Thr PRP potency improved up to 3-fold, metabolic stability dropped significantly in the extended aryl analogues, focusing our further investigation on compounds that retained the 4-benzyloxy group of compound <b>34</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure–Activity Relationships at the Benzofuran 4-Position</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0012.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">cpd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">PAR4 FLIPR IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">γ-Thr PRP IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">liver microsome stability (% remaining, H, R)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>34</b></td><td class="colsep0 rowsep0" align="left">–Ph</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">1600</td><td class="colsep0 rowsep0" align="left">100, 77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>36</b></td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">780</td><td class="colsep0 rowsep0" align="left">89, 43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>37</b></td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>OPh</td><td class="colsep0 rowsep0" align="char" char=".">0.81</td><td class="colsep0 rowsep0" align="char" char=".">480</td><td class="colsep0 rowsep0" align="left">65, 36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>38</b></td><td class="colsep0 rowsep0" align="left">–CH<sub>2</sub>OCH<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">500</td><td class="colsep0 rowsep0" align="left">75, 25</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Reported IC<sub>50</sub> values are typically the mean of at least two experiments.</p></div></div></div><div class="NLM_p">With the objective of improving potency and maintaining pharmacokinetic properties, we investigated substitution on the benzyloxy moiety of compound <b>34</b>. <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> summarizes the biological activity of analogues bearing small substituents, which were synthesized according to the second synthetic sequence described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, from key intermediate <b>35</b>. Addition of substituents at the ortho position of the 4-benzyloxy substituent in compound <b>34</b> did not improve γ-Thr PRP potency (compounds <b>39</b>–<b>42</b>), despite a slight gain in PAR4 FLIPR activity for the methyl and chloro analogues <b>39</b> and <b>40</b>. Similar results were observed with substitution at the para position (compounds <b>49</b>–<b>51</b>). In contrast, the introduction of substituents at the meta position generated more promising results (compounds <b>43</b>–<b>48</b>). Two analogues bearing lipophilic substituents displayed submicromolar potency in the γ-Thr PRP assay along with good metabolic stability (compounds <b>43</b> and <b>48</b>), while more polar analogues bearing a hydroxyl group (<b>45</b> and <b>46</b>) were less active. The cyano analogue <b>47</b> was slightly more potent than the unsubstituted analogue <b>34</b> in the same assay, while the methoxy analogue <b>44</b> lost potency. It is noteworthy that in most of these monosubstituted analogues, stability in human and rat liver microsomes was similar to parent compound <b>34</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Structure–Activity Relationships for 4-Benzyloxy Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0013.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">cpd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">PAR4 FLIPR IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">γ-Thr PRP IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">liver microsome stability (% remaining, H, R)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>34</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">1600</td><td class="colsep0 rowsep0" align="left">100, 77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>39</b></td><td class="colsep0 rowsep0" align="left">2-Me</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">3600</td><td class="colsep0 rowsep0" align="left">90, 46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>40</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">>3000</td><td class="colsep0 rowsep0" align="left">95, 78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>41</b></td><td class="colsep0 rowsep0" align="left">2-OMe</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">82, 28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>42</b></td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>43</b></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">680</td><td class="colsep0 rowsep0" align="left">82, 79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>44</b></td><td class="colsep0 rowsep0" align="left">3-OMe</td><td class="colsep0 rowsep0" align="left">9.4</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">69, 34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>45</b></td><td class="colsep0 rowsep0" align="left">3-OH</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">2700</td><td class="colsep0 rowsep0" align="left">97, 49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>46</b></td><td class="colsep0 rowsep0" align="left">3-CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>47</b></td><td class="colsep0 rowsep0" align="left">3-CN</td><td class="colsep0 rowsep0" align="left">0.98</td><td class="colsep0 rowsep0" align="left">820</td><td class="colsep0 rowsep0" align="left">100, ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>48</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">440</td><td class="colsep0 rowsep0" align="left">93, 79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>49</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">1800</td><td class="colsep0 rowsep0" align="left">79, 90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>50</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>51</b></td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">>3000</td><td class="colsep0 rowsep0" align="left">73, 64</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Reported IC<sub>50</sub> values are typically the mean of at least two experiments. ND = not determined.</p></div></div></div><div class="NLM_p">In light of the enhanced γ-Thr PRP activity for certain analogues with meta substituents on the 4-benzyloxy moiety, a more thorough investigation of structure–activity relationships at this position was undertaken. The synthesis of these analogues followed the second synthetic sequence described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The results for key analogues are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. The addition of a phenyl ring attached with various linkers at the meta position of the benzyloxy side chain was found to be beneficial. The PAR4 FLIPR activity of these compounds remained in the low nanomolar range, and the nature of the linker was found to affect the inhibition of platelet aggregation in plasma. Single-atom linkers, as in the aryl ether and thioether analogues <b>52</b> and <b>53</b>, show 4-fold improved γ-Thr PRP potency relative to <b>34</b>. Most notably, however, an extension to a benzyloxy group (compound <b>54</b>, <b>UDM-001651</b>) enhanced the antiplatelet potency by 64-fold as compared to that of the unsubstituted analogue <b>34</b>, with a γ-Thr PRP IC<sub>50</sub> of 25 nM. Alternative two atom linkers, such as the reverse ether <b>55</b> or ethylene <b>56</b> significantly impaired the γ-Thr PRP activity relative to <b>UDM-001651</b>, indicating that both linker conformation and polarity are important for antiplatelet activity. Finally, the ortho and para benzyloxy regioisomers <b>57</b> and <b>58</b> showed similar potency to parent compound <b>34</b>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Structure–Activity Relationships for 4-Benzyloxy Analogues with Aryl Substituents</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0014.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">cpd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">PAR4 FLIPR IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">γ-Thr PRP IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">liver microsome stability (% remaining, H, R)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>34</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">1600</td><td class="colsep0 rowsep0" align="left">100, 77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>52</b></td><td class="colsep0 rowsep0" align="left">3-OPh</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">390</td><td class="colsep0 rowsep0" align="left">86, 42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>53</b></td><td class="colsep0 rowsep0" align="left">3-SPh</td><td class="colsep0 rowsep0" align="char" char=".">0.89</td><td class="colsep0 rowsep0" align="char" char=".">410</td><td class="colsep0 rowsep0" align="left">80, 45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>54</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="left">85, 76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>55</b></td><td class="colsep0 rowsep0" align="left">3-CH<sub>2</sub>OPh</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">600</td><td class="colsep0 rowsep0" align="left">86, 64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>56</b></td><td class="colsep0 rowsep0" align="left">3-(CH<sub>2</sub>)<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">1200</td><td class="colsep0 rowsep0" align="left">99, 68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>57</b></td><td class="colsep0 rowsep0" align="left">2-OCH<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">2500</td><td class="colsep0 rowsep0" align="left">94, 22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>58</b></td><td class="colsep0 rowsep0" align="left">4-OCH<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">550</td><td class="colsep0 rowsep0" align="left">88, 84</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Reported IC<sub>50</sub> values are typically the mean of at least two experiments.</p></div></div></div><div class="NLM_p">Given its excellent inhibitory potency in platelet-rich plasma, <b>UDM-001651</b> was further characterized both in vitro and in vivo. Direct binding to PAR4 expressed on HEK293 cell membranes was studied using a previously described binding assay (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The data demonstrate that <b>UDM-001651</b> has a single-digit nanomolar affinity for PAR4 using both saturation binding and kinetic assays, with rapid and reversible binding kinetics.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Binding Parameters for <b>UDM-001651</b> to PAR4<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">saturation binding</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub> (nM): 1.4 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">association kinetics</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub> (nM): 3.0 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>on</sub> (nM<sup>–1</sup> min<sup>–1</sup>): 0.004 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>off</sub> (min<sup>–1</sup>): 0.013 ± 0.001</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Reported values are means ± standard deviation, <i>n</i> = 3.</p></div></div></div><div class="NLM_p">In vitro profiling data are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. <b>UDM-001651</b> was found to have excellent in vitro stability in human, rat, mouse, dog, and monkey liver microsomes and did not have any CYP, PXR, cardiac ion channel, or cytotoxicity issues. The compound showed very high protein binding across species. The selectivity of <b>UDM-001651</b> was tested using a variety of platelet agonists in a human platelet aggregation assay (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). <b>UDM-001651</b> showed potent inhibition of platelet aggregation triggered by a PAR4 agonist peptide, but no measurable inhibition of the effects of a PAR1 agonist peptide, adenosine 5′-diphosphate (ADP), collagen, or the thromboxane A2 receptor agonist U46619 on platelets. Taken together, these in vitro data indicate that <b>UDM-001651</b> has excellent properties as a tool compound for mechanistic investigations of PAR4 inhibition. Pharmacokinetic data for <b>UDM-001651</b> are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>. The compound shows low clearance, 6–7 h half-life, and modest bioavailability in rat, dog, and monkey. Importantly, oral exposure was sufficient to enable in vivo efficacy studies in our monkey ECAT model.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vitro Profiling Assay Data for <b>UDM-001651</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LM <i>t</i><sub>1/2</sub>, min (H, R, M, D, Mk)</td><td class="colsep0 rowsep0" align="left">86, 20, 120, 100, 48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM CYP IC<sub>50</sub>, μM</td><td class="colsep0 rowsep0" align="left">all >40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PXR EC<sub>50</sub>, μM</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cytotoxicity IC<sub>50</sub>, μM</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG, Na patch clamp % inh. @ 10 μM</td><td class="colsep0 rowsep0" align="left">≤10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding, % bound (H, R, M, D Mk)</td><td class="colsep0 rowsep0" align="left">99.6, 99.8, 99.5, ≥99.8, >99.8</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Inhibition of Human Platelet Aggregation by <b>UDM-001651</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">platelet agonist</th><th class="colsep0 rowsep0" align="center">platelet aggregation IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAR4 agonist peptide</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAR1 agonist peptide</td><td class="colsep0 rowsep0" align="left">>30 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ADP</td><td class="colsep0 rowsep0" align="left">>30 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">collagen</td><td class="colsep0 rowsep0" align="left">>30 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U46619</td><td class="colsep0 rowsep0" align="left">>30 000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Reported IC<sub>50</sub> values are typically the mean of at least two experiments.</p></div></div></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Pharmacokinetic Data for <b>UDM-001651</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">rat<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">dog<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">monkey<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL, mL/(min kg)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub>, h</td><td class="colsep0 rowsep0" align="left">6.9</td><td class="colsep0 rowsep0" align="left">7.0</td><td class="colsep0 rowsep0" align="left">6.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i>, %</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">iv dose 0.5 mpk, iv vehicle 25/75 propylene glycol/PEG400 at 2 mL/kg, 10 min infusion; po dose 2 mpk, po vehicle 5/5/90 EtOH/TPGS/PEG300 at 5 mL/kg.</p></div><div class="footnote" id="t10fn2"><sup><sup>b</sup></sup><p class="last">iv dose 0.5 mpk, iv vehicle PEG400 at 0.8 mL/kg, 10 min infusion; po dose 2 mpk, po vehicle 40/60 TPGS/PEG400 at 0.5 mL/kg.</p></div></div></div><div class="NLM_p">In the monkey ECAT model, <b>UDM-001651</b> was dosed orally at 0.4, 2, and 10 mg/kg (<i>n</i> = 7 per dose), while the vehicle (40/60 TPGS/PEG400) was dosed orally at 2.5 mL/kg (<i>n</i> = 8). As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>UDM-001651</b> demonstrated dose-dependent antithrombotic efficacy, achieving a maximal thrombus weight reduction of 38% at 2 and 10 mg/kg. Furthermore, the compound did not increase monkey kidney bleeding time (BT) even at the highest dose (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <i>P</i> = 0.2, 10 mg/kg vs vehicle). Overall, <b>UDM-001651</b> showed an effective antithrombotic profile with no prolongation of bleeding time, demonstrating that PAR4 inhibition is an attractive approach to antithrombotic therapy.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antithrombotic efficacy of <b>UDM-001651</b> in the monkey ECAT model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Profile of <b>UDM-001651</b> in the monkey kidney bleeding time model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63582" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63582" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In an effort to advance antithrombotic therapy, we explored PAR4 antagonism as a novel antiplatelet mechanism and developed a tool compound, <b>UDM-001651</b>, suitable for in vivo target validation. We identified an IDT-based chemotype from an HTS designed to detect PAR4 antagonism, with compound <b>4</b> as the initial hit. Detailed SAR investigations regarding <b>4</b> led to the discovery of <b>UDM-001651</b>, a lead compound with nanomolar antagonist potency against PAR4 in platelet-rich plasma, excellent selectivity, and oral bioavailability. Evaluation of <b>UDM-001651</b> in the monkey ECAT model revealed robust antithrombotic efficacy and no prolongation of bleeding time, demonstrating an excellent safety margin for PAR4 antagonism. These results validated PAR4 as an antithrombotic target for our drug discovery effort and strongly supported further investigation of this mechanism toward the discovery of PAR4 antagonist clinical candidates.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> HTS Protocol</h3><div class="NLM_p">Screening of the BMS compound collection for PAR4 antagonists was accomplished via aequorin-based detection of agonist-induced calcium mobilization.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The synthetic peptide AYPGKF, corresponding to the activation sequence derived from native N-terminus cleavage of the PAR4 receptor, served as the agonist in the assay. Following the confirmation of primary hits, the potency of leads was confirmed in a concentration-response manner against the PAR4 receptor. Compounds were further evaluated in calcium-signaling assays to rule out PAR1 antagonist activity, using a selective PAR1 agonist peptide, SFFLRR,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and HEK293 cells endogenously expressing PAR1 receptors.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Synthesis of Compounds <b>4</b>, <b>7</b>–<b>16</b>, <b>21</b>–<b>29</b>, <b>34</b>–<b>58</b></h4><div class="NLM_p last">Detailed synthetic procedures and analytical data are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_001.pdf" class="ext-link">Supporting Information</a>. All compounds with biological data have shown ≥95% purity as determined by analytical high-pressure liquid chromatography (HPLC), with the exception of compounds <b>25</b> (92% purity), <b>41</b> (94% purity), <b>42</b> (89% purity), and <b>44</b> (85% purity).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> FLIPR Assay in PAR4-Expressing HEK293 Cells</h3><div class="NLM_p last">The activity of the PAR4 antagonists was tested in HEK293 cells expressing human PAR4 (HEK293-PAR4) by monitoring PAR4 agonist peptide (AYPGKF- or H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-NH<sub>2</sub>)-induced intracellular calcium mobilization. Briefly, HEK293 aequorin cells that stably express the full-length human PAR4 (PAR4 clone 1.2A, Arctic ID 383940) were utilized for this assay. In addition to PAR4, these cells express endogenous PAR1 and can elicit calcium signaling upon stimulation with a selective PAR1 AP. Therefore, the same cells were also used to determine selectivity against PAR1 and agonist activity for both receptors. HEK293 aequorin PAR4 clone 1.2A cells were grown in Dulbecco’s modified Eagle’s medium (Life Technology Catalog #10564-011) containing 10% heat-inactivated FBS, 1% penicillin–streptomycin, 10 μg/mL blasticidin, and 100 μg/mL zeocin at 37 °C with 5% CO<sub>2</sub>. Cells were plated overnight prior to the experiment in a black 384-well clear-bottom plate at 10 000 cells/well in a 30 μL growth medium and incubated in a humidified chamber at 37 °C with 5% CO<sub>2</sub> overnight. Prior to compound addition, cell medium was replaced with 40 μL of 1× calcium and magnesium-containing Hank’s buffered saline solution [with 20 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES)] and a 1:1000 diluted fluorescent calcium indicator (Codex Biosolutions Catalog #CB080500-111). After a 30 min incubation period at 37 °C and a further 30 min incubation and equilibration period at rt, a 20 μL test compound was added at various concentrations at a 0.17% dimethyl sulfoxide (DMSO) final concentration. Changes in fluorescence intensity were measured using a functional drug screening system (FDSS, Hamamatsu Photonics, Japan) to determine agonist activities. The cells were then incubated for 30 min at rt followed by the addition of 20 μL of agonist peptide for antagonist activity measurement using an FDSS. The PAR4 AP and PAR1 AP (SFFLRR6) were routinely tested to ensure a proper response at the EC<sub>50</sub> value in the assay.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Washed Platelet Aggregation Assays</h3><div class="NLM_p last">(a) Preparation of washed platelets (WPs): Human blood was collected in ACD (85 mM trisodium citrate, 78 mM citric acid, 110 mM <span class="smallcaps smallerCapital">d</span>-glucose, pH 4.4) at a ratio of 1.4 mL per 10 mL blood. PRP was isolated by centrifugation at 170<i>g</i> for 14 min, and platelets were further pelleted by centrifugation at 1300<i>g</i> for 6 min. Platelets were washed once with 10 mL ACD containing 1 mg/mL bovine serum albumin. Platelets were resuspended at ∼2.5 × 10<sup>8</sup>/mL in Tyrode’s buffer (137 mM NaCl, 2 mM KCl, 1.0 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 5 mM glucose, 20 mM HEPES pH 7.4). (b) Assay method: The ability of the compounds to inhibit platelet aggregation induced by γ-thrombin was tested in a 96-well microplate aggregation assay format. Briefly, washed platelet suspension (100 μL) was preincubated for 5 min at room temperature with varying concentrations of compounds. Aggregation was initiated by γ-thrombin (Haematologic Technologies, Essex Junction, VT), which was titrated daily to achieve an 80% platelet aggregation. Refludan at 1 U/mL (Berlex, Montville, NJ) was added to the γ-thrombin sample to prevent PAR1 activation induced by residual α-thrombin contamination. The plate was then placed into a 37 °C molecular device (Sunnyvale, CA) SpectraMax plus plate reader. The plate was mixed for 10 s before the first read and 50 s between each read for up to 15 min at 405 nM. Data was collected with SOFTMAX 4.71 software. The plate also included an untreated control sample, which served as OD<sub>max</sub>, while buffer containing no platelets was the OD<sub>min</sub>. Platelet aggregation was determined by subtracting the OD<sub>max</sub> from the OD<sub>min</sub> for the 100% aggregation value. In experimental samples, the observed transmission was subtracted from the minimum value and then compared to the 100% aggregation value to determine the percentage aggregation. IC<sub>50</sub> values are determined using Excel Fit software. Most reported IC<sub>50</sub> values are an average of at least two independent determinations.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Platelet-Rich Plasma Aggregation Assay</h3><div class="NLM_p last">(a) Preparation of platelet-rich plasma (PRP): Fresh blood was drawn by antecubital venipuncture from normal healthy volunteers who are free of exposure to antiplatelet drugs following institutional informed consent and anticoagulated with a final concentration of 0.38% of sodium citrate. Following centrifugation of the blood at 250<i>g</i> for 10 min at room temperature, PRP was collected. (b) Assay method: PRP aggregation was conducted in a 96-well plate format as described previously.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The test compounds were preincubated with PRP for 5 min at 37 °C, and aggregation was initiated by the addition of 50–100 nM of γ-thrombin (Haematologic Technologies), which was titrated daily to achieve an 80% platelet aggregation. To prevent PAR1 activation induced by residual α-thrombin contamination, PRP was treated with recombinant hirudin (Refludan, Berlex Laboratories) at a final concentration of 1 U/mL. Aggregation was monitored in a plate reader (SpectraMax Plus 384, Molecular Devices, Sunnyvale, CA) and read at 405 nm with mixing between reads. The selectivity of the compounds was tested following the same protocol, except that platelets were stimulated by a PAR1 agonist peptide SFFLRR (10 μM), ADP (5 μM), collagen (25 μg/mL), or the thromboxane A2 mimetic U46619 (2 μM). All of these agonists, when used alone without the compounds, induced an 89–96% maximal platelet aggregation. All data are an average of at least three independent determinations.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Monkey ECAT Model</h3><div class="NLM_p">Experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and the regulations of the Institutional Animal Care and Use Committee of the Bristol-Myers Squibb Company. Healthy cyno monkeys (Bioculture Ltd., Mauritius Island) were used in the study. These monkeys were retired from other pharmacokinetic and pharmacodynamic studies and had at least a 4 week washout period before this study.</div><div class="NLM_p">Twenty-nine retired monkeys were randomly assigned to one of the four groups: (1) vehicle (<i>n</i> = 8), (2) <b>UDM-001651</b> 0.4 mg/kg (<i>n</i> = 7), (3) <b>UDM-001651</b> 2 mg/kg (<i>n</i> = 7), and (4) <b>UDM-001651</b> 10 mg/kg (<i>n</i> = 7). On the day of the experiment, monkeys were dosed orally by gavage with <b>UDM-001651</b> or vehicle (40/60 w/w TPGS/PEG400) at 2 mL/kg, where TPGS is <span class="smallcaps smallerCapital">d</span>-α-tocopheryl polyethylene glycol 1000 succinate and PEG400 is polyethylene glycol 400. At 1.5 h after oral dosing, monkeys were anesthetized and surgically prepared as described before.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The experiment involved a combination of thrombosis and bleeding time (BT) studies in the same animal.</div><div class="NLM_p">The arterial thrombosis model used in this study was the ECAT model.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Briefly, an electromagnetic flow probe was placed on a segment of an isolated carotid artery to monitor blood flow. Thrombosis was induced by electrical stimulation of the carotid artery for 5 min at 10 mA, using an external stainless steel bipolar electrode. Carotid blood flow was measured with a Transonic flow probe and a Transonic perivascular flowmeter (TS420 model, Transonic Systems Inc., Ithaca, NY). It was continuously recorded over a 90 min period to monitor thrombotic occlusion. The thrombus from the injured artery was removed, blotted twice on a weighing paper to remove residual fluid, and weighed.</div><div class="NLM_p last">The BT model used in this study was the kidney BT model.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Briefly, a left flank incision was made to expose the left kidney, and the renal capsule was removed. BT was measured by renal cortex incision. BT was defined as the time from injury until bleeding stopped without rebleeding for 30 s. It was monitored up to a maximum of 20 min and was determined in triplicate.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Synthesis, Purification, and Analytical Methods</h3><div class="NLM_p">All reactions were carried out using commercial-grade reagents and solvents without further purification. NMR chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane. Normal phase flash chromatography was carried out on Teledyne ISCO CombiFlash systems using prepacked silica cartridges and eluted with gradients of the specified solvents. Preparative reverse-phase high-pressure liquid chromatography (HPLC) was carried out on C18 HPLC columns using methanol/water gradients containing 0.1% trifluoroacetic acid (TFA) unless otherwise stated. All new compounds gave satisfactory <sup>1</sup>H NMR, liquid chromatography–mass spectrometry (LC–MS), and/or high-resolution mass spectrometry (HRMS) data. Purity of all final compounds was determined by analytical HPLC using at least one of the following conditions.</div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Analytical HPLC Method A</h4><div class="NLM_p last">Column Phenomenex Luna, C18 5 μm, 4.6 × 50 mm; mobile phase: A = 10% MeOH/90% H<sub>2</sub>O/0.1% TFA, B = 90% MeOH/10% H<sub>2</sub>O/0.1% TFA; gradient: <i>T</i> = 0: 100% A, <i>T</i> = 4 min: 100% B, stop time: 4 min; flow = 4.0 mL/min; UV detection wavelength: 254 nm.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Analytical HPLC Method B</h4><div class="NLM_p last">Column Phenomenex Luna, C18 5 μm, 4.6 × 50 mm; mobile phase: A = MeOH/H<sub>2</sub>O (10:90), B = MeOH/H<sub>2</sub>O (90:10); modifier 10 mM NH<sub>4</sub>OAc; gradient: <i>T</i> = 0: 100% A, <i>T</i> = 4 min: 100% B, stop time: 4 min; flow = 4.0 mL/min; UV detection wavelength: 254 nm.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Analytical HPLC Method C</h4><div class="NLM_p last">Column SunFire C18 3.5 μm C18, 4.6 mm × 150 mm; mobile phase: A = 95% H<sub>2</sub>O/5% MeCN/0.05% TFA, B = 5% H<sub>2</sub>O/95% MeCN/0.05% TFA; gradient: <i>T</i> = 0: 10% B, <i>T</i> = 12 min: 100% B, <i>T</i> = 14.99 min = 100% B; <i>T</i> = 15 min = 10% B; flow = 2 mL/min; monitoring UV absorbance at 220 and/or 254 nm.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Analytical HPLC Method D</h4><div class="NLM_p last">Column Xbridge Phenyl C18 3.5 μm C18, 4.6 mm × 150 mm; mobile phase: A = 95% H<sub>2</sub>O/5% MeCN/0.05% TFA, B = 5% H<sub>2</sub>O/95% MeCN/0.05% TFA; gradient: <i>T</i> = 0: 10% B, <i>T</i> = 12 min: 100% B, <i>T</i> = 14.99 min = 100% B; <i>T</i> = 15 min = 10% B; flow = 2 mL/min; monitoring UV absorbance at 220 and/or 254 nm.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Analytical HPLC Method E</h4><div class="NLM_p last">Column Zorbax XDB-C18 3.5 μm, 4.6 × 30 mm; mobile phase: A = MeOH/H<sub>2</sub>O/TFA (5:95:0.05), B = MeOH/H<sub>2</sub>O/TFA (95:5:0.05); gradient: <i>T</i> = 0: 100% A, <i>T</i> = 2 min: 100% B, stop time: 4 min; flow = 3.0 mL/min; UV detection wavelength: 220 and 254 nm.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Analytical HPLC Method F</h4><div class="NLM_p last">Column Supelco Ascentis C18 2.7 μm, 4.6 × 50 mm; mobile phase: A = acetonitrile/H<sub>2</sub>O (5:95), B = acetonitrile/H<sub>2</sub>O (95:5), modifier 10 mM NH<sub>4</sub>OAc; gradient: <i>T</i> = 0: 100% A, <i>T</i> = 5.5 min: 100% B, stop time: 7 min; flow = 3 mL/min; UV detection wavelength: 220 nm.</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Analytical HPLC Method G</h4><div class="NLM_p last">Column Waters XBridge C18 1.7 μm, 2.1 × 50 mm; mobile phase: A = acetonitrile/H<sub>2</sub>O/TFA (5:95:0.05), B = acetonitrile/H<sub>2</sub>O/TFA (95:5:0.05); gradient: <i>T</i> = 0: 100% A, <i>T</i> = 3.75 min: 100% B, stop time: 4.25 min; flow = 1.1 mL/min; UV detection wavelength: 220 nm.</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Analytical HPLC Method H</h4><div class="NLM_p last">Eclipse XDB-C18 3.5 μm column (4.6 × 30 mm) eluted at 3 mL/min with a 2 min gradient from 100% A to 100% B (A: 5% acetonitrile, 94.95% water, 0.05% TFA; B: 5% water, 94.95% acetonitrile, 0.05% TFA). UV 220 and 254 nm.</div></div><div id="sec4_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Analytical HPLC Method I</h4><div class="NLM_p last">Waters XBridge C18, 2.1 mm × 50 mm, 1.7 μm particles; mobile phase A: 5:95 acetonitrile/water with 10 mM ammonium acetate; mobile phase B: 95:5 acetonitrile/water with 10 mM ammonium acetate; temperature: 50 °C; gradient: 0% B to 100% B over 3 min, then a 0.50 min hold at 100% B; flow: 1 mL/min; detection: MS and UV (220 nm).</div></div><div id="sec4_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Analytical HPLC Method J</h4><div class="NLM_p last">Waters XBridge C18, 2.1 mm × 50 mm, 1.7 μm particles; mobile phase A: 5:95 acetonitrile/water with 0.1% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile/water with 0.1% trifluoroacetic acid; temperature: 50 °C; gradient: 0% B to 100% B over 3 min, then a 0.50 min hold at 100% B; flow: 1 mL/min; detection: MS and UV (220 nm).</div></div><div id="sec4_6_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Analytical HPLC Method K</h4><div class="NLM_p last">Eclipse XDB-C18 3.5 μm column (4.6 × 30 mm) eluted at 3 mL/min with a 2 min gradient from 100% A to 100% B (A: 5% methanol, 94.95% water, 0.05% TFA; B: 5% water, 94.95% methanol, 0.05% TFA). UV 220 and 254 nm.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 6-(Benzofuran-2-yl)-2-(methylthio)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>4</b>)</h3><div class="NLM_p last">5-(Methylthio)-1,3,4-thiadiazol-2-amine (1.85 g, 12.55 mmol) and 1-(benzofuran-2-yl)-2-bromoethanone (3 g, 12.55 mmol) were dissolved in MeOH (20 mL, 0.63 M) in a microwave vial. The reaction was heated to 100 °C in the microwave for 30 min, until the formation of a product was observed by HPLC analysis. The reaction mixture was diluted with EtOAc and washed with H<sub>2</sub>O (2 × 50 mL) followed by brine (sat’d NaCl, 2 × 50 mL). The organic layer was evaporated onto silica, and the crude material was purified by flash chromatography (EtOAc/hexanes 0–100%). The purity of the chromatographed material was further improved by trituration using 10% EtOAc/hexane, thus providing 1.8 g of compound <b>4</b> as a tan solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 2.75–2.79 (m, 3H), 7.03–7.09 (m, 1H), 7.18–7.32 (m, 2H), 7.46–7.53 (m, 1H), 7.55–7.63 (m, 1H), 8.04–8.07 (m, 1H). LC–MS [electrospray ionization (ESI)] <i>m</i>/<i>z</i>: 288.0 [M + H]<sup>+</sup>. Purity: 98% (method A, <i>t</i><sub>R</sub> = 3.9 min).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 6-(Benzofuran-2-yl)-2-(methylsulfonyl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>7</b>)</h3><div class="NLM_p last">Compound <b>4</b> was added to a round-bottom flask and dissolved in THF (109 mL). To this solution was added <i>m</i>-CPBA (5.66 g, 32.8 mmol). The mixture was stirred at rt under nitrogen overnight and monitored periodically by LC–MS. After 1 day, approximately a 1.6–1.0 ratio of sulfoxide to sulfone was observed. Excess <i>m</i>-CPBA (7–8 equiv) was added, and the reaction mixture was stirred overnight. The next morning, only sulfone was present as evident by LC–MS ([M + 1] = 320.0). Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> was added [aqueous (aq), sat’d] to quench any excess oxidant. The reaction product was diluted with EtOAc, washed with NaHCO<sub>3</sub> and brine, and extracted with EtOAc (3×). The combined organics were subsequently dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed in vacuo, and to the yellow solid residue (∼11.6 g) was added MeOH. The solution was heated and then cooled to form solids. The solids were isolated by filtration to afford 1.64 g of compound <b>7</b> as a yellow solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.92 (s, 1H), 7.68 (d, <i>J</i> = 7.15 Hz, 1H), 7.61 (d, <i>J</i> = 8.25 Hz, 1H), 7.33 (t, <i>J</i> = 7.15 Hz, 1H), 7.25–7.30 (m, 2H), 3.68 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 320.0 [M + H]<sup>+</sup>. Purity: 95% (method B, <i>t</i><sub>R</sub> = 3.3 min).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 6-(Benzofuran-2-yl)-2-(ethylthio)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>8</b>)</h3><div class="NLM_p last">Compound <b>8</b> (43.7 mg, 39%), a tan solid, was obtained from 5-(ethylthio)-1,3,4-thiadiazol-2-amine (60 mg, 0.372 mmol) and 1-(benzofuran-2-yl)-2-bromoethanone (89 mg, 0.372 mmol) dissolved in EtOH and processed as described for the preparation of <b>4</b>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.07 (s, 1H), 7.62–7.57 (m, 1H), 7.51 (dd, <i>J</i> = 8.0, 0.8 Hz, 1H), 7.32–7.27 (m, 1H), 7.26–7.22 (m, 1H), 7.08 (s, 1H), 3.31 (q, <i>J</i> = 7.1 Hz, 2H), 1.51 (t, <i>J</i> = 7.4 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 302.0 [M + H]<sup>+</sup>. Purity: 99% (method B, <i>t</i><sub>R</sub> = 4.0 min).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 6-(Benzofuran-2-yl)-2-(phenylthio)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>9</b>)</h3><div class="NLM_p last">Compound <b>7</b> (0.01 g, 0.031 mmol) and benzenethiol (3.20 μL, 0.031 mmol) were dissolved in methanol (0.313 mL). Triethylamine (TEA) (0.013 mL, 0.094 mmol) was added at rt, and the vessel was sealed (microwave tube small 0.2–1 mL). The resulting slurry was subjected to microwave conditions: 70 °C, 5 min. A white solid precipitated from solution upon cooling. LC–MS analysis of the crude mixture revealed the formation of the desired product: [M + 1] = 350.0. The solids were isolated by filtration and air-dried to afford 8.3 mg of compound <b>9</b> as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.64 (s, 1H), 7.78 (d, <i>J</i> = 6.60 Hz, 2H), 7.63 (d, <i>J</i> = 7.70 Hz, 1H), 7.54–7.61 (m, 4H), 7.23–7.31 (m, 2H), 7.13 (s, 1H). LC–MS (ESI) <i>m</i>/<i>z</i>: 350.0 [M + H]<sup>+</sup>. Purity: 99% (method B, <i>t</i><sub>R</sub> = 4.3 min).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> General Synthetic Method A: 6-(Benzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>10</b>)</h3><div class="NLM_p">Compound <b>7</b> (20 mg, 0.063 mmol) was suspended in methanol (2088 μL). Sodium methoxide (5.07 mg, 0.094 mmol) was added to the vessel and sealed, and the reaction mixture was stirred at rt. Over time, the yellow mixture became a white slurry. LC–MS monitoring of the crude mixture revealed the formation of the desired product: LC–MS: 3.603 min, [M + 1] = 270.0 [(MeOH/H<sub>2</sub>O/NH<sub>4</sub>OAc) Phenomenex Luna C18; 4.6 × 50 mm; 4 min gradient]. The mixture was diluted with EtOAc, washed with brine (sat’d NaCl), and extracted with EtOAc (3×). The combined organics were subsequently dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated prior to purification by prep HPLC (Phenomenex Luna AXIA, 30 × 100 mm; 17 min gradient; 0–100% MeCN/H<sub>2</sub>O/TFA) to afford 9.3 mg (54.7%) of compound <b>10</b> as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 7.93 (s, 1H), 7.60 (d, <i>J</i> = 7.70 Hz, 1H), 7.48 (d, <i>J</i> = 8.80 Hz, 1H), 7.22–7.30 (m, 2H), 7.10 (s, 1H), 4.22 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 272.0 [M + H]<sup>+</sup>. Purity: 99% (method B, <i>t</i><sub>R</sub> = 3.6 min).</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route for General Synthetic Method B toward 2-Methoxy-imidazothiadiazoles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> General Synthetic Method B (Steps 1–4): 6-(Benzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>10</b>)</h3><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Step 1: Potassium <i>O</i>-Methyl Carbonodithioate (<b>10A</b>)</h4><div class="NLM_p last">Potassium hydroxide (45 g, 802 mmol) and MeOH (84 mL) were added into a round-bottom flask and refluxed for 1 h. The reaction mixture was cooled to 20 °C, and the potassium methoxide solution was decanted from the solids into another dry 500 mL round-bottom flask. Carbon disulfide (61.1 g, 802 mmol) was added slowly in 15 min to the solution while stirring. The reaction mixture was then cooled to 0 °C, and the precipitated solids were collected in a fritted funnel, washed with Et<sub>2</sub>O (3 × 50 mL), and dried under reduced pressure for 24 h to afford 86 g of <b>10A</b> as a pink solid (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), which was used in the next step without further purification.</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Step 2: 5-Methoxy-1,3,4-thiadiazol-2-amine (<b>10B</b>)</h4><div class="NLM_p last">To <b>10A</b> (15 g, 103 mmol) in a round-bottom flask was added H<sub>2</sub>O (10 mL). The flask was cooled to 0 °C in an ice bath, and hydrazine monohydrate (5.1 mL, 164 mmol) was then added dropwise to the reaction mixture. The mixture was warmed back to 20 °C and stirred upon completion of the addition. Solids precipitated within 15 min of stirring. The resulting slurry was allowed to continue to stir for 2 h at rt and then cooled to 0 °C. The pH of the heterogeneous solution was adjusted to 7 using AcOH (dropwise addition), and then the solids were isolated by filtration. The light yellow solid was dried under reduced pressure for 24 h to afford 8.5 g of the crude thiohydrazide intermediate. This material was placed in a round-bottom flask, and a 2 N NaOH solution (48 mL, 96 mmol) was added. The reaction mixture was cooled to 0 °C, and a solution of CNBr (8.48 g, 80 mmol) in MeOH (8 mL) was added dropwise. The reaction was warmed to rt over a period of 1 h and stirred for 1.5 h at 20 °C. The precipitate was isolated by filtration and dried in vacuo to afford 5.92 g of <b>10B</b> as a brown solid. LC–MS: [M + 1] = 131.8; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 3.85–3.97 (s, 3H), 6.65–6.80 (bs, 2H).</div></div><div id="sec4_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Step 3: 1-(Benzofuran-2-yl)-2-(2-imino-5-methoxy-1,3,4-thiadiazol-3(2<i>H</i>)-yl)ethanone (<b>10C</b>)</h4><div class="NLM_p last"><b>10B</b> (1 g, 7.62 mmol) was dissolved in EtOH (51 mL). 1-(Benzofuran-2-yl)-2-bromoethanone (1.82 g, 7.62 mmol) was added to the vessel, which was sealed under argon and stirred overnight at rt. Upon consumption of the starting material, the slurry was filtered, and the solids were collected and air-dried to afford <b>10C</b> (1.91 g) as an off-white solid, which was used directly in the next step. LC–MS: [M + 1] = 290.1; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.92 (s, 2H), 8.13 (s, 1H), 7.92 (s, 1H), 7.79 (s, 1H), 7.61 (s, 1H), 7.43 (s, 1H), 5.83 (s, 2H), 4.06 (s, 3H).</div></div><div id="sec4_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Step 4: 6-(Benzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>10</b>)</h4><div class="NLM_p last"><b>10C</b> (300 mg, 1.037 mmol) was dissolved in H<sub>2</sub>O (6.9 mL), and ytterbium(III) trifluoromethanesulfonate (64.3 mg, 0.104 mmol) was added. The reaction mixture was warmed to 70 °C. The slurry was stirred overnight, while monitoring via LC–MS. After 21 h, the analysis indicated the consumption of the starting material and the clean formation of compound <b>10</b> (LC–MS: [M + 1] = 272.1). The mixture was cooled. The crude solids were filtered, titurated with MeOH (15 mL) followed by filtration to afford compound <b>10</b> (174.9 mg) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.48 (s, 1H), 7.55–7.64 (m, 2H), 7.21–7.30 (m, 2H), 7.07 (s, 1H), 4.19 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 272.0 [M + H]<sup>+</sup>. Purity: 99% (method B, <i>t</i><sub>R</sub> = 3.6 min).</div></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 6-(Benzofuran-2-yl)-2-ethoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>11</b>)</h3><div class="NLM_p last">Compound <b>7</b> (27 mg, 0.085 mmol) was suspended in ethanol (0.1 M, 845 μL) at rt. Potassium carbonate (35.1 mg, 0.254 mmol) was added to the vessel and sealed, and the reaction mixture was stirred at rt. LC–MS monitoring of the crude mixture revealed the formation of the desired product: LC–MS: 2.883 min, [M + 1] = 286.4 [(MeCN/H<sub>2</sub>O/TFA) Phenomenex Luna C18; 4.6 × 50 mm; 4 min gradient]. The mixture was quenched with H<sub>2</sub>O, diluted with EtOAc, washed with brine (sat’d NaCl), and extracted with EtOAc (3×). The combined organics were subsequently dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated prior to purification by prep HPLC (Phenomenex Luna AXIA, 30 × 100 mm; 17 min gradient; 0–100% MeCN/H<sub>2</sub>O/TFA) to afford 4.31 mg of compound <b>11</b> as a solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.48 (s, 1H), 7.65 (d, <i>J</i> = 7.0 Hz, 1H), 7.58 (d, <i>J</i> = 7.9 Hz, 1H), 7.34–7.22 (m, 2H), 7.10 (s, 1H), 4.61 (q, <i>J</i> = 7.0 Hz, 2H), 1.45 (t, <i>J</i> = 7.2 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 286.1 [M + H]<sup>+</sup>. Purity: 100% (method I, <i>t</i><sub>R</sub> = 2.1 min; method J, <i>t</i><sub>R</sub> = 2.1 min).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 6-(Benzofuran-2-yl)-2-isopropoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>12</b>)</h3><div class="NLM_p last">Compound <b>12</b> (7.43 mg), a solid, was prepared using the procedure described for the synthesis of compound <b>11</b>, using isopropyl alcohol instead of ethanol. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.47 (s, 1H), 7.64 (d, <i>J</i> = 7.3 Hz, 1H), 7.58 (d, <i>J</i> = 7.9 Hz, 1H), 7.36–7.24 (m, 2H), 7.09 (s, 1H), 5.30–5.17 (m, 1H), 1.47 (d, <i>J</i> = 6.4 Hz, 6H). LC–MS (ESI) <i>m</i>/<i>z</i>: 300.1 [M + H]<sup>+</sup>. Purity: 98% (method I, <i>t</i><sub>R</sub> = 2.3 min; method J, <i>t</i><sub>R</sub> = 2.3 min).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 6-(Benzofuran-2-yl)-<i>N</i>-methylimidazo[2,1-<i>b</i>][1,3,4]thiadiazol-2-amine (<b>13</b>)</h3><div class="NLM_p last">Compound <b>7</b> was suspended (0.03 g, 0.094 mmol) in DMF (0.939 mL) in a microwave tube. Methanamine hydrochloride (6.34 mg, 0.094 mmol) and excess TEA (0.039 mL, 0.282 mmol) were added, the vessel was sealed, and the reaction mixture was thermally heated overnight at 70 °C. Upon cooling, the analysis of the crude mixture by LC–MS revealed the formation of the desired product: LC–MS: [M + 1] = 271.0. The reaction mixture was diluted with EtOAc, washed with NaHCO<sub>3</sub>, extracted 3× (EtOAc), and the organics were dried and concentrated prior to purification by prep HPLC (Phenomenex Luna AXIA, 30 × 100 mm; 17 min gradient; 0–100% MeCN/H<sub>2</sub>O/TFA) to afford 9.7 mg (38.3%) of compound <b>13</b> as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 7.85 (s, 1H), 7.63 (d, <i>J</i> = 7.15 Hz, 1H), 7.47 (t, <i>J</i> = 7.15 Hz, 1H), 7.25–7.33 (m, 3H), 6.63 (s, 1H), 3.09 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 271.1 [M + H]<sup>+</sup>. Purity: 100% (method C, <i>t</i><sub>R</sub> = 9.1 min); 100% (method D, <i>t</i><sub>R</sub> = 8.1 min).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 6-(Benzofuran-2-yl)-2-methylimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>14</b>)</h3><div class="NLM_p last">Compound <b>14</b> (30.7 mg, 37%), a white solid, was prepared using the procedure described for the synthesis of compound <b>4</b>, with 5-methyl-1,3,4-thiadiazol-2-amine as a starting material. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.08 (s, 1H), 7.61 (d, <i>J</i> = 7.15 Hz, 1H), 7.49 (t, <i>J</i> = 8.80 Hz, 1H), 7.29 (td, <i>J</i> = 7.70, 1.10 Hz, 1H), 7.24 (d, <i>J</i> = 1.10 Hz, 1H), 7.15 (s, 1H), 2.75 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 256.0 [M + H]<sup>+</sup>. Purity: 99% (method C, <i>t</i><sub>R</sub> = 10.4 min); 98% (method D, <i>t</i><sub>R</sub> = 9.0 min).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 6-(Benzofuran-2-yl)-2-ethylimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>15</b>)</h3><div class="NLM_p last">Compound <b>15</b> (95 mg, 46%), a white solid, was prepared using the procedure described for the synthesis of compound <b>4</b>, with 5-ethyl-1,3,4-thiadiazol-2-amine as a starting material. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.61 (s, 1H), 7.66 (d, <i>J</i> = 7.6 Hz, 1H), 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.35–7.25 (m, 2H), 7.16 (s, 1H), 3.11 (q, <i>J</i> = 7.6 Hz, 2H), 1.37 (t, <i>J</i> = 7.5 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 270.0 [M + H]<sup>+</sup>. Purity: 98% (method A, <i>t</i><sub>R</sub> = 3.8 min).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 6-(Benzofuran-2-yl)-2-cyclopropylimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>16</b>)</h3><div class="NLM_p">Compound <b>16</b> (33.5 mg, 41.4%), a white solid, was prepared using the procedure described for the synthesis of compound <b>4</b>, with 5-cyclopropyl-1,3,4-thiadiazol-2-amine as a starting material. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 8.02 (s, 1H), 7.61 (d, <i>J</i> = 7.70 Hz, 1H), 7.49 (d, <i>J</i> = 7.15 Hz, 1H), 7.28–7.32 (m, 1H), 7.23–7.26 (m, 1H), 7.18 (s, 1H), 2.27 (ddd, <i>J</i> = 13.20, 8.25, 4.95 Hz, 1H), 1.28–1.34 (m, 2H), 1.20 (ddd, <i>J</i> = 7.29, 4.95, 4.81 Hz, 2H). LC–MS (ESI) <i>m</i>/<i>z</i>: 282.1 [M + H]<sup>+</sup>. Purity: 100% (method C, <i>t</i><sub>R</sub> = 11.7 min); 100% (method D, <i>t</i><sub>R</sub> = 9.8 min).</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Initial Synthetic Route for Benzofuranyl Imidazothiadiazoles with Substituent Variation on the Benzofuran<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH, μwave: 150 °C, 5 min; (b) <i>m</i>-CPBA, THF; (c) NaOMe, MeOH, rt.</p></p></figure></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 2-Methoxy-6-(4-methoxybenzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>21</b>)</h3><div id="sec4_19_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Step 1: 6-(4-Methoxybenzofuran-2-yl)-2-(methylthio)imidazole[2,1-<i>b</i>][1,3,4]thiadiazole (<b>21A</b>)</h4><div class="NLM_p last">Compound <b>21A</b> (283 mg, 42.8%) was obtained from 5-(methylthio)-1,3,4-thiadiazol-2-amine (306 mg, 2.081 mmol) and 2-bromo-1-(4-methoxybenzofuran-2-yl)enthanone (560 mg, 2.081 mmol) using the procedure described for the synthesis of compound <b>4</b>. LC–MS (ESI) <i>m</i>/<i>z</i>: 318.0 [M + H]<sup>+</sup> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div></div><div id="sec4_19_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Step 2: 6-(4-Methoxybenzofuran-2-yl)-2-(methylsulfonyl)imidazole[2,1-<i>b</i>][1,3,4]thiadiazole (<b>21B</b>)</h4><div class="NLM_p last">Compound <b>21B</b> (214 mg, 68,7%), a solid, was prepared using the procedure described the synthesis of compound <b>7</b>. LC–MS (ESI) <i>m</i>/<i>z</i>: 350.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_19_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Step 3: 2-Methoxy-6-(4-methoxybenzofuran-2-yl)imidazole[2,1-<i>b</i>][1,3,4]thiadiazole (<b>21</b>)</h4><div class="NLM_p last">Compound <b>21</b> (125 mg, 66.4%), an off-white solid, was prepared as described in general synthetic method A for the synthesis of compound <b>10</b>, using compound <b>21B</b> as a starting material. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.15 (s, 1H), 7.16–7.24 (m, 1H), 7.02–7.12 (m, 2H), 6.74 (d, <i>J</i> = 7.9 Hz, 1H), 4.24 (s, 3H), 3.94 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 302.1 [M + H]<sup>+</sup>. Purity: >95% (method C, <i>t</i><sub>R</sub> = 10.943 min); >95% (method D, <i>t</i><sub>R</sub> = 9.5 min).</div></div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 6-(4-(Benzyloxy)benzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>22</b>)</h3><div id="sec4_20_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Step 1: 5-(Benzyloxy)-2,2-dimethyl-4<i>H</i>-benzo[<i>d</i>][1,3]dioxin-4-one (<b>22A</b>)</h4><div class="NLM_p last">A solution of 5-hydroxy-2,2-dimethyl-4<i>H</i>-benzo[<i>d</i>][1,3]dioxin-4-one (6.00 g, 30.9 mmol) (Hadfield, A.; Schweitzer, H.; Trova, M. P.; Green, K. Synth. Commun., 1994, 24(7), 1025–1028) in <i>N</i>,<i>N</i>-dimethylformamide (35 mL) was treated with powdered anhydrous potassium carbonate (5.15 g, 37.26 mmol) added all at once. The resulting mixture was stirred in vacuo for 10 min and then flushed with nitrogen. The reaction flask was placed in a water bath (22 °C) and treated with benzyl bromide (5.55 g, 32.16 mmol) added dropwise over 15 min. The resulting mixture was then stirred at 22 °C for 18 h. The solid formed was filtered and washed with <i>N</i>,<i>N-</i>dimethylformamide. The filtrate was evaporated in vacuo, and the residual oil was diluted with ethyl acetate (300 mL) and washed with cold 0.1 N hydrochloric acid, saturated sodium bicarbonate, and brine. After drying over anhydrous magnesium sulfate, the evaporation of the solvent gave a thick syrup. Chromatography on silica gel (4 × 13 cm, elution toluene–ethyl acetate 0–5%) gave 8.78 g (100% yield) of the title material (<b>22A</b>) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.69 (s, 6H), 5.23 (s, 2H), 6.53 (d, <i>J</i> = 8.2 Hz, 1H), 6.62 (d, <i>J</i> = 8.4 Hz, 1H), 7.24–7.3 (m, 1H), 7.34–7.4 (m, 3H), 7.52 (broad d, <i>J</i> = 7.4 Hz 2H). Purity: >99% (method K; <i>t</i><sub>R</sub> = 2.0 min).</div></div><div id="sec4_20_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Step 2: 2-(Benzyloxy)-6-hydroxybenzaldehyde (<b>22B</b>)</h4><div class="NLM_p last">A solution of 5-(benzyloxy)-2,2-dimethyl-4<i>H</i>-benzo[<i>d</i>][1,3]dioxin-4-one (<b>22A</b>, 4.00 g, 14.07 mmol) in dichloromethane (80 mL) was cooled to −78 °C and treated with a solution of diisobutylaluminum hydride (6.00 g, 42.2 mmol) in toluene (40 mL) added dropwise over 20 min. The resulting mixture was then stirred at −78 °C for 3 h. The reaction mixture was quenched by the careful addition of methanol (5 mL) added dropwise over 15 min, followed by 4 N hydrochloric acid (20 mL) added dropwise over 15 min. The cooling bath was then removed, an additional 80 mL of 4 N hydrochloric acid was added over 10 min, and the mixture was stirred vigorously at 22 °C for 4 h. The reaction mixture was diluted with ethyl acetate (200 mL), washed with brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. The resulting oil was chromatographed on silica gel (4 × 10 cm, elution toluene) to give 2.25 g (70% yield) of <b>22B</b> as a pale yellow solid. HRMS (ESI) calcd for C<sub>14</sub>H<sub>13</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 229.0859, found 229.0859. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 5.12 (s, 2H), 6.43 (d, <i>J</i> = 8.25 Hz, 1H), 6.52 (d, <i>J</i> = 8.46 Hz, 1H), 7.34–7.4 (m, 6H), 10.39 (s, 1H), 11.95 (s, 1H). Purity: >99% (method G; <i>t</i><sub>R</sub> = 2.2 min).</div></div><div id="sec4_20_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Step 3: 1-(4-(Benzyloxy)benzofuran-2-yl)ethanone (<b>22C</b>)</h4><div class="NLM_p last">A solution of 2-(benzyloxy)-6-hydroxybenzaldehyde (<b>22B</b>, 11.10 g, 48.63 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (120 mL) was treated with powdered anhydrous cesium carbonate (15.8 g, 48.63 mmol) added all at once. The resulting mixture was stirred in vacuo for 10 min and then flushed with nitrogen. The reaction flask was placed in a water bath (22 °C) and treated with chloroacetone (4.65 mL, 58.4 mmol) added dropwise over 10 min. The resulting mixture was then stirred at 22 °C for 18 h (no starting aldehyde left by tlc and formation of the intermediate alkylated aldehyde). The reaction mixture was then maintained under vacuum (10 mbar) for 15 min to remove any unreacted chloroacetone and flushed with nitrogen. Then, anhydrous cesium carbonate (1.0 g, 3.1 mmol) was added, and the mixture was heated at 55 °C and stirred for 40 h (more cesium carbonate, 1 g, was added at 24 h and 32 h) until complete conversion of the intermediate alkylated aldehyde into the benzofuran as observed by thin-layer chromatography (TLC). The solid was filtered and washed with <i>N</i>,<i>N</i>-dimethylformamide. The filtrate was evaporated in vacuo, and the residual oil was diluted with ethyl acetate (400 mL) and washed with cold 0.1 N hydrochloric acid, saturated sodium bicarbonate, and brine. After drying over anhydrous magnesium sulfate, the evaporation of the solvent gave a thick syrup. Chromatography on silica gel (4.5 × 12 cm, elution toluene–ethyl acetate 2–4%) gave 11.67 g (90% yield) of <b>22C</b> as a light yellow solid. Recrystallization from a mixture of ethyl acetate (40 mL) and hexane (40 mL) gave colorless prisms (10.50 g). HRMS (ESI) calcd for C<sub>17</sub>H<sub>15</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 267.1016, found 267.1022. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 2.56 (s, 3H), 5.20 (s, 2H), 6.73 (d, <i>J</i> = 8.0 Hz, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 7.3–7.5 (m, 6H), 7.63 (s, 1H). Purity: >99% (method K; <i>t</i><sub>R</sub> = 2.1 min).</div></div><div id="sec4_20_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Step 4: 1-(4-(Benzyloxy)benzofuran-2-yl)-2-bromoethanone (<b>22D</b>)</h4><div class="NLM_p last">A 250 mL, three-necked flask equipped with a magnetic stirring bar and purged with a nitrogen atmosphere was charged with anhydrous tetrahydrofuran (40 mL) followed by 21.6 mL (21.6 mmol) of a 1 M solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran. The mixture was cooled to −78 °C and treated with a solution of 1-(4-(benzyloxy)benzofuran-2-yl)ethanone (<b>22C</b>, 5.00 g, 18.77 mmol) in tetrahydrofuran (20 mL) added dropwise over 10 min. The resulting mixture was then stirred at −78 °C for 45 min. Then, chlorotrimethylsilane (2.74 mL, 21.6 mmol) was added dropwise over 5 min, and the resulting solution was stirred at −78 °C for another 20 min. The cooling bath was then removed, and the mixture was allowed to warm to room temperature over 30 min. The reaction mixture was then quenched by the addition to a cold solution of ethyl acetate (300 mL), saturated sodium bicarbonate (40 mL), and ice. The organic phase was rapidly dried over anhydrous magnesium sulfate (magnetic stirring) and evaporated in vacuo to give the silyl enol ether as oil, which is coevaporated with toluene (20 mL). The silyl enol ether was then dissolved in dry tetrahydrofuran (80 mL), cooled to −25 °C, and treated with solid sodium bicarbonate (0.10 g), followed by <i>N</i>-bromosuccinimide (3.34 g, 18.8 mmol) added in small portions over 10 min. The reaction mixture was allowed to warm to 0 °C over 2 h and then quenched by the addition of ethyl acetate (350 mL) and saturated sodium bicarbonate. The organic phase was washed with brine, dried over anhydrous magnesium sulfate, and evaporated to give an orange oil. Chromatography on silica gel (4.5 × 12 cm, elution toluene–ethyl acetate 0–1%) gave 6.13 g of 1-(4-(benzyloxy)benzofuran-2-yl)-2-bromoethanone (<b>22D</b>) as a yellow solid. Recrystallization from ethyl acetate (20 mL) and hexane (40 mL) gave pale yellow prisms (4.93 g, 76% yield). HRMS (ESI) calcd for C<sub>17</sub>H<sub>14</sub>BrO [M + H]<sup>+</sup><i>m</i>/<i>z</i> 345.0121, found 345.0109. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 4.39 (s, 2H), 5.20 (s, 2H), 6.75 (d, <i>J</i> = 7.86 Hz, 1H), 7.17 (d, <i>J</i> = 8.25 Hz, 1H), 7.34–7.46 (m, 6H), 7.78 (s, 1H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.2 min).</div></div><div id="sec4_20_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Step 5: 6-(4-(Benzyloxy)benzofuran-2-yl)-2-bromoimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>22E</b>)</h4><div class="NLM_p last">A mixture of 1-(4-(benzyloxy)benzofuran-2-yl)-2-bromoethanone (<b>22D</b>, 3.00 g, 8.69 mmol) and 5-bromo-1,3,4-thiadiazol-2-amine (1.80 g, 10.0 mmol) in isopropyl alcohol (100 mL) was heated in a pressure flask equipped with a magnetic stirring bar at 80 °C for 20 h (homogeneous after 20 min and then formation of a precipitate after 2 h). The cooled mixture was then transferred into five 20 mL microwave vials and heated in a microwave apparatus to 150 °C for 30 min. Each vial was then diluted with dichloromethane (250 mL), washed with saturated sodium bicarbonate (25 mL) and brine (25 mL), and dried over anhydrous magnesium sulfate. The fractions were combined and concentrated in vacuo. Chromatography of the orange-brown residual solid on silica gel (4 × 10 cm, slow elution with dichloromethane) gave 2.82 g of 6-(4-(benzyloxy)benzofuran-2-yl)-2-bromoimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>22E</b>) contaminated with some 1-(4-(benzyloxy)benzofuran-2-yl)ethanone. The solid material was triturated with ethyl acetate (15 mL), filtered, washed with ethyl acetate (10 mL), and dried in vacuo to give 2.37 g (64% yield) of pure title imidazothiadiazole as an off-white solid, which is used as such for the next step. HRMS (ESI) calcd for C<sub>19</sub>H<sub>13</sub>BrN<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 425.9906, found 425.9893. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 5.21 (s, 2H), 6.72 (d, <i>J</i> = 8.07 Hz, 1H), 7.13 (d, <i>J</i> = 8.26 Hz, 1H), 7.18 (broad t, 1H), 7.25 (s, 1H), 7.32 (broad t, 1H), 7.38 (broad t, 2H), 7.47 (broad d, 2H), 8.09 (s, 1H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.4 min).</div></div><div id="sec4_20_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Step 6: 6-(4-(Benzyloxy)benzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>22</b>)</h4><div class="NLM_p last">A solution of 6-(4-(benzyloxy)benzofuran-2-yl)-2-bromoimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>22E</b>, 3.22 g, 7.55 mmol) in a mixture of dichloromethane (400 mL) and methanol (50 mL) was treated at 22 °C with 6.3 mL of a 25 wt % solution of sodium methoxide in methanol (30.2 mmol) added in one portion. More methanol (45 mL) was added, and the mixture was stirred for 40 min. The reaction mixture was quenched by the addition of 40 mL of 1 N hydrochloric acid followed by 10 mL of saturated sodium bicarbonate. The solvent was evaporated under reduced pressure, and the residue was diluted with dichloromethane (400 mL), washed with brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. Crystallization of the white solid residue from 1,2-dichloroethane (30 mL) gave 2.19 g of 6-(4-(benzyloxy)benzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>22</b>) as a white solid. Chromatography of the mother liquors on silica gel (3 × 10 cm, elution with dichloromethane–ethyl acetate 0–1%) gave another 0.46 g of product (total yield 2.65 g, 93%). HRMS (ESI) calcd for C<sub>20</sub>H<sub>16</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 378.0907, found 378.0911. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 4.18 (s, 3H), 5.21 (s, 2H), 6.71 (dd, <i>J</i> = 7.4, 0.95 Hz, 1H), 7.12–7.17 (m, 3H), 7.32 (broad t, 1H), 7.38 (broad t, 2H), 7.47 (broad d, 2H), 7.88 (s, 1H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.4 min).</div></div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 2-Methoxy-6-(5-methoxybenzofuran-2-yl)imidazole[2,1-<i>b</i>][1,3,4]thiadiazole (<b>23</b>)</h3><div class="NLM_p last">Compound <b>23</b> (117.7 mg, 31%), a white solid, was prepared as described in general synthetic method B for the preparation of compound <b>10</b>, where the 2-bromo-1-(5-methoxybenzofuran-2-yl)ethanone intermediate was synthesized using the methods described for the preparation of <b>21B</b>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 7.90 (s, 1H), 7.36 (d, <i>J</i> = 8.80 Hz, 1H), 7.03 (d, <i>J</i> = 2.75 Hz, 1H), 6.99 (s, 1H), 6.85 (dd, <i>J</i> = 8.80, 2.75 Hz, 1H), 4.20 (s, 3H), 3.84 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 302.1 [M + H]<sup>+</sup>. Purity: 100% (method C, <i>t</i><sub>R</sub> = 10.680 min); >95% (method D, <i>t</i><sub>R</sub> = 9.3 min).</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 2-Methoxy-6-(6-methoxybenzofuran-2-yl)imidazole[2,1-<i>b</i>][1,3,4]thiadiazole (<b>24</b>)</h3><div class="NLM_p last">Compound <b>24</b> (75 mg, 51.3%), a white solid, was prepared using the procedures described for the synthesis of compound <b>21</b>, using 2-bromo-1-(6-methoxybenzofuran-2-yl)ethanone as the starting material. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 8.10 (s, 1H), 7.43 (d, <i>J</i> = 8.2 Hz, 1H), 7.08 (d, <i>J</i> = 1.6 Hz, 1H), 6.94 (s, 1H), 6.86 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 4.24 (s, 3H), 3.84 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 302.1 [M + H]<sup>+</sup>. Purity: 95% (method C, <i>t</i><sub>R</sub> = 10.704 min); 95% (method D, <i>t</i><sub>R</sub> = 9.3 min).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 6-(6-(Benzyloxy)benzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>25</b>)</h3><div id="sec4_23_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Step 1: 1-(6-(Benzyloxy)benzofuran-2-yl)ethan-1-one (<b>25A</b>)</h4><div class="NLM_p last">4-(Benzyloxy)-2-hydroxybenzaldehyde (15.45 g, 67.7 mmol) was weighed into a tared round-bottom flask charged with cesium carbonate (33.1 g, 102 mmol). To the reactants dissolved in DMF (100 mL), 1-chloropropan-2-one (7.02 mL, 88 mmol) was added slowly over 5 min, and the reaction mixture was heated at 60 °C overnight. The next day, the reaction was diluted with EtOAc (300 mL), washed with a one-to-one solution of sat’d NaCl and H<sub>2</sub>O (4 × 50 mL), dried over MgSO<sub>4</sub>, filtered, and evaporated to dryness in vacuo. The residue was purified via normal phase column chromatography (ISCO) to afford 13.8 g of compound <b>25A</b>. LC–MS (ESI) <i>m</i>/<i>z</i>: 267 [M + H]<sup>+</sup>.</div></div><div id="sec4_23_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Step 2: 1-(6-(Benzyloxy)benzofuran-2-yl)-2-bromoethan-1-one (<b>25B</b>)</h4><div class="NLM_p last">To compound <b>25A</b> (4 g, 15.02 mmol) dissolved in THF (100 mL), phenyltrimethylammonium tribromide (5.65 g, 15.02 mmol) was added. The reaction mixture was stirred at rt for 3 h until the reaction was determined to be complete. The crude mixture was poured into H<sub>2</sub>O (300 mL), diluted with EtOAc (300 mL), washed with sat’d NaCl (3 × 10 mL), dried over MgSO<sub>4</sub>, filtered, and evaporated to dryness in vacuo to afford compound <b>25B</b> (5 g, 87% yield) as a yellow solid. LC–MS (ESI) <i>m</i>/<i>z</i>: 346 [M + H]<sup>+</sup>.</div></div><div id="sec4_23_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Step 3: 6-(6-(Benzyloxy)benzofuran-2-yl)-2-(methylthio)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>25C</b>)</h4><div class="NLM_p last">Compound <b>25C</b> (2.2 g, 36.2%) was prepared from 5-(methylthio)-1,3,4-thiadiazol-2-amine (2.047 g, 13.91 mmol) and intermediate <b>25B</b> (4.8 mg, 13.91 mmol) in EtOH (90 mL) using the procedure described for the synthesis of <b>4</b>. LC–MS (ESI) <i>m</i>/<i>z</i>: 392 [M + H]<sup>+</sup>.</div></div><div id="sec4_23_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Step 4: 6-(6-(Benzyloxy)benzofuran-2-yl)-2-(methylsulfonyl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>25D</b>)</h4><div class="NLM_p last">Compound <b>21D</b> (400 mg, 88%), a solid, was prepared using the method described for the synthesis of compound <b>7</b>. LC–MS (ESI) <i>m</i>/<i>z</i>: 426.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_23_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Step 5: 6-(6-(Benzyloxy)benzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>25</b>)</h4><div class="NLM_p last">Compound <b>25</b> (3.4 mg), a yellow solid, was prepared from intermediate <b>25D</b> as described in general synthetic method A for the synthesis of compound <b>10</b>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 4.21 (s, 3H), 5.13 (s, 2H), 6.94 (s, 1H), 7.29–7.37 (m, 1H), 7.40 (s, 3H), 7.42–7.46 (m, 3H), 7.46 (s, 1H), 7.87 (s, 1H). LC–MS (ESI) <i>m</i>/<i>z</i>: 378.0 [M + H]<sup>+</sup>. Purity: 92% (method C, <i>t</i><sub>R</sub> = 12.819 min); 92% (method D, <i>t</i><sub>R</sub> = 11.0 min).</div></div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 2-Methoxy-6-(7-methoxybenzofuran-2-yl)imidazole[2,1-<i>b</i>][1,3,4]thiadiazole (<b>26</b>)</h3><div class="NLM_p last">Compound <b>26</b> (112 mg, 55.3%), a white solid, was prepared using the method described for the synthesis of compound <b>21</b>, using 2-bromo-1-(7-methoxybenzofuran-2-yl)enthanone as the starting material. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 8.19 (s, 1H), 7.12–7.18 (m, 2H), 7.01 (s, 1H), 6.87 (dd, <i>J</i> = 6.2, 2.6 Hz, 1H), 4.25 (s, 3H), 4.00 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 302.0 [M + H]<sup>+</sup>. Purity: 98% (method C, <i>t</i><sub>R</sub> = 10.576 min); 98% (method D, <i>t</i><sub>R</sub> = 9.3 min).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 6-(6,7-Dimethoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>27</b>)</h3><div id="sec4_25_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Step 1: 1-(6,7-Dimethoxybenzofuran-2-yl)ethanone (<b>27A</b>)</h4><div class="NLM_p last">2-Hydroxy-3,4-dimethoxybenzaldehyde (1.3 g, 7.14 mmol) was dissolved in MeOH (16.4 mL) in a round-bottom flask. KOH (0.400 g, 7.14 mmol), previously pulverized with a mortar and pestle, was added. The reaction mixture was heated to reflux for 30 min. The mixture was cooled, and 1-chloropropan-2-one (8.56 g, 7.89 mmol) was added dropwise to the solution at 0–10 °C. The newly prepared solution was warmed to rt and stirred over 48 h. Upon reaction completion, as shown by TLC analysis, the MeOH was removed in vacuo, the residue was dissolved in EtOAc, and H<sub>2</sub>O was added. The crude product was washed with brine (sat’d NaCl), extracted 3× with EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford a dark oil. The crude material was purified by flash chromatography (EtOAc/hexanes 0–100%) to provide 1 g of <b>27A</b>. LC–MS: [M + 1] = 221.1; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 2.48–2.60 (s, 3H), 3.88–3.95 (s, 3H), 4.02–4.10 (s, 3H), 7.05–7.16 (m, 1H), 7.37–7.44 (m, 1H), 7.61–7.68 (s, 1H).</div></div><div id="sec4_25_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Step 2: 2-Bromo-1-(6,7-dimethoxybenzofuran-2-yl)ethanone (<b>27B</b>)</h4><div class="NLM_p last">To <b>27A</b> (1 g, 4.54 mmol) dissolved in EtOAc (30 mL) was added copper(II) bromide (1.27 g, 5.68 mmol), and the resulting mixture was heated under Ar to reflux (80 °C) overnight. The dark solution was filtered through a plug of silica. The media was rinsed with 10% EtOAc/hexanes. The filtrate was concentrated and dried in vacuo, and the crude material was purified by flash chromatography (EtOAc/hexanes 0–20%) to provide 710 mg of <b>27B</b>. LC–MS: [M + 1] = 301.0; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 3.93–3.95 (s, 3H), 4.07–4.09 (s, 3H), 4.53–4.57 (s, 2H), 7.12–7.16 (m, 1H), 7.41–7.45 (m, 1H), 7.78–7.81 (s, 1H).</div></div><div id="sec4_25_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Step 3: 6-(6,7-Dimethoxybenzofuran-2-yl)-2-(methylthio)imidazo[2,1-<i>b</i>]-[1,3,4]thiadiazole (<b>27C</b>)</h4><div class="NLM_p last"><b>27C</b> was prepared as described in general synthetic method A for compound <b>10</b> from 5-(methylthio)-1,3,4-thiadiazol-2-amine (148 mg, 1.00 mmol) and <b>27B</b> (300 mg, 1.00 mmol). The crude product was dried onto silica gel and purified by flash chromatography (0–15% EtOAc/hexanes) to provide 135 mg of <b>27C</b> as a solid. LC–MS: [M + 1] = 348.1; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 2.78–2.85 (s, 3H), 3.86–3.93 (s, 3H), 4.06–4.12 (s, 3H), 6.95–7.03 (m, 2H), 7.18–7.24 (m, 1H), 8.24–8.32 (s, 1H).</div></div><div id="sec4_25_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Step 4: 6-(6,7-Dimethoxybenzofuran-2-yl)-2-(methylsulfonyl)imidazo-[2,1-<i>b</i>][1,3,4]thiadiazole (<b>27D</b>)</h4><div class="NLM_p last"><b>27C</b> (135 mg, 0.398 mmol) and <i>m</i>-CPBA (335 mg, 1.94 mmol) were added to a round-bottom flask containing THF (4 mL, 0.1 M). The resulting mixture was stirred for 12 h at 20 °C. Upon completion, the reaction mixture was diluted with EtOAc and washed with H<sub>2</sub>O (2 × 25 mL), followed by brine (sat’d NaCl, 2 × 25 mL). The biphasic mixture was extracted with EtOAc (3×), and the combined organics were dried directly onto SiO<sub>2</sub> gel. The crude residue was purified by flash chromatography (0–30% EtOAc/hexanes) to provide <b>27D</b> (71 mg) as a solid. LC–MS: [M + 1] = 380.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.42–3.47 (s, 3H), 3.93–3.98 (s, 3H), 4.17–4.22 (s, 3H), 6.92–6.97 (m, 1H), 7.11–7.16 (s, 1H), 7.20–7.25 (m, 1H), 8.21–8.26 (s, 1H).</div></div><div id="sec4_25_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Step 5: 6-(6,7-Dimethoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>27</b>)</h4><div class="NLM_p last">MeOH (3.7 mL, 0.05 M) and sodium methoxide (30 mg, 0.531 mmol) were added to a round-bottom flask containing <b>27D</b> (71 mg, 0.187 mmol). The resulting mixture was stirred at 20 °C for 12 h. Upon complete consumption of the starting material, the solution was diluted with EtOAc and washed with H<sub>2</sub>O (2 × 25 mL), followed by brine (sat’d NaCl, 2 × 25 mL). The biphasic mixture was extracted with EtOAc (3×), and the combined organics were concentrated directly onto silica. The crude residue was purified by flash chromatography (0–30% EtOAc/hexanes) to provide 40 mg of compound <b>27</b> as a solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 3.88–3.93 (s, 3H), 4.07–4.13 (s, 3H), 4.23–4.28 (s, 3H), 6.93–7.02 (m, 2H), 7.16–7.24 (m, 1H), 8.15–8.20 (s, 1H). LC–MS (ESI) <i>m</i>/<i>z</i>: 332.1 [M + H]<sup>+</sup>. Purity: 95% (method C, <i>t</i><sub>R</sub> = 10.1 min).</div></div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 6-(4,7-Dimethoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>28</b>)</h3><div class="NLM_p last">Compound <b>28</b> (38.6 mg, 55.7%), a pale yellow solid isolated upon final purification via flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/hexanes), was prepared using the methods described for the synthesis of a compound for <b>27</b>, using 2-hydroxy-3,6-dimethoxybenzaldehyde as the starting material. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 7.97 (s, 1H), 7.12 (s, 1H), 6.68 (d, <i>J</i> = 8.25 Hz, 1H), 6.53 (d, <i>J</i> = 8.80 Hz, 1H), 4.19 (s, 3H), 3.98 (s, 3H), 3.90 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 332.1 [M + H]<sup>+</sup>. Purity: 95% (method C, <i>t</i><sub>R</sub> = 10.570 min); 98% (method D, <i>t</i><sub>R</sub> = 9.3 min).</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 6-(4,6-Dimethoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>29</b>)</h3><div class="NLM_p last">Compound <b>29</b> (43 mg, 21.9%), an orange solid isolated upon final purification via flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/hexanes), was prepared using the methods described for the synthesis of compound for <b>27</b>, using 2-hydroxy-4,6-dimethoxybenzaldehyde as the starting material. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 8.07 (s, 1H), 6.97 (s, 1H), 6.71 (d, <i>J</i> = 1.1 Hz, 1H), 6.38 (d, <i>J</i> = 1.6 Hz, 1H), 4.25 (s, 3H), 3.91 (s, 3H), 3.84 (s, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: 332.1 [M + H]<sup>+</sup>. Purity: 97% (method C, <i>t</i><sub>R</sub> = 10.794 min); 98% (method D, <i>t</i><sub>R</sub> = 9.4 min).</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 5-(Benzyloxy)-7-methoxy-2,2-dimethyl-4<i>H</i>-benzo[<i>d</i>][1,3]dioxin-4-one (<b>32</b>)</h3><div class="NLM_p last">A solution of <b>31</b> (30.00 g, 0.134 mol, see ref <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> for preparation) in <i>N</i>,<i>N</i>-dimethylformamide (400 mL) was treated with powdered anhydrous potassium carbonate (19.41 g, 0.14 mol), added all at once. The resulting mixture was stirred in vacuo for 10 min and then flushed with nitrogen. The reaction flask was placed in a water bath (22 °C) and treated with benzyl bromide (24.03 g, 0.14 mol) added dropwise over 15 min. The resulting mixture was then stirred at 22 °C for 18 h (no starting material remained by TLC). The solid was filtered and washed with <i>N</i>,<i>N</i>-dimethylformamide. The filtrate was concentrated in vacuo, and the residual oil was diluted with ethyl acetate (500 mL) and washed with cold 0.1 N hydrochloric acid, saturated sodium bicarbonate, and brine. After drying over anhydrous magnesium sulfate, the evaporation of the solvent gave a thick syrup. Crystallization from ethyl acetate (50 mL) and hexane (150 mL) gave 35.17 g of <b>32</b> as large colorless prisms. Chromatography of the mother liquors on silica gel (4 × 13 cm column, elution with toluene–ethyl acetate 0–5%) gave 6.64 g of additional material to afford a total yield of 41.81 g (99%). HRMS (ESI) calcd for C<sub>18</sub>H<sub>19</sub>O<sub>5</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 315.1227, found 315.1386. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 1.68 (s, 6H), 3.77 (s, 3H), 5.19 (s, 2H), 5.19 (s, 2H), 6.04 (d, <i>J</i> = 2.03 Hz, 1H), 6.15 (d, <i>J</i> = 2.03 Hz, 1H), 7.27 (broad t, 1H), 7.36 (broad t, 2H), 7.52 (broad d, 2H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.0 min).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 2-(Benzyloxy)-6-hydroxy-4-methoxybenzaldehyde (<b>33</b>)</h3><div class="NLM_p last">A solution of <b>32</b> (6.76 g, 21.5 mmol) in dichloromethane (120 mL) was cooled to −78 °C and treated with 43 mL (64.5 mmol) of a 1.5 M solution of diisobutylaluminum hydride in toluene, added dropwise over 20 min. The resulting mixture was stirred at −78 °C for 3 h. The reaction mixture was quenched by the careful addition of methanol (5 mL) added dropwise over 15 min, followed by 1 N hydrochloric acid (50 mL) added dropwise over 15 min. The cooling bath was then removed, and an additional 150 mL of 1 N hydrochloric acid was added over 20 min. The mixture was stirred at 22 °C for 2 h and diluted with dichloromethane (400 mL). The organic phase was collected, and the aqueous phase (pH ∼ 1) was extracted with dichloromethane (3 × 50 mL). The combined organic extracts were washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residual oil was diluted with tetrahydrofuran (70 mL), treated with 10 mL of 0.1 N hydrochloric acid, and stirred at 20 °C for 2 h. The reaction mixture was diluted with ethyl acetate (300 mL), washed with brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo to give a clear oil. Chromatography on silica gel (4 × 13 cm, elution with toluene) gave 4.08 g (73% yield) of <b>33</b> as a clear oil, which solidified to a white solid on standing. HRMS (ESI) calcd for C<sub>15</sub>H<sub>15</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 259.0965, found 259.1153. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 3.80 (s, 3H), 5.07 (s, 2H), 5.97 (d, <i>J</i> = 2.1 Hz, 1H), 6.01 (d, <i>J</i> = 2.1 Hz, 1H), 7.3–7.4 (m, 5H), 10.15 (s, 1H), 12.49 (s, 1H). Purity: >95% (method E; <i>t</i><sub>R</sub> = 2.1 min).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 6-(4-(Benzyloxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>34</b>)</h3><div id="sec4_30_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Step 1: 1-(4-(Benzyloxy)-6-methoxybenzofuran-2-yl)ethanone (<b>34A</b>)</h4><div class="NLM_p last">A solution of <b>33</b> (3.46 g, 13.4 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (50 mL) was treated with powdered anhydrous cesium carbonate (4.58 g, 14.05 mmol) added all at once. The resulting mixture was stirred in vacuo for 10 min and then flushed with nitrogen. The reaction flask was placed in a water bath (22 °C) and treated with chloroacetone (1.74 g, 18.7 mmol) added dropwise over 5 min. The resulting mixture was then stirred at 22 °C for 18 h (no starting aldehyde left by TLC and formation of the intermediate alkylated aldehyde). The solid was filtered and washed with <i>N</i>,<i>N</i>-dimethylformamide. The filtrate was evaporated in vacuo, and the residual oil was diluted with ethyl acetate (300 mL) and washed with cold 0.1 N hydrochloric acid, saturated sodium bicarbonate, and brine. After drying over anhydrous magnesium sulfate, the evaporation of the solvent gave a thick syrup. This syrup was diluted with tetrahydrofuran (50 mL) and ethyl acetate (50 mL), treated with <i>p</i>-toluenesulfonic acid monohydrate (0.2 g), and stirred at 20 °C for 1 h (TLC indicated complete cyclization of the intermediate alkylated aldehyde). The reaction mixture was diluted with ethyl acetate (300 mL) and washed with saturated sodium bicarbonate and brine. After drying over anhydrous magnesium sulfate, the evaporation of the solvent gave a thick syrup. Chromatography on silica gel (4 × 12 cm, elution toluene–ethyl acetate 2–4%) gave 3.51 g (88% yield) of <b>34A</b> as a yellow solid. Recrystallization from ethyl acetate (10 mL) and hexane (20 mL) gave the title material as large yellow prisms (3.15 g). HRMS (ESI) calcd for C<sub>18</sub>H<sub>17</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 297.1121, found 297.1092. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 2.51 (s, 3H), 3.82 (s, 3H), 5.13 (s, 2H), 6.37 (d, <i>J</i> = 1.77 Hz, 1H), 6.63 (broad s, 1H), 7.34 (broad t, 1H), 7.39 (broad t, 2H), 7.44 (broad d, 2H), 7.55 (d, <i>J</i> = 0.7 Hz,1H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.1 min).</div></div><div id="sec4_30_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Step 2: 1-(4-(Benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoethanone (<b>34B</b>)</h4><div class="NLM_p last">A 250 mL, three-necked flask equipped with a magnetic stirring bar and purged with a nitrogen atmosphere was charged with anhydrous tetrahydrofuran (25 mL) followed by 9.3 mL (9.3 mmol) of a 1 M solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran. The mixture was cooled to −78 °C and treated with a solution of <b>34A</b> (2.40 g, 8.1 mmol) in tetrahydrofuran (20 mL) added dropwise over 10 min. The resulting mixture was then stirred at −78 °C for 45 min. Chlorotrimethylsilane (1.18 mL, 9.31 mmol) was added dropwise over 5 min, and the resulting solution was stirred at −78 °C for another 20 min. The cooling bath was removed, and the mixture was allowed to warm to room temperature over 30 min. The reaction mixture was then quenched by the addition to a cold solution of ethyl acetate (200 mL), saturated sodium bicarbonate (30 mL), and ice. The organic phase was rapidly dried over anhydrous magnesium sulfate (magnetic stirring) and evaporated in vacuo to give the silyl enol ether as oil, which was coevaporated with toluene (20 mL). The silyl enol ether was then dissolved in dry tetrahydrofuran (40 mL), cooled to −20 °C, and treated with solid sodium bicarbonate (0.10 g) followed by <i>N</i>-bromosuccinimide (1.44 g, 8.1 mmol), added in small portions over 15 min. The reaction mixture was allowed to warm to 0 °C over 2 h and then quenched by the addition of ethyl acetate (300 mL) and saturated sodium bicarbonate. The organic phase was washed with brine, dried over anhydrous magnesium sulfate, and evaporated to give an orange oil. Chromatography on silica gel (4 × 12 cm, elution with toluene–ethyl acetate 0–5%) gave 2.62 g (86% yield) of <b>34B</b> as a yellow solid. Recrystallization from ethyl acetate (10 mL) and hexane (20 mL) gave yellow prisms (2.30 g). HRMS (ESI) calcd for C<sub>18</sub>H<sub>16</sub>BrO<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 375.0226, found 375.0277. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 3.84 (s, 3H), 4.33 (s, 2H), 5.14 (s, 2H), 6.38 (d, <i>J</i> = 1.76 Hz, 1H), 6.64 (broad s, 1H), 7.35 (broad t, 1H), 7.40 (broad t, 2H), 7.44 (broad d, 2H), 7.70 (s, 1H). Purity: >95% (method E; <i>t</i><sub>R</sub> = 2.2 min).</div></div><div id="sec4_30_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Step 3: 6-(4-(Benzyloxy)-6-methoxybenzofuran-2-yl)-2-bromoimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>34C</b>)</h4><div class="NLM_p last">A mixture of <b>34B</b> (3.00 g, 8.0 mmol) and 5-bromo-1,3,4-thiadiazol-2-amine (1.65 g, 9.16 mmol) in isopropyl alcohol (100 mL) was heated in a pressure flask equipped with a magnetic stirring bar at 78–80 °C for 18 h (homogeneous after 20 min and then the formation of a precipitate after 2 h). The cooled mixture was transferred into five 20 mL microwave vials and then heated in a microwave apparatus to 150 °C for 30 min. Each vial was then diluted with dichloromethane (250 mL), washed with saturated sodium bicarbonate (25 mL) and brine (25 mL), and dried over anhydrous magnesium sulfate. The fractions were combined and concentrated in vacuo. Chromatography of the orange-brown residual solid on silica gel (4 × 10 cm, slow elution with dichloromethane due to poor solubility) gave 2.96 g of the title imidazothiadiazole contaminated with some 1-(4-(benzyloxy)-6-methoxybenzofuran-2-yl)ethanone. The solid material was triturated with ethyl acetate (20 mL), filtered, washed with ethyl acetate (10 mL), and dried in vacuo to give 2.34 g (64% yield) of pure <b>34C</b> as an off-white solid, which was used as such for the next step. HRMS (ESI) calcd for C<sub>20</sub>H<sub>15</sub>BrN<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 456.00175, found 456.00397. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 3.82 (s, 3H), 5.16 (s, 2H), 6.38 (d, <i>J</i> = 1.67 Hz, 1H), 6.66 (broad s, 1H), 7.15 (s, 1H), 7.31 (broad t, 1H), 7.38 (broad t, 2H), 7.45 (broad d, 2H), 8.02 (s, 1H). Purity: >95% (method E; <i>t</i><sub>R</sub> = 2.4 min).</div></div><div id="sec4_30_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Step 4: 6-(4-(Benzyloxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>34</b>)</h4><div class="NLM_p last">A solution of <b>34C</b> (2.30 g, 5.04 mmol) in a mixture of dichloromethane (180 mL) and methanol (45 mL) was treated at 22 °C with 4.2 mL of a 25 wt % solution of sodium methoxide in methanol (0.2 mmol) added in one portion. More methanol (45 mL) was added, and the mixture was stirred for 1 h. The reaction mixture was quenched by the addition of 25 mL of 1 N hydrochloric acid, followed by 20 mL of saturated sodium bicarbonate. The solvent was evaporated under reduced pressure, and the residue was diluted with dichloromethane (400 mL), washed with brine, dried over anhydrous magnesium sulfate, and evaporated in vacuo. Chromatography of the residue on silica gel (3 × 10 cm, elution with dichloromethane–ethyl acetate 0–4%) gave 1.70 g (83% yield) of <b>34</b> as a white solid. This material was recrystallized from ethyl acetate (30 mL/g, 80% recovery) to give white needles. HRMS (ESI) calcd for C<sub>21</sub>H<sub>18</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 408.1013, found 408.1024. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 3.81 (s, 3H), 4.18 (s, 3H), 5.16 (s, 2H), 6.37 (d, <i>J</i> = 1.75 Hz, 1H), 6.67 (broad s, 1H), 7.07 (s, 1H), 7.31 (broad t, 1H), 7.37 (broad t, 2H), 7.45 (broad d, 2H), 7.81 (s, 1H). Purity: >99% (method H; <i>t</i><sub>R</sub> = 2.1 min).</div></div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 6-Methoxy-2-(2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazol-6-yl)benzofuran-4-ol (<b>35</b>)</h3><div class="NLM_p last">A mixture of <b>34</b> (1.250 g, 3.06 mmol) and pentamethylbenzene (3.17 g, 21.4 mmol) in dichloromethane (200 mL) was cooled to −78 °C under a nitrogen atmosphere and then treated immediately (to avoid crystallization) with 8 mL (8 mmol) of a 1 M solution of boron trichloride in dichloromethane, added dropwise over 3 min. The resulting mixture was stirred at −78 °C for 1 h. The reaction mixture was then quenched by the addition of a solution of sodium bicarbonate (6 g) in water (100 mL) added in one portion. The cooling bath was removed, and the resulting mixture was stirred at room temperature for 1 h. The solid formed was filtered and washed successively with water (50 mL) and dichloromethane (50 mL). The filter cake was allowed to soak with anhydrous ethanol (15 mL) and then sucked dry. The white solid obtained was then dried under vacuum for 24 h to give 0.788 g (80% yield) of a pure title material (>95% by HPLC). The combined filtrate and washings were diluted with dichloromethane (600 mL) and stirred in a warm water bath until the organic phase was clear with no apparent solid in suspension. The organic phase was collected, dried over anhydrous magnesium sulfate, and rapidly filtered while still warm. The filtrate was evaporated, the residue (product and pentamethylbenzene) was triturated with toluene (20 mL), and the solid collected and washed with toluene (20 mL) to give 0.186 g (19% yield, 99% combined yield) of <b>35</b> as a tan solid. HRMS (ESI) calcd for C<sub>14</sub>H<sub>12</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 318.0543, found 318.0578. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz) δ 3.71 (s, 3H), 4.16 (s, 3H), 6.21 (d, <i>J</i> = 1.87 Hz, 1H), 6.61 (broad s, 1H), 6.95 (s, 1H), 8.29 (s, 1H), 9.96 (s, 1H). Purity: >95% (method E; <i>t</i><sub>R</sub> = 2.0 min).</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> General Synthetic Method C: Mitsunobu Reaction with Compound <b>35</b></h3><div class="NLM_p last">A mixture of 6-methoxy-2-(2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazol-6-yl)benzofuran-4-ol (<b>35</b>) (0.100 g, 0.315 mmol), triphenylphosphine (1.2 equiv), and the selected alcohol (1.2 equiv) in anhydrous tetrahydrofuran (10 mL) and under nitrogen was treated at 23 °C with a solution of diisopropyl azodicarboxylate (1.2 equiv) in tetrahydrofuran (2 mL) added dropwise over 10 min. The heterogeneous mixture usually became homogeneous after 20 min (with sonication), and the reaction was complete by LC–MS analysis after 3 h. The reaction mixture was then diluted with dichloromethane, washed with brine, and dried over anhydrous magnesium sulfate. Evaporation of the solvent and chromatography of the residue on silica gel gave the coupled product in 40–80% yield. Alternatively in the Mitsunobu reaction, tri-<i>n</i>-butylphosphine (3.0 equiv ) and 1,1-(azodicarbonyl)dipiperidine (2.5 equiv ) were also used. Alkylation of the phenol 35 can also be done with a reactive benzyl bromide under conditions similar to those described for compound <b>32</b>, but both product and substrate appeared less stable under these basic conditions.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> 2-Methoxy-6-(6-methoxy-4-phenethoxybenzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>36</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 2-phenylethanol to give <b>36</b> (56% yield). MS (ESI): calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 422.1169, found 422.1222. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.37 (s, 1H), 7.37 (d, <i>J</i> = 7.65 Hz, 2H), 7.33 (t, <i>J</i> = 7.5 Hz, 2H), 7.23 (t, <i>J</i> = 7.2 Hz, 1H), 6.86 (s, 1H), 6.79 (s, 1H), 6.44 (s, 1H), 4.30 (t, <i>J</i> = 6.4 Hz, 2H), 4.20 (s, 3H), 3.79 (s, 3H), 3.10 (t, <i>J</i> = 6.4 Hz, 2H). Purity: >95% (method E; <i>t</i><sub>R</sub> = 2.4 min).</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 2-Methoxy-6-(6-methoxy-4-(2-phenoxyethoxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>37</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 2-phenoxylethanol to give <b>37</b>. MS (ESI): calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 418.1118, found 422.1135. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.39 (s, 1H), 7.32 (d, <i>J</i> = 8.5 Hz, 1H), 7.30 (d, <i>J</i> = 7.3 Hz, 1H), 7.02 (d, <i>J</i> = 7.9 Hz, 2H), 6.96 (t, <i>J</i> = 7.3 Hz, 1H), 6.91 (s, 1H), 6.84 (s, 1H), 6.51 (d, <i>J</i> = 1.8 Hz, 1H), 4.44–4.47 (m, 2H), 4.37–4.40 (m, 2H), 4.20 (s, 3H), 3.81 (s, 3H). Purity: >95% (method E; <i>t</i><sub>R</sub> = 2.3 min).</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 6-(4-(2-(Benzyloxy)ethoxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>38</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 2-(benzyloxy)ethanol to give <b>38</b>. MS (ESI): calcd for C<sub>23</sub>H<sub>22</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 452.1275, found 452.1317. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (s, 1H), 7.33–7.41 (m, 4H), 7.25–7.33 (m, 1H), 6.93 (s, 1H), 6.81 (s, 1H), 6.46 (s, 1H), 4.61 (s, 2H), 4.28 (t, <i>J</i> = 4.4 Hz, 2H), 4.20 (s, 3H), 3.83 (t, <i>J</i> = 4.4 Hz, 2H), 3.80 (s, 3H). Purity: >95% (method E; <i>t</i><sub>R</sub> = 2.6 min).</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 2-Methoxy-6-(6-methoxy-4-((2-methylbenzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>39</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 2-methylbenzyl alcohol to give <b>39</b> (75% yield). MS (ESI): calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 422.1175, found 422.1166. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.39 (s, 1H), 7.44–7.51 (m, 1H), 7.18–7.33 (m, 3H), 6.95 (s, 1H), 6.84 (s, 1H), 6.59 (d, <i>J</i> = 2.05 Hz, 1H), 5.23 (s, 2H), 4.20 (s, 3H), 3.81 (s, 3H), 2.36 (s, 3H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.4 min).</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 6-(4-((2-Chlorobenzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>40</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 2-chlorobenzyl alcohol to give <b>40</b>. MS (ESI): calcd for C<sub>21</sub>H<sub>17</sub>ClN<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 442.0623, found 442.0628. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (s, 1H), 7.64–7.71 (m, 1H), 7.54 (dd, <i>J</i> = 3.66, 5.71 Hz, 1H), 7.38–7.45 (m, 2H), 6.98 (s, 1H), 6.86 (br s, 1H), 6.55 (br s, 1H), 5.30 (s, 2H), 4.20 (s, 3H), 3.80 (s, 3H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.5 min).</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 2-Methoxy-6-(6-methoxy-4-((2-methoxybenzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>41</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 2-methoxybenzyl alcohol to give <b>41</b> (4.2 mg, 22%). MS (ESI): calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 438.1, found 437.9. Purity: 94% (method G; <i>t</i><sub>R</sub> = 2.3 min).</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 2-Methoxy-6-(6-methoxy-4-((2-(trifluoromethyl)benzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>42</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 2-(trifluoromethyl)benzyl alcohol to give <b>42</b> (2.0 mg, 8.4%). MS (ESI): calcd for C<sub>22</sub>H<sub>17</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 476.1, found 475.8. Purity: 89% (method G; <i>t</i><sub>R</sub> = 2.4 min).</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 6-(4-((3-Chlorobenzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>43</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 3-chlorobenzyl alcohol to give <b>43</b> (70% yield). LC–MS (ESI): calcd for C<sub>21</sub>H<sub>17</sub>ClN<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 442.0623, found 442.0583. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.82 (s, 1H), 7.46 (s, 1H), 7.28–7.32 (m, 3H), 7.07 (s, 1H), 6.68 (d, <i>J</i> = 0.93 Hz, 1H), 6.34 (d, <i>J</i> = 1.81 Hz, 1H), 5.13 (s, 2H), 4.18 (s, 3H), 3.81 (s, 3H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.4 min).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> 2-Methoxy-6-(6-methoxy-4-((3-methoxybenzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>44</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 3-methoxybenzyl alcohol to give <b>44</b> (2.8 mg, 10%). MS (ESI): calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m/z</i> 438.1, found 437.9. Purity: 85% (method G; <i>t</i><sub>R</sub> = 2.3 min).</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> 3-(((6-Methoxy-2-(2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)phenol (<b>45</b>)</h3><div class="NLM_p">Step 1: 6-Methoxy-2-(2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazol-6-yl)benzofuran-4-ol (<b>35</b>) was reacted with 3-(<i>tert</i>-butyldimethylsilyloxy)benzyl alcohol (Grieco, P. A.; Markworth, C J. Tetrahedron Lett. 1999, 40, 665–666) according to general synthetic method C to give 6-(4-((3-((<i>tert</i>-butyldimethylsilyl)oxy)benzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (61% yield). MS (ESI): calcd for C<sub>27</sub>H<sub>32</sub>N<sub>3</sub>O<sub>5</sub>SSi [M + H]<sup>+</sup><i>m</i>/<i>z</i> 538.1826, found 538.183. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.64 (s, 1H), 7.04 (t, <i>J</i> = 7.8 Hz, 1H), 6.86–6.88 (m, 2H), 6.74 (s, 1H), 6.60 (dd, <i>J</i> = 8.03, 1.84 Hz, 1H), 6.49 (s, 1H), 6.18 (d, <i>J</i> = 1.17 Hz, 1H), 4.94 (s, 2H), 4.01 (s, 3H), 3.63 (s, 3H), 0.78 (s, 9H), 0.00 (s, 6H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.7 min).</div><div class="NLM_p last">Step 2: A solution of 6-(4-((3-((<i>tert</i>-butyldimethylsilyl)oxy)benzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (0.115 g, 0.21 mmol) in tetrahydrofuran (6 mL) was treated at 23 °C with acetic acid (0.1 mL, 0.017 mmol) followed by tetrabutylammonium fluoride hydrate (0.20 g, 0.76 mmol) added in one portion. After 1.5 h, the reaction mixture was diluted with dichloromethane, washed with saturated aqueous sodium bicarbonate and brine, and dried over anhydrous magnesium sulfate. Evaporation of the solvent and chromatography of the residue on silica gel (gradient of ethyl acetate in dichloromethane) gave 0.069 g (77% yield) of compound <b>45</b> as a white solid. MS (ESI): calcd for C<sub>21</sub>H<sub>18</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 424.0962, found 424.0972. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 9.41 (s, 1H), 8.34 (s, 1H), 7.15 (t, <i>J</i> = 8.0 Hz, 1H), 6.93 (s, 1H), 6.84–6.87 (m, 2H), 6.77 (d, <i>J</i> = 0.83 Hz, 1H), 6.67 (d, <i>J</i> = 8.43 Hz, 1H), 6.45 (d, <i>J</i> = 1.8 Hz, 1H), 5.13 (s, 2H), 4.16 (s, 3H), 3.74 (s, 3H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.2 min).</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> (3-{[(6-Methoxy-2-{2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazol-6-yl}-1-benzofuran-4-yl)oxy]methyl}phenyl)methanol (<b>46</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 3-hydroxymethylbenzyl alcohol to give <b>46</b> (0.8 mg, 3.7%). MS (ESI): calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 438.1, found 437.8. Purity: >99% (method G; <i>t</i><sub>R</sub> = 1.9 min).</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> 3-(((6-Methoxy-2-(2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)benzonitrile (<b>47</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 3-(hydroxymethyl)benzonitrile to give <b>47</b> (74% yield). MS (ESI): calcd for C<sub>22</sub>H<sub>17</sub>N<sub>4</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 433.0965, found 433.0946. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.83 (s, 1H), 7.75 (s, 1H), 7.69 (d, <i>J</i> = 7.84 Hz, 1H), 7.60 (d, <i>J</i> = 7.7 Hz, 1H), 7.49 (t, <i>J</i> = 7.8 Hz, 1H), 7.05 (s, 1H), 6.70 (s, 1H), 6.32 (d, <i>J</i> = 1.74 Hz, 1H), 5.18 (s, 2H), 4.18 (s, 3H), 3.82 (s, 3H). Purity: >95% (method E; <i>t</i><sub>R</sub> = 2.3 min).</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> 2-Methoxy-6-(6-methoxy-4-((3-(trifluoromethyl)benzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>48</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 3-trifluoromethylbenzyl alcohol to give <b>48</b> (0.8 mg, 3% yield). MS (ESI): calcd for C<sub>22</sub>H<sub>17</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 476.1, found 476.0. Purity: 97% (method F; <i>t</i><sub>R</sub> = 3.5 min).</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> 2-Methoxy-6-(6-methoxy-4-((4-(trifluoromethyl)benzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>49</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 4-trifluoromethylbenzyl alcohol to give <b>49</b> (2.7 mg, 10% yield). MS (ESI): calcd for C<sub>22</sub>H<sub>17</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 476.1, found 476.0. Purity: 98.3% (method F; <i>t</i><sub>R</sub> = 3.5 min).</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> 6-(4-((4-Chlorobenzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>50</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 4-chlorobenzyl alcohol to give <b>50</b>. MS (ESI): calcd for C<sub>21</sub>H<sub>17</sub>ClN<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 442.0623, found 442.0628. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.39 (s, 1H), 7.54 (d, <i>J</i> = 8.35 Hz, 2H), 7.48 (d, <i>J</i> = 8.35 Hz, 2H), 6.98 (s, 1H), 6.83 (s, 1H), 6.51 (d, <i>J</i> = 2.05 Hz, 1H), 5.25 (s, 2H), 4.20 (s, 3H), 3.79 (s, 3H). Purity: 97% (method E; <i>t</i><sub>R</sub> = 2.4 min).</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> 2-Methoxy-6-(6-methoxy-4-((4-methoxybenzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>51</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 4-methoxybenzyl alcohol to give <b>51</b>. MS (ESI): calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 438.1119, found 438.1124. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (s, 1H), 7.43 (d, <i>J</i> = 8.79 Hz, 2H), 6.96 (d, <i>J</i> = 8.79 Hz, 2H), 6.93 (s, 1H), 6.81 (s, 1H), 6.52 (d, <i>J</i> = 2.05 Hz, 1H), 5.16 (s, 2H), 4.20 (s, 3H), 3.79 (s, 3H), 3.76 (s, 3H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.4 min).</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> 2-Methoxy-6-(6-methoxy-4-((3-phenoxybenzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>52</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 3-phenoxybenzyl alcohol to give <b>52</b> (66% yield). MS (ESI): calcd for C<sub>27</sub>H<sub>22</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 500.1275, found 500.127. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.81 (s, 1H), 7.3–7.34 (m, 3H), 7.19 (d, <i>J</i> = 7.62 Hz, 1H), 7.11 (s, 1H), 7.08 (t, <i>J</i> = 7.4 Hz, 1H), 7.03 (s, 1H), 7.01 (d, <i>J</i> = 7.72 Hz, 2H), 6.94 (dd, <i>J</i> = 8.08, 2.06 Hz, 1H), 6.67 (d, <i>J</i> = 0.92 Hz, 1H), 6.34 (d, <i>J</i> = 1.8 Hz, 1H), 5.13 (s, 2H), 4.18 (s, 3H), 3.81 (s, 3H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.5 min).</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> 2-Methoxy-6-(6-methoxy-4-((3-(phenylthio)benzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>53</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 3-(phenylthio)-benzenemethanol to give <b>53</b> (31% yield). MS (ESI): calcd for C<sub>27</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i> 516.1946, found 516.109. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.82 (s, 1H), 7.40 (s, 1H), 7.5–7.36 (m, 8H), 7.01 (s, 1H), 6.67 (d, <i>J</i> = 0.82 Hz, 1H), 6.32 (d, <i>J</i> = 1.76 Hz, 1H), 5.11 (s, 2H), 4.19 (s, 3H), 3.81 (s, 3H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.6 min).</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> 6-(4-((3-(Benzyloxy)benzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>54</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with 3-benzyloxybenzyl alcohol to give <b>54</b> (70% yield). HRMS (ESI) calcd for C<sub>28</sub>H<sub>24</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 514.1431, found 514.1406. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm, 3.79 (s, 3H), 4.19 (s, 3H), 5.12 (s, 2H), 5.22 (s, 2H), 6.51 (d, <i>J</i> = 1.57 Hz, 1H), 6.82 (s, 1H), 6.95–7.01 (m, 2H), 7.07 (d, <i>J</i> = 7.43 Hz, 1H), 7.15 (s, 1H), 7.32 (t, <i>J</i> = 7.83 Hz, 2H), 7.36–7.42 (m, 2H), 7.42–7.48 (m, 2H), 8.36 (s, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100.5 MHz) δ 55.68, 60.37, 69.16, 69.37, 88.84, 95.93, 97.94, 111.18, 112.28, 113.77, 114.13, 119.73, 127.67, 127.80, 128.40, 129.61, 134.42, 136.99, 138.54, 149.17, 151.71, 155.47, 158.45, 158.61, 169.41. Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.5 min).</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> 2-Methoxy-6-(6-methoxy-4-((3-(phenoxymethyl)benzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>55</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with (3-(phenoxymethyl)phenyl)methanol to give <b>55</b>. HRMS (ESI) calcd for C<sub>28</sub>H<sub>24</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 514.1431, found 514.1439. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 3.84 (s, 3H), 4.20 (s, 3H), 5.10 (s, 2H), 5.20 (s, 2H), 6.39 (d, <i>J</i> = 1.7 Hz, 1H), 6.70 (s, 1H), 6.95–7.0 (m, 3H), 7.09 (s, 1H), 7.28–7.31 (m, 2H), 7.41–7.45 (m, 3H), 7.55 (s, 1H), 7.84 (s, 1H). Purity: 95% (method E; <i>t</i><sub>R</sub> = 2.5 min).</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> 2-Methoxy-6-(6-methoxy-4-((3-phenethylbenzyl)oxy)benzofuran-2-yl)imidazo[2,1-<i>b</i>][1,3,4]thiadiazol (<b>56</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with (3-phenethylphenyl)methanol to give <b>56</b>. HRMS (ESI) calcd for C<sub>29</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 512.1639, found 512.165. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) δ 2.94 (s, 4H), 3.84 (s, 3H), 4.20 (s, 3H), 5.15 (s, 2H), 5.20 (s, 2H), 6.40 (s, 1H), 6.69 (s, 1H), 7.09 (s, 1H), 7.19–7.21 (m, 4H), 7.27–7.31 (m, 2H), 7.39 (d, <i>J</i> = 7.9 Hz, 2H), 7.84 (s, 1H). Purity: 95% (method E; <i>t</i><sub>R</sub> = 2.6 min).</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> 6-(4-((2-(Benzyloxy)benzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>57</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with (2-(benzyloxy)phenyl)methanol to give <b>57</b> (57% yield). MS (ESI): calcd for C<sub>28</sub>H<sub>24</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 514.1431, found 514.1448. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.81 (s, 1H), 7.55 (d, <i>J</i> = 7.4 Hz, 1H), 7.40 (d, <i>J</i> = 7.43 Hz, 2H), 7.34 (t, <i>J</i> = 7.5 Hz, 2H), 7.25–7.30 (m, 2H), 7.09 (s, 1H), 6.98 (t, 1H), 6.94 (d, <i>J</i> = 8.22 Hz, 1H), 6.66 (s, 1H), 6.41 (d, <i>J</i> = 1.51 Hz, 1H), 5.27 (s, 2H), 5.12 (s, 2H), 4.18 (s, 3H), 3.80 (s, 3H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.5 min).</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> 6-(4-((4-(Benzyloxy)benzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-<i>b</i>][1,3,4]thiadiazole (<b>58</b>)</h3><div class="NLM_p last">Prepared according to general synthetic method C with (4-(benzyloxy)phenyl)methanol to give <b>58</b> (44% yield). MS (ESI): calcd for C<sub>28</sub>H<sub>24</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup><i>m</i>/<i>z</i> 514.1431, found 514.1453. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.81 (s, 1H), 7.42 (d, <i>J</i> = 7.5 Hz, 2H), 7.36–7.38 (m, 4H), 7.31 (t, <i>J</i> = 7.2 Hz, 1H), 7.04 (s, 1H), 6.97 (d, <i>J</i> = 8.35 Hz, 2H), 6.66 (s, 1H), 6.38 (s, 1H), 5.09 (s, 2H), 5.07 (s, 2H), 4.18 (s, 3H), 3.82 (s, 3H). Purity: >99% (method E; <i>t</i><sub>R</sub> = 2.5 min).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i114"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00186" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60187" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60187" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00186" class="ext-link">10.1021/acs.jmedchem.9b00186</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Proton and carbon NMR spectra for compound <b>54</b>; single-crystal X-ray data for compound <b>4</b>; biotransformation studies of compounds <b>4</b> and <b>15</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_001.pdf">jm9b00186_si_001.pdf (406.07 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_002.csv">jm9b00186_si_002.csv (3.39 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00186" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">E. Scott Priestley</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span>; 
    <span>Present Address:
                        Bristol-Myers Squibb Research & Development, 350 Carter Road, Hopewell, New Jersey 08540, United States (T.J.F., J.J.H., R.R.W., R.M.L., and E.S.P.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8390-1143" title="Orcid link">http://orcid.org/0000-0001-8390-1143</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#592a3a362d2d77292b303c2a2d353c20193b342a773a3634"><span class="__cf_email__" data-cfemail="5625353922227826243f3325223a332f16343b257835393b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anne Marinier</span> - <span class="hlFld-Affiliation affiliation">Institute
for Research in Immunology and Cancer, Université
de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#187976767d3675796a7176717d6a587b707175717d36716a717b367b79"><span class="__cf_email__" data-cfemail="b6d7d8d8d398dbd7c4dfd8dfd3c4f6d5dedfdbdfd398dfc4dfd598d5d7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael M. Miller</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span>; 
    <span>Present Address:
                        Bristol-Myers Squibb Research & Development, 3551 Lawrenceville Road, Princeton, New Jersey 08540, United States (M.M.M. and D.A.S.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacques Banville</span> - <span class="hlFld-Affiliation affiliation">Institute
for Research in Immunology and Cancer, Université
de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Todd J. Friends</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span>; 
    <span>Present Address:
                        Bristol-Myers Squibb Research & Development, 350 Carter Road, Hopewell, New Jersey 08540, United States (T.J.F., J.J.H., R.R.W., R.M.L., and E.S.P.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Gagnon</span> - <span class="hlFld-Affiliation affiliation">Institute
for Research in Immunology and Cancer, Université
de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jon J. Hangeland</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span>; 
    <span>Present Address:
                        Bristol-Myers Squibb Research & Development, 350 Carter Road, Hopewell, New Jersey 08540, United States (T.J.F., J.J.H., R.R.W., R.M.L., and E.S.P.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8234-8857" title="Orcid link">http://orcid.org/0000-0002-8234-8857</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-François Lavallée</span> - <span class="hlFld-Affiliation affiliation">Institute
for Research in Immunology and Cancer, Université
de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alain Martel</span> - <span class="hlFld-Affiliation affiliation">Institute
for Research in Immunology and Cancer, Université
de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harold O’Grady</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roger Rémillard</span> - <span class="hlFld-Affiliation affiliation">Institute
for Research in Immunology and Cancer, Université
de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward Ruediger</span> - <span class="hlFld-Affiliation affiliation">Institute
for Research in Immunology and Cancer, Université
de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">François Tremblay</span> - <span class="hlFld-Affiliation affiliation">Institute
for Research in Immunology and Cancer, Université
de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shana L. Posy</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research & Development, 3551 Lawrenceville Road, Princeton, New Jersey 08540, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nick J. Allegretto</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor R. Guarino</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David G. Harden</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research & Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        Bristol-Myers Squibb Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States (D.G.H.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy W. Harper</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Hartl</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan Josephs</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah Malmstrom</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carol Watson</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanou Yang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ge Zhang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pancras Wong</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Yang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michel Bouvier</span> - <span class="hlFld-Affiliation affiliation">Institute
for Research in Immunology and Cancer, Université
de Montréal, P.O. Box 6128, Downtown Station, Montréal, Québec H3C 3J7, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Biochemistry and Molecular
Medicine, Université de Montréal, Montréal, Québec H3C 3J7, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1128-0100" title="Orcid link">http://orcid.org/0000-0003-1128-0100</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dietmar A. Seiffert</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span>; 
    <span>Present Address:
                        Bristol-Myers Squibb Research & Development, 3551 Lawrenceville Road, Princeton, New Jersey 08540, United States (M.M.M. and D.A.S.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ruth R. Wexler</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span>; 
    <span>Present Address:
                        Bristol-Myers Squibb Research & Development, 350 Carter Road, Hopewell, New Jersey 08540, United States (T.J.F., J.J.H., R.R.W., R.M.L., and E.S.P.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Michael Lawrence</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb
Research & Development, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States</span>; 
    <span>Present Address:
                        Bristol-Myers Squibb Research & Development, 350 Carter Road, Hopewell, New Jersey 08540, United States (T.J.F., J.J.H., R.R.W., R.M.L., and E.S.P.)</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.M.M. and J.B. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Many of the authors on this manuscript are employed by Bristol-Myers Squibb Co,., which provided funding for this research.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6920-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i119">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Prof. Phil Baran of The Scripps Research Institute for suggesting pentamethylbenzene as a cation scavenger for deprotection of <b>34</b>, during a consulting visit. The authors also thank Sylwia Stachura and Lauren Haque for the synthesis of several compounds disclosed in this manuscript in parallel synthesis libraries and Michael Galella for determining the X-ray crystal structure of compound <b>4</b>. Financial support for this research was provided by Bristol-Myers Squibb. The work also benefited from funding from the “Fonds pour un Québec Innovant et en Santé” from the Ministry of Economy, Science and Innovation of Québec.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ECAT</td><td class="NLM_def"><p class="first last">electrolytic carotid artery thrombosis</p></td></tr><tr><td class="NLM_term">FLIPR</td><td class="NLM_def"><p class="first last">fluorescent imaging plate reader</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">IDT</td><td class="NLM_def"><p class="first last">imidazo[2,1-<i>b</i>][1,3,4]-thiadiazole</p></td></tr><tr><td class="NLM_term">PAR</td><td class="NLM_def"><p class="first last">protease-activated receptor</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45484" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45484" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mozaffarian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozaffarian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnett, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaha, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ferranti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Després, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isasi, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissela, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisabeth, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magid, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohler, E. R.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muntner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolino, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumar, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaniappan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosamond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorlie, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towfighi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turan, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virani, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, M. B.</span></span>; <span class="NLM_contrib-group">on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee</span> <span> </span><span class="NLM_article-title">Heart disease and stroke statistics—2016 update: a report from the American Heart Association</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">e38</span>– <span class="NLM_lpage">e360</span>, <span class="refDoi"> DOI: 10.1161/cir.0000000000000350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1161%2Fcir.0000000000000350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=26673558" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2016&pages=e38-e360&author=D.+Mozaffarianauthor=D.+Mozaffarianauthor=A.+S.+Goauthor=D.+K.+Arnettauthor=M.+J.+Blahaauthor=M.+Cushmanauthor=S.+R.+Dasauthor=S.+de+Ferrantiauthor=J.-P.+Despr%C3%A9sauthor=H.+J.+Fullertonauthor=V.+J.+Howardauthor=M.+D.+Huffmanauthor=C.+R.+Isasiauthor=M.+C.+Jimenezauthor=S.+E.+Juddauthor=B.+M.+Kisselaauthor=J.+H.+Lichtmanauthor=L.+D.+Lisabethauthor=S.+Liuauthor=R.+H.+Mackayauthor=D.+J.+Magidauthor=D.+K.+McGuireauthor=E.+R.+Mohlerauthor=C.+S.+Moyauthor=P.+Muntnerauthor=M.+E.+Mussolinoauthor=K.+Nasirauthor=R.+W.+Neumarauthor=G.+Nicholauthor=L.+Palaniappanauthor=D.+K.+Pandeyauthor=M.+J.+Reevesauthor=C.+J.+Rodriguezauthor=W.+Rosamondauthor=P.+D.+Sorlieauthor=J.+Steinauthor=A.+Towfighiauthor=T.+N.+Turanauthor=S.+S.+Viraniauthor=D.+Wooauthor=R.+W.+Yehauthor=M.+B.+Turnerauthor=on+behalf+of+the+American+Heart+Association+Statistics+Committee+and+Stroke+Statistics+Subcommittee&title=Heart+disease+and+stroke+statistics%E2%80%942016+update%3A+a+report+from+the+American+Heart+Association&doi=10.1161%2Fcir.0000000000000350"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1161%2Fcir.0000000000000350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fcir.0000000000000350%26sid%3Dliteratum%253Aachs%26aulast%3DMozaffarian%26aufirst%3DD.%26aulast%3DMozaffarian%26aufirst%3DD.%26aulast%3DGo%26aufirst%3DA.%2BS.%26aulast%3DArnett%26aufirst%3DD.%2BK.%26aulast%3DBlaha%26aufirst%3DM.%2BJ.%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DS.%2BR.%26aulast%3Dde%2BFerranti%26aufirst%3DS.%26aulast%3DDespr%25C3%25A9s%26aufirst%3DJ.-P.%26aulast%3DFullerton%26aufirst%3DH.%2BJ.%26aulast%3DHoward%26aufirst%3DV.%2BJ.%26aulast%3DHuffman%26aufirst%3DM.%2BD.%26aulast%3DIsasi%26aufirst%3DC.%2BR.%26aulast%3DJimenez%26aufirst%3DM.%2BC.%26aulast%3DJudd%26aufirst%3DS.%2BE.%26aulast%3DKissela%26aufirst%3DB.%2BM.%26aulast%3DLichtman%26aufirst%3DJ.%2BH.%26aulast%3DLisabeth%26aufirst%3DL.%2BD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMackay%26aufirst%3DR.%2BH.%26aulast%3DMagid%26aufirst%3DD.%2BJ.%26aulast%3DMcGuire%26aufirst%3DD.%2BK.%26aulast%3DMohler%26aufirst%3DE.%2BR.%26aulast%3DMoy%26aufirst%3DC.%2BS.%26aulast%3DMuntner%26aufirst%3DP.%26aulast%3DMussolino%26aufirst%3DM.%2BE.%26aulast%3DNasir%26aufirst%3DK.%26aulast%3DNeumar%26aufirst%3DR.%2BW.%26aulast%3DNichol%26aufirst%3DG.%26aulast%3DPalaniappan%26aufirst%3DL.%26aulast%3DPandey%26aufirst%3DD.%2BK.%26aulast%3DReeves%26aufirst%3DM.%2BJ.%26aulast%3DRodriguez%26aufirst%3DC.%2BJ.%26aulast%3DRosamond%26aufirst%3DW.%26aulast%3DSorlie%26aufirst%3DP.%2BD.%26aulast%3DStein%26aufirst%3DJ.%26aulast%3DTowfighi%26aufirst%3DA.%26aulast%3DTuran%26aufirst%3DT.%2BN.%26aulast%3DVirani%26aufirst%3DS.%2BS.%26aulast%3DWoo%26aufirst%3DD.%26aulast%3DYeh%26aufirst%3DR.%2BW.%26aulast%3DTurner%26aufirst%3DM.%2BB.%26aulast%3D%26atitle%3DHeart%2520disease%2520and%2520stroke%2520statistics%25E2%2580%25942016%2520update%253A%2520a%2520report%2520from%2520the%2520American%2520Heart%2520Association%26jtitle%3DCirculation%26date%3D2016%26volume%3D133%26spage%3De38%26epage%3De360%26doi%3D10.1161%2Fcir.0000000000000350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eikelboom, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz, J. I.</span></span> <span> </span><span class="NLM_article-title">Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">e89S</span>– <span class="NLM_lpage">e119S</span>, <span class="refDoi"> DOI: 10.1378/chest.11-2293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1378%2Fchest.11-2293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=22315278" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2012&pages=e89S-e119S&author=J.+W.+Eikelboomauthor=J.+Hirshauthor=F.+A.+Spencerauthor=T.+P.+Baglinauthor=J.+I.+Weitz&title=Antiplatelet+drugs%3A+antithrombotic+therapy+and+prevention+of+thrombosis%2C+9th+ed%3A+American+College+of+Chest+Physicians+evidence-based+clinical+practice+guidelines&doi=10.1378%2Fchest.11-2293"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1378%2Fchest.11-2293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.11-2293%26sid%3Dliteratum%253Aachs%26aulast%3DEikelboom%26aufirst%3DJ.%2BW.%26aulast%3DHirsh%26aufirst%3DJ.%26aulast%3DSpencer%26aufirst%3DF.%2BA.%26aulast%3DBaglin%26aufirst%3DT.%2BP.%26aulast%3DWeitz%26aufirst%3DJ.%2BI.%26atitle%3DAntiplatelet%2520drugs%253A%2520antithrombotic%2520therapy%2520and%2520prevention%2520of%2520thrombosis%252C%25209th%2520ed%253A%2520American%2520College%2520of%2520Chest%2520Physicians%2520evidence-based%2520clinical%2520practice%2520guidelines%26jtitle%3DChest%26date%3D2012%26volume%3D141%26spage%3De89S%26epage%3De119S%26doi%3D10.1378%2Fchest.11-2293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dridi, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmvang, L.</span></span> <span> </span><span class="NLM_article-title">Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology</span>. <i>Cardiovasc. Drugs Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1007/s10557-013-6444-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1007%2Fs10557-013-6444-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23380983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12rsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=239-245&author=P.+Clemmensenauthor=N.+P.+Dridiauthor=L.+Holmvang&title=Dual+antiplatelet+therapy+with+prasugrel+or+ticagrelor+versus+clopidogrel+in+interventional+cardiology&doi=10.1007%2Fs10557-013-6444-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Antiplatelet Therapy with Prasugrel or Ticagrelor Versus Clopidogrel in Interventional Cardiology</span></div><div class="casAuthors">Clemmensen, Peter; Dridi, Nadia Paarup; Holmvang, Lene</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drugs and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-245</span>CODEN:
                <span class="NLM_cas:coden">CDTHET</span>;
        ISSN:<span class="NLM_cas:issn">0920-3206</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  For several years, clopidogrel plus aspirin has been the dual antiplatelet therapy (DAPT) of choice for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation.  More recently, prasugrel and ticagrelor have demonstrated greater efficacy than clopidogrel.  In TRITON-TIMI 38, the risk of TIMI major bleeding unrelated to coronary artery bypass graft (CABG) surgery was similar for prasugrel and clopidogrel after excluding subgroups with increased bleeding risk (previous stroke or transient ischemic event; age ≥75 years; wt. <60 kg).  In the PLATO trial, rates of TIMI major bleeding were similar for ticagrelor and clopidogrel, but ticagrelor was assocd. with a significantly higher rate of non-CABG-related TIMI major bleeding.  Current evidence suggests that prasugrel or ticagrelor plus aspirin should be the DAPT of choice in patients with ACS undergoing PCI unless they are at particularly high risk of bleeding.  No studies have yet compared prasugrel and ticagrelor in ACS patients, however prasugrel and ticagrelor have different side effect profiles, and the choice of agent should be made either as a default choice and/or on an individual patient basis.  Ongoing trials in ACS patients will increase the evidence base for new P2Y12 receptor inhibitors and help to establish the most effective DAPT regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3f27ZiuBAp7Vg90H21EOLACvtfcHk0li0L1_Sb7HHmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12rsrw%253D&md5=d519560540e6e74a84bb5423cd2d9558</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs10557-013-6444-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10557-013-6444-2%26sid%3Dliteratum%253Aachs%26aulast%3DClemmensen%26aufirst%3DP.%26aulast%3DDridi%26aufirst%3DN.%2BP.%26aulast%3DHolmvang%26aufirst%3DL.%26atitle%3DDual%2520antiplatelet%2520therapy%2520with%2520prasugrel%2520or%2520ticagrelor%2520versus%2520clopidogrel%2520in%2520interventional%2520cardiology%26jtitle%3DCardiovasc.%2520Drugs%2520Ther.%26date%3D2013%26volume%3D27%26spage%3D239%26epage%3D245%26doi%3D10.1007%2Fs10557-013-6444-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurbel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlinge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neely, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neely, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakaran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantry, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. T.</span></span>; <span class="NLM_contrib-group">TRILOGY ACS Platelet Function Substudy Investigators</span> <span> </span><span class="NLM_article-title">Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1785</span>– <span class="NLM_lpage">1794</span>, <span class="refDoi"> DOI: 10.1001/jama.2012.17312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1001%2Fjama.2012.17312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23117779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKisL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=1785-1794&author=P.+A.+Gurbelauthor=D.+Erlingeauthor=E.+M.+Ohmanauthor=B.+Neelyauthor=M.+Neelyauthor=S.+G.+Goodmanauthor=K.+Huberauthor=M.+Y.+Chanauthor=J.+H.+Cornelauthor=E.+Brownauthor=C.+Zhouauthor=J.+A.+Jakubowskiauthor=H.+D.+Whiteauthor=K.+A.+Foxauthor=D.+Prabhakaranauthor=P.+W.+Armstrongauthor=U.+S.+Tantryauthor=M.+T.+Roeauthor=TRILOGY+ACS+Platelet+Function+Substudy+Investigators&title=Platelet+function+during+extended+prasugrel+and+clopidogrel+therapy+for+patients+with+ACS+treated+without+revascularization%3A+the+TRILOGY+ACS+platelet+function+substudy&doi=10.1001%2Fjama.2012.17312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization. The TRILOGY ACS platelet function substudy</span></div><div class="casAuthors">Gurbel, Paul A.; Erlinge, David; Ohman, E. Magnus; Neely, Benjamin; Neely, Megan; Goodman, Shaun G.; Huber, Kurt; Chan, Mark Y.; Cornel, Jan H.; Brown, Eileen; Zhou, Chunmei; Jakubowski, Joseph A.; White, Harvey D.; Fox, Keith A. A.; Prabhakaran, Dorairaj; Armstrong, Paul W.; Tantry, Udaya S.; Roe, Matthew T.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1785-1794</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context. The relationship of platelet function testing measurements with outcomes in patients with acute coronary syndromes (ACS) initially managed medically without revascularization is unknown.  Objective. To characterize the differences and evaluate clin. outcomes assocd. with platelet reactivity among patients with ACS treated with clopidogrel or prasugrel.  Design, Setting, and Patients. Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel.  Of 9326 participants, 27.5% were included in a platelet function substudy: 1286 treated with prasugrel and 1278 treated with clopidogrel.  Interventions. Aspirin with either prasugrel (10 or 5 mg/d) or clopidogrel (75 mg/d); those 75 years or older and younger than 75 years but who weighed less than 60 kg received a 5-mg prasugrel maintenance dose.  Main Outcome Measures. Platelet reactivity, measured in P2Y12 reaction units (PRUs), was performed at baseline, at 2 h, and at 1, 3, 6, 12, 18, 24, and 30 mo after randomization.  The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke through 30 mo.  Results. Among participants younger than 75 years and weighing 60 kg or more, the median PRU values at 30 days were 64 (interquartile range [IQR], 33-128) in the prasugrel group vs 200 (IQR, 141-260) in the clopidogrel group (P < .001), a difference that persisted through all subsequent time points.  For participants younger than 75 years and weighing less than 60 kg, the median 30-day PRU values were 139 (IQR, 86-203) for the prasugrel group vs 209 (IQR, 148-283) for the clopidogrel group (P < .001), and for participants 75 years or older, the median PRU values were 164 (IQR, 105-216) for the prasugrel group vs 222 (IQR, 148-268) for the clopidogrel group (P < .001).  At 30 mo the rate of the primary efficacy end point was 17.2% (160 events) in the prasugrel group vs 18.9% (180 events) in the clopidogrel group (P = .29).  There were no significant differences in the continuous distributions of 30-day PRU values for participants with a primary efficacy end point event after 30 days (n = 214) compared with participants without an event (n = 1794; P = .07) and no significant relationship between the occurrence of the primary efficacy end point and continuous PRU values (adjusted hazard ratio [HR] for increase of 60 PRUs, 1.03; 95% CI, 0.96-1.11; P = .44).  Similar findings were obsd. with 30-day PRU cut points used to define high on-treatment platelet reactivity - PRU more than 208 (adjusted HR, 1.16; 95% CI, 0.89-1.52, P = .28) and PRU more than 230 (adjusted HR, 1.20; 95% CI, 0.90-1.61; P = .21).  Conclusions. Among patients with ACS without ST-segment elevation and initially managed without revascularization, prasugrel was assocd. with lower platelet reactivity than clopidogrel, irresp. of age, wt., and dose.  Among those in the platelet substudy, no significant differences existed between prasugrel vs clopidogrel in the occurrence of the primary efficacy end point through 30 mo and no significant assocn. existed between platelet reactivity and occurrence of ischemic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdFeyZN3FOLVg90H21EOLACvtfcHk0li1XvD3Vc7ynQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKisL3O&md5=b2a3a3dae92830c1da6526366ced1587</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Fjama.2012.17312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2012.17312%26sid%3Dliteratum%253Aachs%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26aulast%3DErlinge%26aufirst%3DD.%26aulast%3DOhman%26aufirst%3DE.%2BM.%26aulast%3DNeely%26aufirst%3DB.%26aulast%3DNeely%26aufirst%3DM.%26aulast%3DGoodman%26aufirst%3DS.%2BG.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DM.%2BY.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DH.%2BD.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DPrabhakaran%26aufirst%3DD.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DTantry%26aufirst%3DU.%2BS.%26aulast%3DRoe%26aufirst%3DM.%2BT.%26aulast%3D%26atitle%3DPlatelet%2520function%2520during%2520extended%2520prasugrel%2520and%2520clopidogrel%2520therapy%2520for%2520patients%2520with%2520ACS%2520treated%2520without%2520revascularization%253A%2520the%2520TRILOGY%2520ACS%2520platelet%2520function%2520substudy%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D1785%26epage%3D1794%26doi%3D10.1001%2Fjama.2012.17312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, M. J.</span></span> <span> </span><span class="NLM_article-title">Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1806</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1001/jama.2012.34011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1001%2Fjama.2012.34011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23117783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKisLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=1806-1808&author=M.+J.+Price&title=Measured+drug+effect+and+cardiovascular+outcomes+in+patients+receiving+platelet+P2Y12+receptor+antagonists%3A+clarifying+the+time+and+place+for+intensive+inhibition&doi=10.1001%2Fjama.2012.34011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition</span></div><div class="casAuthors">Price, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1806-1808</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfOCV5PV4gJrVg90H21EOLACvtfcHk0li1XvD3Vc7ynQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKisLjJ&md5=6b1b5e1a555d6dcb2bd2e1cf273570b8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.2012.34011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2012.34011%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DM.%2BJ.%26atitle%3DMeasured%2520drug%2520effect%2520and%2520cardiovascular%2520outcomes%2520in%2520patients%2520receiving%2520platelet%2520P2Y12%2520receptor%2520antagonists%253A%2520clarifying%2520the%2520time%2520and%2520place%2520for%2520intensive%2520inhibition%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D1806%26epage%3D1808%26doi%3D10.1001%2Fjama.2012.34011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakaran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardissino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boden, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzyllo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiva-Pons, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhomenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topacio, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlides, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudev, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkely, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbalan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinteza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLendon, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokhnygina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylward, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohman, E. M.</span></span>; <span class="NLM_contrib-group">TRILOGY ACS Investigators</span> <span> </span><span class="NLM_article-title">Prasugrel versus clopidogrel for acute coronary syndromes without revascularization</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1297</span>– <span class="NLM_lpage">1309</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1205512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1056%2FNEJMoa1205512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=22920930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFWksL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1297-1309&author=M.+T.+Roeauthor=P.+W.+Armstrongauthor=K.+A.+Foxauthor=H.+D.+Whiteauthor=D.+Prabhakaranauthor=S.+G.+Goodmanauthor=J.+H.+Cornelauthor=D.+L.+Bhattauthor=P.+Clemmensenauthor=F.+Martinezauthor=D.+Ardissinoauthor=J.+C.+Nicolauauthor=W.+E.+Bodenauthor=P.+A.+Gurbelauthor=W.+Ruzylloauthor=A.+J.+Dalbyauthor=D.+K.+McGuireauthor=J.+L.+Leiva-Ponsauthor=A.+Parkhomenkoauthor=S.+Gottliebauthor=G.+O.+Topacioauthor=C.+Hammauthor=G.+Pavlidesauthor=A.+R.+Goudevauthor=A.+Otoauthor=C.+D.+Tsengauthor=B.+Merkelyauthor=V.+Gasparovicauthor=R.+Corbalanauthor=M.+Cintezaauthor=R.+C.+McLendonauthor=K.+J.+Wintersauthor=E.+B.+Brownauthor=Y.+Lokhnyginaauthor=P.+E.+Aylwardauthor=K.+Huberauthor=J.+S.+Hochmanauthor=E.+M.+Ohmanauthor=TRILOGY+ACS+Investigators&title=Prasugrel+versus+clopidogrel+for+acute+coronary+syndromes+without+revascularization&doi=10.1056%2FNEJMoa1205512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel versus clopidogrel for acute coronary syndromes without revascularization</span></div><div class="casAuthors">Roe, Matthew T.; Armstrong, Paul W.; Fox, Keith A. A.; White, Harvey D.; Prabhakaran, Dorairaj; Goodman, Shaun G.; Cornel, Jan H.; Bhatt, Deepak L.; Clemmensen, Peter; Martinez, Felipe; Ardissino, Diego; Nicolau, Jose C.; Boden, William E.; Gurbel, Paul A.; Ruzyllo, Witold; Dalby, Anthony J.; McGuire, Darren K.; Leiva-Pons, Jose L.; Parkhomenko, Alexander; Gottlieb, Shmuel; Topacio, Gracita O.; Hamm, Christian; Pavlides, Gregory; Goudev, Assen R.; Oto, Ali; Tseng, Chuen-Den; Merkely, Bela; Gasparovic, Vladimir; Corbalan, Ramon; Cinteza, Mircea; McLendon, R. Craig; Winters, Kenneth J.; Brown, Eileen B.; Lokhnygina, Yuliya; Aylward, Philip E.; Huber, Kurt; Hochman, Judith S.; Ohman, E. Magnus</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1297-1309</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated.  Methods: In this double-blind, randomized trial, in a primary anal. involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 mo of treatment with prasugrel (10 mg daily) vs. clopidogrel (75 mg daily).  In a secondary anal. involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel vs. 75 mg of clopidogrel.  Results: At a median follow-up of 17 mo, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P = 0.21).  Similar results were obsd. in the overall population.  The prespecified anal. of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P = 0.04).  Rates of severe and intracranial bleeding were similar in the two groups in all age groups.  There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group.  Conclusions: Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSPwjePprYy7Vg90H21EOLACvtfcHk0lhrnztrrlukqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFWksL3K&md5=a6634ae5efa951bc11b56019ff980c5f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1205512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1205512%26sid%3Dliteratum%253Aachs%26aulast%3DRoe%26aufirst%3DM.%2BT.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DWhite%26aufirst%3DH.%2BD.%26aulast%3DPrabhakaran%26aufirst%3DD.%26aulast%3DGoodman%26aufirst%3DS.%2BG.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26aulast%3DBhatt%26aufirst%3DD.%2BL.%26aulast%3DClemmensen%26aufirst%3DP.%26aulast%3DMartinez%26aufirst%3DF.%26aulast%3DArdissino%26aufirst%3DD.%26aulast%3DNicolau%26aufirst%3DJ.%2BC.%26aulast%3DBoden%26aufirst%3DW.%2BE.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26aulast%3DRuzyllo%26aufirst%3DW.%26aulast%3DDalby%26aufirst%3DA.%2BJ.%26aulast%3DMcGuire%26aufirst%3DD.%2BK.%26aulast%3DLeiva-Pons%26aufirst%3DJ.%2BL.%26aulast%3DParkhomenko%26aufirst%3DA.%26aulast%3DGottlieb%26aufirst%3DS.%26aulast%3DTopacio%26aufirst%3DG.%2BO.%26aulast%3DHamm%26aufirst%3DC.%26aulast%3DPavlides%26aufirst%3DG.%26aulast%3DGoudev%26aufirst%3DA.%2BR.%26aulast%3DOto%26aufirst%3DA.%26aulast%3DTseng%26aufirst%3DC.%2BD.%26aulast%3DMerkely%26aufirst%3DB.%26aulast%3DGasparovic%26aufirst%3DV.%26aulast%3DCorbalan%26aufirst%3DR.%26aulast%3DCinteza%26aufirst%3DM.%26aulast%3DMcLendon%26aufirst%3DR.%2BC.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26aulast%3DBrown%26aufirst%3DE.%2BB.%26aulast%3DLokhnygina%26aufirst%3DY.%26aulast%3DAylward%26aufirst%3DP.%2BE.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DHochman%26aufirst%3DJ.%2BS.%26aulast%3DOhman%26aufirst%3DE.%2BM.%26aulast%3D%26atitle%3DPrasugrel%2520versus%2520clopidogrel%2520for%2520acute%2520coronary%2520syndromes%2520without%2520revascularization%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1297%26epage%3D1309%26doi%3D10.1056%2FNEJMoa1205512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collet, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuisset, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangé, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elhadad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouillot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motreff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrié, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boueri, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Belle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monségu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabouret, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abtan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerneis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Etienne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthélémy, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beygui, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicaut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalescot, G.</span></span>; <span class="NLM_contrib-group">ARCTIC Investigators</span> <span> </span><span class="NLM_article-title">Bedside monitoring to adjust antiplatelet therapy for coronary stenting</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">2100</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1209979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1056%2FNEJMoa1209979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23121439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyltrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2100-2109&author=J.-P.+Colletauthor=T.+Cuissetauthor=G.+Rang%C3%A9author=G.+Caylaauthor=S.+Elhadadauthor=C.+Pouillotauthor=P.+Henryauthor=P.+Motreffauthor=D.+Carri%C3%A9author=Z.+Boueriauthor=L.+Belleauthor=E.+Van+Belleauthor=H.+Rousseauauthor=P.+Aubryauthor=J.+Mons%C3%A9guauthor=P.+Sabouretauthor=S.+A.+O%E2%80%99Connorauthor=J.+Abtanauthor=M.+Kerneisauthor=C.+Saint-Etienneauthor=O.+Barth%C3%A9l%C3%A9myauthor=F.+Beyguiauthor=J.+Silvainauthor=E.+Vicautauthor=G.+Montalescotauthor=ARCTIC+Investigators&title=Bedside+monitoring+to+adjust+antiplatelet+therapy+for+coronary+stenting&doi=10.1056%2FNEJMoa1209979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Bedside monitoring to adjust antiplatelet therapy for coronary stenting</span></div><div class="casAuthors">Collet, Jean-Philippe; Cuisset, Thomas; Range, Gregoire; Cayla, Guillaume; Elhadad, Simon; Pouillot, Christophe; Henry, Patrick; Motreff, Pascal; Carrie, Didier; Boueri, Ziad; Belle, Loic; Van Belle, Eric; Rousseau, Helene; Aubry, Pierre; Monsegu, Jacques; Sabouret, Pierre; O'Connor, Stephen A.; Abtan, Jeremie; Kerneis, Mathieu; Saint-Etienne, Christophe; Barthelemy, Olivier; Beygui, Farzin; Silvain, Johanne; Vicaut, Eric; Montalescot, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2100-2109</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Patients' responses to oral antiplatelet therapy are subject to variation.  Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy.  METHODS We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment in patients who had a poor response to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment.  The primary end point was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 yr after stent implantation.  For patients in the monitoring group, the VerifyNow P2Y12 and aspirin point-of-care assays were used in the catheterization lab. before stent implantation and in the outpatient clinic 2 to 4 wk later.  RESULTS In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an addnl. bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure.  The primary end point occurred in 34.6% of the patients in the monitoring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval [CI], 0.98 to 1.29; P = 0.10).  The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional-treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P = 0.77).  The rate of major bleeding events did not differ significantly between groups.  CONCLUSIONS This study showed no significant improvements in clin. outcomes with platelet-function monitoring and treatment adjustment for coronary stenting, as compared with std. antiplatelet therapy without monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJgxC6EfcYPrVg90H21EOLACvtfcHk0lhrnztrrlukqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyltrvL&md5=7f75c29e6d4c25cef68fc44212af7d2f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209979%26sid%3Dliteratum%253Aachs%26aulast%3DCollet%26aufirst%3DJ.-P.%26aulast%3DCuisset%26aufirst%3DT.%26aulast%3DRang%25C3%25A9%26aufirst%3DG.%26aulast%3DCayla%26aufirst%3DG.%26aulast%3DElhadad%26aufirst%3DS.%26aulast%3DPouillot%26aufirst%3DC.%26aulast%3DHenry%26aufirst%3DP.%26aulast%3DMotreff%26aufirst%3DP.%26aulast%3DCarri%25C3%25A9%26aufirst%3DD.%26aulast%3DBoueri%26aufirst%3DZ.%26aulast%3DBelle%26aufirst%3DL.%26aulast%3DVan%2BBelle%26aufirst%3DE.%26aulast%3DRousseau%26aufirst%3DH.%26aulast%3DAubry%26aufirst%3DP.%26aulast%3DMons%25C3%25A9gu%26aufirst%3DJ.%26aulast%3DSabouret%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DS.%2BA.%26aulast%3DAbtan%26aufirst%3DJ.%26aulast%3DKerneis%26aufirst%3DM.%26aulast%3DSaint-Etienne%26aufirst%3DC.%26aulast%3DBarth%25C3%25A9l%25C3%25A9my%26aufirst%3DO.%26aulast%3DBeygui%26aufirst%3DF.%26aulast%3DSilvain%26aufirst%3DJ.%26aulast%3DVicaut%26aufirst%3DE.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3D%26atitle%3DBedside%2520monitoring%2520to%2520adjust%2520antiplatelet%2520therapy%2520for%2520coronary%2520stenting%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2100%26epage%3D2109%26doi%3D10.1056%2FNEJMoa1209979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brass, L. F.</span></span> <span> </span><span class="NLM_article-title">Thrombin and platelet activation</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">18S</span>– <span class="NLM_lpage">25S</span>, <span class="refDoi"> DOI: 10.1378/chest.124.3_suppl.18S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1378%2Fchest.124.3_suppl.18S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=12970120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVensLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2003&pages=18S-25S&author=L.+F.+Brass&title=Thrombin+and+platelet+activation&doi=10.1378%2Fchest.124.3_suppl.18S"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Thrombin and platelet activation</span></div><div class="casAuthors">Brass, Lawrence F.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3, Suppl.</span>),
    <span class="NLM_cas:pages">18S-25S</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">A review.  The accumulation of thrombin at sites of vascular injury provides 1 of the chief means for recruiting platelets into a growing hemostatic plug.  Studies completed over the past 10 yr show that platelet responses to thrombin are mediated by a subset of G protein-coupled receptors known as protease-activated receptors.  These receptors are activated on cleavage by thrombin, initiating the intracellular signaling events needed to transform mobile, non-adhesive platelets into cells that can participate in the growth of an immobile hemostatic plug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDuAPi0r-_GbVg90H21EOLACvtfcHk0lhrnztrrlukqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVensLs%253D&md5=67ced0996920b2d26ada7ea7bf5b6791</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1378%2Fchest.124.3_suppl.18S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.124.3_suppl.18S%26sid%3Dliteratum%253Aachs%26aulast%3DBrass%26aufirst%3DL.%2BF.%26atitle%3DThrombin%2520and%2520platelet%2520activation%26jtitle%3DChest%26date%3D2003%26volume%3D124%26spage%3D18S%26epage%3D25S%26doi%3D10.1378%2Fchest.124.3_suppl.18S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toschi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lettino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ortiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesebro, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badimon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemerson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuster, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badimon, J. J.</span></span> <span> </span><span class="NLM_article-title">Tissue factor modulates the thrombogenicity of human atherosclerotic plaques</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.95.3.594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1161%2F01.CIR.95.3.594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=9024145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVCisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1997&pages=594-599&author=V.+Toschiauthor=R.+Galloauthor=M.+Lettinoauthor=J.+T.+Fallonauthor=S.+D.+Gertzauthor=A.+Fernandez-Ortizauthor=J.+H.+Chesebroauthor=L.+Badimonauthor=Y.+Nemersonauthor=V.+Fusterauthor=J.+J.+Badimon&title=Tissue+factor+modulates+the+thrombogenicity+of+human+atherosclerotic+plaques&doi=10.1161%2F01.CIR.95.3.594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue factor modulates the thrombogenicity of human atherosclerotic plaques</span></div><div class="casAuthors">Toschi, Vincenzo; Gallo, Richard; Lettino, Maddalena; Fallon, John T.; Gertz, S. David; Fernandez-Ortiz, Antonio; Chesebro, James H.; Badimon, Lina; Nemerson, Yale; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">594-599</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">American Heart Association</span>)
        </div><div class="casAbstract">The thrombogenicity of a disrupted atherosclerotic lesion is dependent on the nature and extent of the plaque components exposed to flowing blood together with local rheol. and a variety of systemic factors.  The authors previously reported on the different thrombogenicity of the various types of human atherosclerotic lesions when exposed to flowing blood in a well-characterized perfusion system.  This study examines the role of tissue factor in the thrombogenicity of different types of atherosclerotic plaques and their components.  Fifty human arterial segments (5 foam cell-rich, 9 collagen-rich, and 10 lipid-rich atherosclerotic lesions and 26 normal, nonatherosclerotic segments) were exposed to heparinized blood at high shear rate conditions in the Badimon perfusion chamber.  The thrombogenicity of the arterial specimens was assessed by IIIIn-labeled platelets.  After perfusion, specimens were stained for tissue factor by use of an in situ binding assay for factor VIIa.  Tissue factor in specimens was semiquant. assessed on a scale of 0 to 3.  Platelet deposition on the lipid-rich atheromatous core was significantly higher than on all other substrates.  The lipid-rich core also exhibited the most intense tissue factor staining (3±0.1 arbitrary units) compared with other arterial components.  Comparison of all specimens showed a pos. correlation between quant. platelet deposition and tissue factor staining score (r=.35).  The results show that tissue factor is present in lipid-rich human atherosclerotic plaques and suggest that it is an important determinant of the thrombogenicity of human atherosclerotic lesions after spontaneous or mech. plaque disruption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfE7kYFCOU2bVg90H21EOLACvtfcHk0lieAk5Gd0Ging"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVCisL4%253D&md5=387140d483b5b6143142cd889e6857eb</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.95.3.594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.95.3.594%26sid%3Dliteratum%253Aachs%26aulast%3DToschi%26aufirst%3DV.%26aulast%3DGallo%26aufirst%3DR.%26aulast%3DLettino%26aufirst%3DM.%26aulast%3DFallon%26aufirst%3DJ.%2BT.%26aulast%3DGertz%26aufirst%3DS.%2BD.%26aulast%3DFernandez-Ortiz%26aufirst%3DA.%26aulast%3DChesebro%26aufirst%3DJ.%2BH.%26aulast%3DBadimon%26aufirst%3DL.%26aulast%3DNemerson%26aufirst%3DY.%26aulast%3DFuster%26aufirst%3DV.%26aulast%3DBadimon%26aufirst%3DJ.%2BJ.%26atitle%3DTissue%2520factor%2520modulates%2520the%2520thrombogenicity%2520of%2520human%2520atherosclerotic%2520plaques%26jtitle%3DCirculation%26date%3D1997%26volume%3D95%26spage%3D594%26epage%3D599%26doi%3D10.1161%2F01.CIR.95.3.594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Thrombin signalling and protease-activated receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/35025229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1038%2F35025229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=11001069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVSls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=258-264&author=S.+R.+Coughlin&title=Thrombin+signalling+and+protease-activated+receptors&doi=10.1038%2F35025229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Thrombin signalling and protease-activated receptors</span></div><div class="casAuthors">Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6801</span>),
    <span class="NLM_cas:pages">258-264</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 64 refs.  How does the coagulation protease thrombin regulate cellular behavior.  The protease-activated receptors (PARs) provide one answer.  In concert with the coagulation cascade, these receptors provide an elegant mechanism linking mech. information in the form of tissue injury or vascular leakage to cellular responses.  Roles for PARs are beginning to emerge in hemostasis and thrombosis, inflammation, and perhaps even blood vessel development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry0F_6k5PRO7Vg90H21EOLACvtfcHk0lieAk5Gd0Ging"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVSls7w%253D&md5=6fe64606d9f20fdc0688d5e76672f2b6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F35025229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35025229%26sid%3Dliteratum%253Aachs%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DThrombin%2520signalling%2520and%2520protease-activated%2520receptors%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D258%26epage%3D264%26doi%3D10.1038%2F35025229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faruqi, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">19728</span>– <span class="NLM_lpage">19734</span>, <span class="refDoi"> DOI: 10.1074/jbc.M909960199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1074%2Fjbc.M909960199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10779527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkslaht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=19728-19734&author=T.+R.+Faruqiauthor=E.+J.+Weissauthor=M.+J.+Shapiroauthor=W.+Huangauthor=S.+R.+Coughlin&title=Structure-function+analysis+of+protease-activated+receptor+4+tethered+ligand+peptides.+Determinants+of+specificity+and+utility+in+assays+of+receptor+function&doi=10.1074%2Fjbc.M909960199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function</span></div><div class="casAuthors">Faruqi, Tatjana R.; Weiss, Ethan J.; Shapiro, Michael J.; Huang, Wei; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">19728-19734</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Thrombin activates protease-activated receptors (PARs) by specific cleavage of their amino-terminal exodomains to unmask a tethered ligand that binds intramolecularly to the body of the receptor to effect transmembrane signaling.  Peptides that mimic such ligands are valuable as agonists for probing PAR function, but the tethered ligand peptide for PAR4, GYPGKF, lacks potency and is of limited utility.  In a structure-activity anal. of PAR4 peptides, AYPGKF was ∼10-fold more potent than GYPGKF and, unlike GYPGKF, elicited PAR4-mediated responses comparable in magnitude to those elicited by thrombin.  AYPGKF was relatively specific for PAR4 in part due to the tyrosine at position 2; substitution of phenylalanine or p-fluorophenylalanine at this position produced peptides that activated both PAR1 and PAR4.  Because human platelets express both PAR1 and PAR4, it might be desirable to inhibit both receptors.  Identifying a single agonist for both receptors raises the possibility that a single antagonist for both receptors might be developed.  The AYPGKF peptide is a useful new tool for probing PAR4 function.  For example, AYPGKF activated and desensitized PAR4 in platelets and, like thrombin, triggered phosphoinositide hydrolysis but not inhibition of adenylyl cyclase in PAR4-expressing cells.  The latter shows that, unlike PAR1, PAR4 couples to Gq and not Gi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJqqbRQv7g7Vg90H21EOLACvtfcHk0lhb61ENfczO1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkslaht70%253D&md5=219d9a016b747a408bea922e7192155f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M909960199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M909960199%26sid%3Dliteratum%253Aachs%26aulast%3DFaruqi%26aufirst%3DT.%2BR.%26aulast%3DWeiss%26aufirst%3DE.%2BJ.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DStructure-function%2520analysis%2520of%2520protease-activated%2520receptor%25204%2520tethered%2520ligand%2520peptides.%2520Determinants%2520of%2520specificity%2520and%2520utility%2520in%2520assays%2520of%2520receptor%2520function%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D19728%26epage%3D19734%26doi%3D10.1074%2Fjbc.M909960199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammes, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: evidence for a novel mechanism for preventing or terminating signaling by PAR1’s tethered ligand</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2486</span>– <span class="NLM_lpage">2493</span>, <span class="refDoi"> DOI: 10.1021/bi982527i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi982527i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK1MXnsF2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=2486-2493&author=S.+R.+Hammesauthor=S.+R.+Coughlin&title=Protease-activated+receptor-1+can+mediate+responses+to+SFLLRN+in+thrombin-desensitized+cells%3A+evidence+for+a+novel+mechanism+for+preventing+or+terminating+signaling+by+PAR1%E2%80%99s+tethered+ligand&doi=10.1021%2Fbi982527i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Protease-Activated Receptor-1 Can Mediate Responses to SFLLRN in Thrombin-Desensitized Cells: Evidence for a Novel Mechanism for Preventing or Terminating Signaling by PAR1's Tethered Ligand</span></div><div class="casAuthors">Hammes, Stephen R.; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2486-2493</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The thrombin receptor PAR1 is activated when thrombin cleaves the receptor's amino-terminal exodomain to reveal the new N-terminal sequence SFLLRN which then acts as a tethered peptide ligand.  Free SFLLRN activates PAR1 independent of receptor cleavage and has been used to probe PAR1 function in various cells and tissues.  PAR1-expressing cells desensitized to thrombin retain responsiveness to SFLLRN.  Toward detg. the mechanism of such responses, we utilized fibroblasts derived from a PAR1-deficient mouse.  These cells were unresponsive to thrombin and SFLLRN and became sensitive to both ligands after transfection with human PAR1 cDNA.  Moreover, PAR1-transfected cells responded to SFLLRN after thrombin-desensitization, indicating that signaling of thrombin-desensitized cells to SFLLRN was mediated by PAR1 itself.  SFLLRN caused signaling in thrombin-desensitized cells when no uncleaved PAR1 was detectable on the cell surface; however, cleaved PAR1 was present.  To det. whether the cleaved receptors could still signal, fibroblasts were transfected with a PAR1 mutant contg. a trypsin site/SFLLRN sequence carboxyl terminal to the native thrombin site.  These cells retained responsiveness to trypsin after thrombin-desensitization.  Conversely, fibroblasts expressing a PAR1 mutant with the trypsin site/SFLLRN sequence amino terminal to the native thrombin site retained responsiveness to thrombin after trypsin-desensitization.  This suggests that a population of thrombin-cleaved PAR1 can respond both to exogenous SFLLRN and to a second tethered ligand.  In this population, the tethered ligand unmasked by thrombin cleavage must not be functional, suggesting the possibility of a novel mechanism of receptor shutoff involving sequestration or modification of the tethered ligand to prevent or terminate its function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7IY_MeOPstLVg90H21EOLACvtfcHk0lhb61ENfczO1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnsF2lsg%253D%253D&md5=430d9497d7ff88fc24eac18c4a06656c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fbi982527i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi982527i%26sid%3Dliteratum%253Aachs%26aulast%3DHammes%26aufirst%3DS.%2BR.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DProtease-activated%2520receptor-1%2520can%2520mediate%2520responses%2520to%2520SFLLRN%2520in%2520thrombin-desensitized%2520cells%253A%2520evidence%2520for%2520a%2520novel%2520mechanism%2520for%2520preventing%2520or%2520terminating%2520signaling%2520by%2520PAR1%25E2%2580%2599s%2520tethered%2520ligand%26jtitle%3DBiochemistry%26date%3D1999%26volume%3D38%26spage%3D2486%26epage%3D2493%26doi%3D10.1021%2Fbi982527i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tricoci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moliterno, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Werf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylward, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallentin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokhnygina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorick, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilian, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cequier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jukema, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoff, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalescot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfisterer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzyllo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinnaeve, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valgimigli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whellan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widimsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahaffey, K. W.</span></span> <span> </span><span class="NLM_article-title">Thrombin-receptor antagonist vorapaxar in acute coronary syndromes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1109719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1056%2FNEJMoa1109719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=22077816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=20-33&author=P.+Tricociauthor=Z.+Huangauthor=C.+Heldauthor=D.+J.+Moliternoauthor=P.+W.+Armstrongauthor=F.+Van+de+Werfauthor=H.+D.+Whiteauthor=P.+E.+Aylwardauthor=L.+Wallentinauthor=E.+Chenauthor=Y.+Lokhnyginaauthor=J.+Peiauthor=S.+Leonardiauthor=T.+L.+Rorickauthor=A.+M.+Kilianauthor=L.+H.+Jenningsauthor=G.+Ambrosioauthor=C.+Bodeauthor=A.+Cequierauthor=J.+H.+Cornelauthor=R.+Diazauthor=A.+Erkanauthor=K.+Huberauthor=M.+P.+Hudsonauthor=L.+Jiangauthor=J.+W.+Jukemaauthor=B.+S.+Lewisauthor=A.+M.+Lincoffauthor=G.+Montalescotauthor=J.+C.+Nicolauauthor=H.+Ogawaauthor=M.+Pfistererauthor=J.+C.+Prietoauthor=W.+Ruzylloauthor=P.+R.+Sinnaeveauthor=R.+F.+Storeyauthor=M.+Valgimigliauthor=D.+J.+Whellanauthor=P.+Widimskyauthor=J.+Stronyauthor=R.+A.+Harringtonauthor=K.+W.+Mahaffey&title=Thrombin-receptor+antagonist+vorapaxar+in+acute+coronary+syndromes&doi=10.1056%2FNEJMoa1109719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Thrombin-receptor antagonist vorapaxar in acute coronary syndromes</span></div><div class="casAuthors">Tricoci, Pierluigi; Huang, Zhen; Held, Claes; Moliterno, David J.; Armstrong, Paul W.; Van de Werf, Frans; White, Harvey D.; Aylward, Philip E.; Wallentin, Lars; Chen, Edmond; Lokhnygina, Yuliya; Pei, Jinglan; Leonardi, Sergio; Rorick, Tyrus L.; Kilian, Ann M.; Jennings, Lisa H. K.; Ambrosio, Giuseppe; Bode, Christoph; Cequier, Angel; Cornel, Jan H.; Diaz, Rafael; Erkan, Aycan; Huber, Kurt; Hudson, Michael P.; Jiang, Lixin; Jukema, J. Wouter; Lewis, Basil S.; Lincoff, A. Michael; Montalescot, Gilles; Nicolau, Jose Carlos; Ogawa, Hisao; Pfisterer, Matthias; Prieto, Juan Carlos; Ruzyllo, Witold; Sinnaeve, Peter R.; Storey, Robert F.; Valgimigli, Marco; Whellan, David J.; Widimsky, Petr; Strony, John; Harrington, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-33</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.  In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation.  The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization.  Follow-up in the trial was terminated early after a safety review.  After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar vs. 1102 of 6471 patients receiving placebo (Kaplan-Meier 2-yr rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P = 0.07).  A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients. in the vorapaxar group vs. 910 in the placebo group (14.7% and 16.4%, resp.; hazard ratio, 0.89; 95% CI, 0.81 to 0.98; P = 0.02).  Rates of moderate and severe bleeding were 7.2% in the vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; P < 0.001).  Intracranial hemorrhage rates were 1.1% and 0.2%, resp. (hazard ratio, 3.39; 95% CI, 1.78 to 6.45; P < 0.001).  Rates of nonhemorrhagic adverse events were similar in the two groups.  In patients with acute coronary syndromes, the addn. of vorapaxar to std. therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3g6zpddY-rLVg90H21EOLACvtfcHk0lgD3bplr5zxdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKit7c%253D&md5=8d75130f9c31dab2ee272c401da53aa8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1109719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1109719%26sid%3Dliteratum%253Aachs%26aulast%3DTricoci%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DHeld%26aufirst%3DC.%26aulast%3DMoliterno%26aufirst%3DD.%2BJ.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DVan%2Bde%2BWerf%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DH.%2BD.%26aulast%3DAylward%26aufirst%3DP.%2BE.%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DLokhnygina%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLeonardi%26aufirst%3DS.%26aulast%3DRorick%26aufirst%3DT.%2BL.%26aulast%3DKilian%26aufirst%3DA.%2BM.%26aulast%3DJennings%26aufirst%3DL.%2BH.%26aulast%3DAmbrosio%26aufirst%3DG.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DCequier%26aufirst%3DA.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DErkan%26aufirst%3DA.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DHudson%26aufirst%3DM.%2BP.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DJukema%26aufirst%3DJ.%2BW.%26aulast%3DLewis%26aufirst%3DB.%2BS.%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DNicolau%26aufirst%3DJ.%2BC.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DPfisterer%26aufirst%3DM.%26aulast%3DPrieto%26aufirst%3DJ.%2BC.%26aulast%3DRuzyllo%26aufirst%3DW.%26aulast%3DSinnaeve%26aufirst%3DP.%2BR.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DValgimigli%26aufirst%3DM.%26aulast%3DWhellan%26aufirst%3DD.%2BJ.%26aulast%3DWidimsky%26aufirst%3DP.%26aulast%3DStrony%26aufirst%3DJ.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26aulast%3DMahaffey%26aufirst%3DK.%2BW.%26atitle%3DThrombin-receptor%2520antagonist%2520vorapaxar%2520in%2520acute%2520coronary%2520syndromes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D20%26epage%3D33%26doi%3D10.1056%2FNEJMoa1109719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunwald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaca, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ameriso, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipka, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ophuis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolasso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scirica, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiviott, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. A.</span></span> <span> </span><span class="NLM_article-title">Vorapaxar in the secondary prevention of atherothrombotic events</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1200933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1056%2FNEJMoa1200933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=22443427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=1404-1413&author=D.+A.+Morrowauthor=E.+Braunwaldauthor=M.+P.+Bonacaauthor=S.+F.+Amerisoauthor=A.+J.+Dalbyauthor=M.+P.+Fishauthor=K.+A.+Foxauthor=L.+J.+Lipkaauthor=X.+Liuauthor=J.+C.+Nicolauauthor=A.+J.+Ophuisauthor=E.+Paolassoauthor=B.+M.+Sciricaauthor=J.+Spinarauthor=P.+Therouxauthor=S.+D.+Wiviottauthor=J.+Stronyauthor=S.+A.+Murphy&title=Vorapaxar+in+the+secondary+prevention+of+atherothrombotic+events&doi=10.1056%2FNEJMoa1200933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Vorapaxar in the secondary prevention of atherothrombotic events</span></div><div class="casAuthors">Morrow, David A.; Braunwald, Eugene; Bonaca, Marc P.; Ameriso, Sebastian F.; Dalby, Anthony J.; Fish, Mary Polly; Fox, Keith A. A.; Lipka, Leslie J.; Liu, Xuan; Nicolau, Jose Carlos; Oude Ophuis, A. J.; Paolasso, Ernesto; Scirica, Benjamin M.; Spinar, Jindrich; Theroux, Pierre; Wiviott, Stephen D.; Strony, John; Murphy, Sabina A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1404-1413</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Thrombin potently activates platelets through the protease-activated receptor PAR-1.  Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1.  We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 mo.  The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke.  After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage.  At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001).  Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P = 0.001).  Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001).  There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001).  Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving std. therapy.  However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvIsD7zdTXXbVg90H21EOLACvtfcHk0lgD3bplr5zxdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOrsLk%253D&md5=11e0c03c44b88b5e74583748a4f97a7c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200933%26sid%3Dliteratum%253Aachs%26aulast%3DMorrow%26aufirst%3DD.%2BA.%26aulast%3DBraunwald%26aufirst%3DE.%26aulast%3DBonaca%26aufirst%3DM.%2BP.%26aulast%3DAmeriso%26aufirst%3DS.%2BF.%26aulast%3DDalby%26aufirst%3DA.%2BJ.%26aulast%3DFish%26aufirst%3DM.%2BP.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DLipka%26aufirst%3DL.%2BJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DNicolau%26aufirst%3DJ.%2BC.%26aulast%3DOphuis%26aufirst%3DA.%2BJ.%26aulast%3DPaolasso%26aufirst%3DE.%26aulast%3DScirica%26aufirst%3DB.%2BM.%26aulast%3DSpinar%26aufirst%3DJ.%26aulast%3DTheroux%26aufirst%3DP.%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DStrony%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DS.%2BA.%26atitle%3DVorapaxar%2520in%2520the%2520secondary%2520prevention%2520of%2520atherothrombotic%2520events%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D1404%26epage%3D1413%26doi%3D10.1056%2FNEJMoa1200933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span> <i>Zontivity (Vorapaxar) [Package Insert]</i>; <span class="NLM_publisher-name">Merck Sharp & Dohme Corp.</span>: <span class="NLM_publisher-loc">Whitehouse
Station, NJ</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Zontivity+%28Vorapaxar%29+%5BPackage+Insert%5D%3B+Merck+Sharp+%26+Dohme+Corp.%3A+Whitehouse%0AStation%2C+NJ%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DZontivity%2520%2528Vorapaxar%2529%2520%255BPackage%2520Insert%255D%26pub%3DMerck%2520Sharp%2520%2526%2520Dohme%2520Corp%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiviott, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiolillo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalescot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeymer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylward, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guetta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziecina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contant, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flather, M. D.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1853</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.110.000786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1161%2FCIRCULATIONAHA.110.000786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=21502577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVynsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2011&pages=1843-1853&author=M.+L.+O%E2%80%99Donoghueauthor=D.+L.+Bhattauthor=S.+D.+Wiviottauthor=S.+G.+Goodmanauthor=D.+J.+Fitzgeraldauthor=D.+J.+Angiolilloauthor=S.+Gotoauthor=G.+Montalescotauthor=U.+Zeymerauthor=P.+E.+Aylwardauthor=V.+Guettaauthor=D.+Dudekauthor=R.+Ziecinaauthor=C.+F.+Contantauthor=M.+D.+Flather&title=Safety+and+tolerability+of+atopaxar+in+the+treatment+of+patients+with+acute+coronary+syndromes%3A+the+lessons+from+antagonizing+the+cellular+effects+of+Thrombin-Acute+Coronary+Syndromes+Trial&doi=10.1161%2FCIRCULATIONAHA.110.000786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes: The Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes Trial</span></div><div class="casAuthors">O'Donoghue, Michelle L.; Bhatt, Deepak L.; Wiviott, Stephen D.; Goodman, Shaun G.; Fitzgerald, Desmond J.; Angiolillo, Dominick J.; Goto, Shinya; Montalescot, Gilles; Zeymer, Uwe; Aylward, Philip E.; Guetta, Victor; Dudek, Dariusz; Ziecina, Rafal; Contant, Charles F.; Flather, Marcus D.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1843-1853</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Atopaxar (E5555) is a reversible protease-activated receptor-1 thrombin receptor antagonist that interferes with platelet signaling.  The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT-ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS.  603 Subjects were randomized within 72 h of non-ST-elevation ACS to 1 of 3 doses of atopaxar (400-mg loading dose followed by 50, 100, or 200 mg daily) or matching placebo.  The incidence of Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) major or minor bleeding did not differ significantly between the combined atopaxar and placebo groups (3.08% vs. 2.17%, resp.; P=0.63), and there was no dose-related trend (P=0.80).  The incidence of CURE major bleeding was numerically higher in the atopaxar group compared with the placebo group (1.8% vs. 0%; P=0.12).  The incidence of cardiovascular death, myocardial infarction, stroke, or recurrent ischemia was similar between the atopaxar and placebo arms (8.03% vs. 7.75%; P=0.93).  The incidence of CV death, MI, or stroke was 5.63% in the placebo group and 3.25% in the combined atopaxar group (P=0.20).  Dose-dependent trends for efficacy were not seen.  Atopaxar significantly reduced ischemia on continuous ECG monitoring (Holter) at 48 h compared with placebo (relative risk, 0.67; P=0.02).  Transient dose-dependent transaminase elevation and relative QTc prolongation were obsd. with the highest doses of atopaxar.  In patients after ACS, atopaxar significantly reduced early ischemia on Holter monitoring without a significant increase in major or minor bleeding.  Larger trials are required to fully establish the efficacy and safety of atopaxar.  Clin. TRIAL REGISTRATION-: URL: http://www.ClinicalTrials.gov.  Unique identifier: NCT00548587.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcFv8Lncggy7Vg90H21EOLACvtfcHk0lgD3bplr5zxdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVynsb8%253D&md5=3e3f75d17c6b78e4f2c19765e629acd3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.110.000786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.110.000786%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DM.%2BL.%26aulast%3DBhatt%26aufirst%3DD.%2BL.%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DGoodman%26aufirst%3DS.%2BG.%26aulast%3DFitzgerald%26aufirst%3DD.%2BJ.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DZeymer%26aufirst%3DU.%26aulast%3DAylward%26aufirst%3DP.%2BE.%26aulast%3DGuetta%26aufirst%3DV.%26aulast%3DDudek%26aufirst%3DD.%26aulast%3DZiecina%26aufirst%3DR.%26aulast%3DContant%26aufirst%3DC.%2BF.%26aulast%3DFlather%26aufirst%3DM.%2BD.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520atopaxar%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520acute%2520coronary%2520syndromes%253A%2520the%2520lessons%2520from%2520antagonizing%2520the%2520cellular%2520effects%2520of%2520Thrombin-Acute%2520Coronary%2520Syndromes%2520Trial%26jtitle%3DCirculation%26date%3D2011%26volume%3D123%26spage%3D1843%26epage%3D1853%26doi%3D10.1161%2FCIRCULATIONAHA.110.000786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiviott, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flather, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guetta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contant, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiolillo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, D. L.</span></span> <span> </span><span class="NLM_article-title">Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">1854</span>– <span class="NLM_lpage">1863</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.110.001404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1161%2FCIRCULATIONAHA.110.001404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=21502571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVynsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2011&pages=1854-1863&author=S.+D.+Wiviottauthor=M.+D.+Flatherauthor=M.+L.+O%E2%80%99Donoghueauthor=S.+Gotoauthor=D.+J.+Fitzgeraldauthor=F.+Curaauthor=P.+Aylwardauthor=V.+Guettaauthor=D.+Dudekauthor=C.+F.+Contantauthor=D.+J.+Angiolilloauthor=D.+L.+Bhatt&title=Randomized+trial+of+atopaxar+in+the+treatment+of+patients+with+coronary+artery+disease%3A+the+lessons+from+antagonizing+the+cellular+effect+of+Thrombin-Coronary+Artery+Disease+Trial&doi=10.1161%2FCIRCULATIONAHA.110.001404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease: The Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease Trial</span></div><div class="casAuthors">Wiviott, Stephen D.; Flather, Marcus D.; O'Donoghue, Michelle L.; Goto, Shinya; Fitzgerald, Desmond J.; Cura, Fernando; Aylward, Philip; Guetta, Victor; Dudek, Dariusz; Contant, Charles F.; Angiolillo, Dominick J.; Bhatt, Deepak L.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1854-1863</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Thrombin is a key mediator of platelet activation.  Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects.  The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examd. the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD.  Subjects with a qualifying history were randomized in a double-blind fashion to 3 dosing regimens of atopaxar (50, 100, or 200 mg daily) or matching placebo for 24 wk and followed up for an addnl. 4 wk.  The key safety end points were bleeding according to the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Thrombolysis in Myocardial Infarction (TIMI) classifications.  Secondary objectives included platelet aggregation and major adverse cardiac events.  720 Subjects were randomized.  Overall bleeding rates tended to be higher with atopaxar compared with placebo by CURE criteria (placebo, 0.6%; atopaxar, 3.9%; relative risk, 6.82, P=0.03; 50 mg, 3.9%; 100 mg, 1.7%; 200 mg, 5.9%; P for trend=0.01) and TIMI criteria (placebo, 6.8%; atopaxar, 10.3%; relative risk, 1.52, P=0.17; 50 mg, 9.9%; 100 mg, 8.1%; 200 mg, 12.9%; P for trend=0.07).  There was no difference in major bleeding.  Major adverse cardiac events were numerically lower in the atopaxar subjects.  All atopaxar regimens achieved high levels of platelet inhibition.  A transient elevation in liver transaminases and dose-dependent QTc prolongation without apparent complications were obsd. in higher-dose atopaxar treatment groups.  In this dose-ranging study of patients with CAD, treatment with atopaxar resulted in platelet inhibition, more minor bleeding, and numerically but not statistically fewer ischemic events.  Larger-scale trials are needed to det. whether these patterns translate into clin. meaningful effects.  Clin. TRIAL REGISTRATION-: URL: http://www.ClinicalTrials.gov.  Unique identifier: NCT00312052.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9dgWqGgNN8LVg90H21EOLACvtfcHk0ljMqX9iTaNN4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVynsbw%253D&md5=4e7fec4a660ef09121e0f6090cfcf86c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.110.001404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.110.001404%26sid%3Dliteratum%253Aachs%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DFlather%26aufirst%3DM.%2BD.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DM.%2BL.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DFitzgerald%26aufirst%3DD.%2BJ.%26aulast%3DCura%26aufirst%3DF.%26aulast%3DAylward%26aufirst%3DP.%26aulast%3DGuetta%26aufirst%3DV.%26aulast%3DDudek%26aufirst%3DD.%26aulast%3DContant%26aufirst%3DC.%2BF.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26aulast%3DBhatt%26aufirst%3DD.%2BL.%26atitle%3DRandomized%2520trial%2520of%2520atopaxar%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520coronary%2520artery%2520disease%253A%2520the%2520lessons%2520from%2520antagonizing%2520the%2520cellular%2520effect%2520of%2520Thrombin-Coronary%2520Artery%2520Disease%2520Trial%26jtitle%3DCirculation%26date%3D2011%26volume%3D123%26spage%3D1854%26epage%3D1863%26doi%3D10.1161%2FCIRCULATIONAHA.110.001404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brass, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalker, T. J.</span></span> <span> </span><span class="NLM_article-title">Minding the gaps to promote thrombus growth and stability</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3385</span>– <span class="NLM_lpage">3392</span>, <span class="refDoi"> DOI: 10.1172/JCI26869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1172%2FJCI26869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=16322784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=3385-3392&author=L.+F.+Brassauthor=L.+Zhuauthor=T.+J.+Stalker&title=Minding+the+gaps+to+promote+thrombus+growth+and+stability&doi=10.1172%2FJCI26869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Minding the gaps to promote thrombus growth and stability</span></div><div class="casAuthors">Brass, Lawrence F.; Zhu, Li; Stalker, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3385-3392</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Efforts to understand the role of platelets in hemostasis and thrombosis have largely focused on the earliest events of platelet activation, those that lead to aggregation.  Although much remains to be learned about those early events, this review examines a later series of events: the interactions between platelets that can only occur once aggregation has begun, bringing platelets into close contact with each other, creating a protected environment in the gaps between aggregated platelets, and fostering the continued growth and stability of the hemostatic plug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaZgDGfW0SbLVg90H21EOLACvtfcHk0ljMqX9iTaNN4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqtL3I&md5=edec92e6a129c209ae5f1a5130a32711</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1172%2FJCI26869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI26869%26sid%3Dliteratum%253Aachs%26aulast%3DBrass%26aufirst%3DL.%2BF.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DStalker%26aufirst%3DT.%2BJ.%26atitle%3DMinding%2520the%2520gaps%2520to%2520promote%2520thrombus%2520growth%2520and%2520stability%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D3385%26epage%3D3392%26doi%3D10.1172%2FJCI26869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gresele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcinelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momi, S.</span></span> <span> </span><span class="NLM_article-title">Potentiation and priming of platelet activation: a potential target for antiplatelet therapy</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2008.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.tips.2008.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=18539343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVGls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=352-360&author=P.+Greseleauthor=E.+Falcinelliauthor=S.+Momi&title=Potentiation+and+priming+of+platelet+activation%3A+a+potential+target+for+antiplatelet+therapy&doi=10.1016%2Fj.tips.2008.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation and priming of platelet activation: a potential target for antiplatelet therapy</span></div><div class="casAuthors">Gresele, Paolo; Falcinelli, Emanuela; Momi, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">352-360</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Ischemic cardiovascular events represent the leading cause of mortality and morbidity worldwide, and platelet aggregation and thrombus formation are the main effectors of acute arterial ischemic events.  Although antiplatelet therapy is the cornerstone of antithrombotic treatment of ischemic cardiovascular disorders, available antiplatelet agents have less than satisfactory efficacy; thus, the identification of novel potential target candidates for antiplatelet therapy is highly warranted.  Recent evidence suggests that several mols. that amplify the aggregation response of platelets to activating stimuli, which are either released by platelets (potentiating mols.) or present in the milieu before platelets get activated (primers), play a major role in pathol. thrombus formation without being significantly involved in primary haemostasis.  These mols. appear to be a particularly appealing novel potential pharmacol. target for antiplatelet therapy.  Here, we review the present knowledge on some mols. acting as potentiators or primers of platelet activation and discuss their possible pharmacol. modulation for antithrombotic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNl4_XDglcIrVg90H21EOLACvtfcHk0lhqd3nQMC4RIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVGls7o%253D&md5=13c32ce51fcd39c88c04540c1fc8ce75</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2008.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2008.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DGresele%26aufirst%3DP.%26aulast%3DFalcinelli%26aufirst%3DE.%26aulast%3DMomi%26aufirst%3DS.%26atitle%3DPotentiation%2520and%2520priming%2520of%2520platelet%2520activation%253A%2520a%2520potential%2520target%2520for%2520antiplatelet%2520therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D352%26epage%3D360%26doi%3D10.1016%2Fj.tips.2008.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi-Matsui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1172/JCI6042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1172%2FJCI6042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10079109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFarsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1999&pages=879-887&author=M.+L.+Kahnauthor=M.+Nakanishi-Matsuiauthor=M.+J.+Shapiroauthor=H.+Ishiharaauthor=S.+R.+Coughlin&title=Protease-activated+receptors+1+and+4+mediate+activation+of+human+platelets+by+thrombin&doi=10.1172%2FJCI6042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin</span></div><div class="casAuthors">Kahn, Mark L.; Nakanishi-Matsui, Mayumi; Shapiro, Michael J.; Ishihara, Hiroaki; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">879-887</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Because of the role of thrombin and platelets in myocardial infarction and other pathol. processes, identifying and blocking the receptors by which thrombin activates platelets has been an important goal.  Three protease-activated receptors (PARs) for thrombin - PAR1, PAR3, and PAR4 - are now known.  PAR1 functions in human platelets, and the recent observation that a PAR4-activating peptide activates human platelets suggests that PAR4 also acts in these cells.  Whether PAR1 and PAR4 account for activation of human platelets by thrombin, or whether PAR3 or still other receptors contribute, is unknown.  The authors have examd. the roles of PAR1, PAR3, and PAR4 in platelets.  PAR1 and PAR4 mRNA and protein were detected in human platelets.  Activation of either receptor was sufficient to trigger platelet secretion and aggregation.  Inhibition of PAR1 alone by antagonist, blocking antibody, or desensitization blocked platelet activation by 1 nM thrombin but only modestly attenuated platelet activation by 30 nM thrombin.  Inhibition of PAR4 alone using a blocking antibody had little effect at either thrombin concn.  Strikingly, simultaneous inhibition of both PAR1 and PAR4 virtually ablated platelet secretion and aggregation, even at 30 nM thrombin.  These observations suggest that PAR1 and PAR4 account for most, if not all, thrombin signaling in platelets and that antagonists that block these receptors might be useful antithrombotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp--YosyMXoerVg90H21EOLACvtfcHk0lhqd3nQMC4RIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFarsro%253D&md5=8156b7cef30813aa382918f94b351d25</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI6042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI6042%26sid%3Dliteratum%253Aachs%26aulast%3DKahn%26aufirst%3DM.%2BL.%26aulast%3DNakanishi-Matsui%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DIshihara%26aufirst%3DH.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DProtease-activated%2520receptors%25201%2520and%25204%2520mediate%2520activation%2520of%2520human%2520platelets%2520by%2520thrombin%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D103%26spage%3D879%26epage%3D887%26doi%3D10.1172%2FJCI6042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Covic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresser, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuliopulos, A.</span></span> <span> </span><span class="NLM_article-title">Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">5458</span>– <span class="NLM_lpage">5467</span>, <span class="refDoi"> DOI: 10.1021/bi9927078</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9927078" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3cXit1yjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=5458-5467&author=L.+Covicauthor=A.+L.+Gresserauthor=A.+Kuliopulos&title=Biphasic+kinetics+of+activation+and+signaling+for+PAR1+and+PAR4+thrombin+receptors+in+platelets&doi=10.1021%2Fbi9927078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Biphasic Kinetics of Activation and Signaling for PAR1 and PAR4 Thrombin Receptors in Platelets</span></div><div class="casAuthors">Covic, Lidija; Gresser, Amy L.; Kuliopulos, Athan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5458-5467</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Thrombin activates platelets in an ordered sequence of events that includes shape change, increase in cytoplasmic Ca2+, activation of the αIIbβ3 integrin, granule secretion, aggregation, and formation of a stable hemostatic plug.  Activation of this process has also been implicated in the pathogenesis of atherosclerosis, stroke, and thrombosis.  There are two identified thrombin-activated receptors on the surface of human platelets. PAR1 is a high-affinity thrombin receptor, and PAR4 is a low apparent affinity thrombin receptor of uncertain function.  The goal of these studies is to det. the kinetics of thrombin activation of PAR1 and PAR4 and to relate the individual inputs from each receptor to platelet Ca2+ signaling, secondary autocrine stimulation, and aggregation.  Using a combination of PAR-specific peptide ligands and anti-PAR1 reagents, we sepd. the biphasic thrombin Ca2+ response of platelets into two discrete components-a rapid spike response caused by PAR1, followed by a slower prolonged response from PAR4.  Despite having a 20-70-fold slower rate of activation, PAR4 produces the majority of the integrated Ca2+ signal that is sustained by the continuous presence of catalytically active thrombin. Surprisingly, PAR4 activation is much more effective than PAR1 activation in mounting secondary autocrine Ca2+ signals from secreted ADP.  The strong ADP response due to activated PAR4, however, requires prior activation of PAR1 as would normally occur during treatment of platelets with thrombin. Thus, the late signal generated by activated PAR4 is not redundant with the early signal from PAR1 and instead serves to greatly extend the high intracellular Ca2+ levels that support the late phase of the platelet aggregation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3W8JjBktbX7Vg90H21EOLACvtfcHk0lhqd3nQMC4RIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXit1yjsr0%253D&md5=8c79d7882a3052a9738be0a845aedbf5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fbi9927078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9927078%26sid%3Dliteratum%253Aachs%26aulast%3DCovic%26aufirst%3DL.%26aulast%3DGresser%26aufirst%3DA.%2BL.%26aulast%3DKuliopulos%26aufirst%3DA.%26atitle%3DBiphasic%2520kinetics%2520of%2520activation%2520and%2520signaling%2520for%2520PAR1%2520and%2520PAR4%2520thrombin%2520receptors%2520in%2520platelets%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D5458%26epage%3D5467%26doi%3D10.1021%2Fbi9927078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">9780</span>– <span class="NLM_lpage">9786</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=7683662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK3sXktVGlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=9780-9786&author=K.+Ishiiauthor=L.+Heinauthor=B.+Kobilkaauthor=S.+R.+Coughlin&title=Kinetics+of+thrombin+receptor+cleavage+on+intact+cells.+Relation+to+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling</span></div><div class="casAuthors">Ishii, Kenji; Hein, Lutz; Kobilka, Brian; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9780-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Thrombin, a protease generated at sites of vascular injury, signals cellular responses vital for hemostasis and thrombosis.  How thrombin, an enzyme rather than a classical ligand, effects graded and concn.-dependent responses in its target cells has been a long-standing question.  Thrombin activates its receptor by cleaving off an activation peptide to unmask a tethered peptide ligand.  The authors utilized a thrombin receptor with an epitope-tagged activation peptide to directly demonstrate thrombin receptor cleavage and to examine the kinetics of receptor activation on intact cells.  The rate of thrombin receptor cleavage was proportional to thrombin concn. over the physiol. range, but low thrombin concns. ultimately cleaved and activated all receptors.  Cumulative phosphoinositide hydrolysis in response to thrombin correlated precisely with cumulative receptor cleavage.  These data strongly suggest that each cleaved and activated thrombin receptor produces a quantum of phosphatidylinositol hydrolysis, then shuts off.  Surprisingly, this shut off occurred despite the continued presence of cleaved and activated receptors on the cell surface and at a time when the cells were refractory to thrombin but sensitive to agonist peptide, suggesting that a novel shut off mechanism may have evolved to deal with the tethered ligand.  Unlike the case with classical ligands, cells thus cannot detect differences in thrombin concns. as differences in fractional occupancy but rather must sense different rates of receptor activation.  Because each cleaved thrombin receptor generates a quantum of second messenger, the magnitude of the cell's response to thrombin must be detd. by the balance between rates of receptor activation and second messenger clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSs7Qk7D9ktLVg90H21EOLACvtfcHk0lhqd3nQMC4RIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVGlu7c%253D&md5=62f20291c541d308cedac61114511032</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DHein%26aufirst%3DL.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DKinetics%2520of%2520thrombin%2520receptor%2520cleavage%2520on%2520intact%2520cells.%2520Relation%2520to%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D9780%26epage%3D9786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span>; <span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Seiffert, D. A.</span>; <span class="NLM_string-name">Posy, S. L.</span>; <span class="NLM_string-name">Wong, P. C.</span>; <span class="NLM_string-name">Banville, J.</span>; <span class="NLM_string-name">Ruediger, E. H.</span>; <span class="NLM_string-name">Deon, D. H.</span>; <span class="NLM_string-name">Martel, A.</span>; <span class="NLM_string-name">Tremblay, F.</span>; <span class="NLM_string-name">Guy, J.</span>; <span class="NLM_string-name">Lavallee, J.-F.</span>; <span class="NLM_string-name">Gagnon, M.</span></span> <span> </span><span class="NLM_article-title">Imidazothiadiazole Derivatives as Protease Activated Receptor 4 (PAR4) Inhibitors</span>. PCT Int. Appl. <span class="NLM_patent">WO2013/163244</span>, Oct 31, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+M.+Lawrence&author=M.+M.+Miller&author=D.+A.+Seiffert&author=S.+L.+Posy&author=P.+C.+Wong&author=J.+Banville&author=E.+H.+Ruediger&author=D.+H.+Deon&author=A.+Martel&author=F.+Tremblay&author=J.+Guy&author=J.-F.+Lavallee&author=M.+Gagnon&title=Imidazothiadiazole+Derivatives+as+Protease+Activated+Receptor+4+%28PAR4%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26atitle%3DImidazothiadiazole%2520Derivatives%2520as%2520Protease%2520Activated%2520Receptor%25204%2520%2528PAR4%2529%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giancarli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banville, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priestley, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">eaaf5294</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaf5294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1126%2Fscitranslmed.aaf5294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=28053157" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&author=P.+C.+Wongauthor=D.+Seiffertauthor=J.+E.+Birdauthor=C.+A.+Watsonauthor=J.+S.+Bostwickauthor=M.+Giancarliauthor=N.+Allegrettoauthor=J.+Huaauthor=D.+Hardenauthor=J.+Guayauthor=M.+Callejoauthor=M.+M.+Millerauthor=R.+M.+Lawrenceauthor=J.+Banvilleauthor=J.+Guyauthor=B.+D.+Maxwellauthor=E.+S.+Priestleyauthor=A.+Marinierauthor=R.+R.+Wexlerauthor=M.+Bouvierauthor=D.+A.+Gordonauthor=W.+A.+Schumacherauthor=J.+Yang&title=Blockade+of+protease-activated+receptor-4+%28PAR4%29+provides+robust+antithrombotic+activity+with+low+bleeding&doi=10.1126%2Fscitranslmed.aaf5294"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaf5294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaf5294%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DSeiffert%26aufirst%3DD.%26aulast%3DBird%26aufirst%3DJ.%2BE.%26aulast%3DWatson%26aufirst%3DC.%2BA.%26aulast%3DBostwick%26aufirst%3DJ.%2BS.%26aulast%3DGiancarli%26aufirst%3DM.%26aulast%3DAllegretto%26aufirst%3DN.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DHarden%26aufirst%3DD.%26aulast%3DGuay%26aufirst%3DJ.%26aulast%3DCallejo%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%2BM.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DBanville%26aufirst%3DJ.%26aulast%3DGuy%26aufirst%3DJ.%26aulast%3DMaxwell%26aufirst%3DB.%2BD.%26aulast%3DPriestley%26aufirst%3DE.%2BS.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DSchumacher%26aufirst%3DW.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DBlockade%2520of%2520protease-activated%2520receptor-4%2520%2528PAR4%2529%2520provides%2520robust%2520antithrombotic%2520activity%2520with%2520low%2520bleeding%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26doi%3D10.1126%2Fscitranslmed.aaf5294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole analogues as novel antiplatelet agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3746</span>– <span class="NLM_lpage">3749</span>, <span class="refDoi"> DOI: 10.1021/jm010001h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010001h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntVyntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3746-3749&author=F.+Y.+Leeauthor=J.+C.+Lienauthor=L.+J.+Huangauthor=T.+M.+Huangauthor=S.+C.+Tsaiauthor=C.+M.+Tengauthor=C.+C.+Wuauthor=F.+C.+Chengauthor=S.+C.+Kuo&title=Synthesis+of+1-benzyl-3-%285%E2%80%B2-hydroxymethyl-2%E2%80%B2-furyl%29indazole+analogues+as+novel+antiplatelet+agents&doi=10.1021%2Fjm010001h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole Analogues as Novel Antiplatelet Agents</span></div><div class="casAuthors">Lee, Fang-Yu; Lien, Jin-Cherng; Huang, Li-Jiau; Huang, Tsang-Miao; Tsai, Sheng-Chung; Teng, Che-Ming; Wu, Chin-Chung; Cheng, Fong-Chi; Kuo, Sheng-Chu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3746-3749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (YC-1) was selected as the lead compd. for systemic structural modification.  After screening for antiplatelet activity, SARs of YC-1 analogs were established.  Several potent active derivs. functioned as potent activators of sGC and inhibitors of PDE5 with potency comparable to that of YC-1.  In addn., the indazole deriv. (I) was found to be a selective and potent inhibitor of protease-activated receptor type 4 (PAR4)-dependent platelet activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvq6NAuBVgbLVg90H21EOLACvtfcHk0lhohqzE1pyGiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntVyntLs%253D&md5=33c7e6ad37c20ce72b54e12a9fe4ff04</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm010001h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010001h%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLien%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DL.%2BJ.%26aulast%3DHuang%26aufirst%3DT.%2BM.%26aulast%3DTsai%26aufirst%3DS.%2BC.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DCheng%26aufirst%3DF.%2BC.%26aulast%3DKuo%26aufirst%3DS.%2BC.%26atitle%3DSynthesis%2520of%25201-benzyl-3-%25285%25E2%2580%25B2-hydroxymethyl-2%25E2%2580%25B2-furyl%2529indazole%2520analogues%2520as%2520novel%2520antiplatelet%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3746%26epage%3D3749%26doi%3D10.1021%2Fjm010001h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3</span>. <i>Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1026</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1055/s-0037-1613128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1055%2Fs-0037-1613128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=12083482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVyrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=1026-1033&author=C.+C.+Wuauthor=T.+L.+Hwangauthor=C.+H.+Liaoauthor=S.+C.+Kuoauthor=F.+Y.+Leeauthor=C.+Y.+Leeauthor=C.+M.+Teng&title=Selective+inhibition+of+protease-activated+receptor+4-dependent+platelet+activation+by+YD-3&doi=10.1055%2Fs-0037-1613128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3</span></div><div class="casAuthors">Wu, Chin-Chung; Hwang, Tsong-Long; Liao, Chang-Hui; Kuo, Sheng-Chu; Lee, Fang-Yu; Lee, Chun-Yann; Teng, Che-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1026-1033</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">In the present study, the antiplatelet effect and its mechanism of a new synthetic compd. YD-3 [1-benzyl-3-(ethoxycarbonylphenyl)-indazole] were examd.  YD-3 inhibited the aggregation of washed human platelets caused by protease-activated receptor (PAR) 4 agonist peptide GYPGKF (IC50=0.13±0.02 μM), but had no or little effect on that by thrombin, PAR1 agonist peptide SFLLRN, collagen or U46619.  YD-3 produced a parallel, rightward shift of the concn.-response curve for GYPGKF without decreasing of the max. platelet aggregation, indicating a competitive antagonism.  In contrast to human platelets, both thrombin- and GYPGKF-induced mouse platelet shape change and aggregation were completely inhibited by YD-3.  YD-3 also selectively prevented GYPGKF-induced intracellular Ca2+ mobilization in human platelets.  Furthermore, in the PAR1-desensitized human platelets, thrombin induced a relatively slow rise and decay of calcium mobilization that was significantly inhibited by YD-3.  In addn., the synergistic effect of SFLLRN and GYPGKF on platelet activation was prevented by YD-3.  YD-3 also inhibits both fMLP-stimulated neutrophil- and purified cathepsin G-induced platelet aggregation, which has been demonstrated to be PAR4-dependent.  Taken together, the authors' results suggest that YD-3 selectively inhibits PAR4-dependent platelet activation through blockade of PAR4.  To the best of the authors' knowledge, it is the first non-peptide PAR4 antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6z0pKOY8eOLVg90H21EOLACvtfcHk0lilThyVgPbUlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVyrur8%253D&md5=70096eac66d29ca5837d09b8179e39b5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-0037-1613128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0037-1613128%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DHwang%26aufirst%3DT.%2BL.%26aulast%3DLiao%26aufirst%3DC.%2BH.%26aulast%3DKuo%26aufirst%3DS.%2BC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BY.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DSelective%2520inhibition%2520of%2520protease-activated%2520receptor%25204-dependent%2520platelet%2520activation%2520by%2520YD-3%26jtitle%3DThromb.%2520Haemostasis%26date%3D2002%26volume%3D87%26spage%3D1026%26epage%3D1033%26doi%3D10.1055%2Fs-0037-1613128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1278</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.10.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.bmc.2007.10.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=17988878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvVWhurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=1262-1278&author=H.+S.+Chenauthor=S.+C.+Kuoauthor=C.+M.+Tengauthor=F.+Y.+Leeauthor=J.+P.+Wangauthor=Y.+C.+Leeauthor=C.+W.+Kuoauthor=C.+C.+Huangauthor=C.+C.+Wuauthor=L.+J.+Huang&title=Synthesis+and+antiplatelet+activity+of+ethyl+4-%281-benzyl-1H-indazol-3-yl%29benzoate+%28YD-3%29+derivatives&doi=10.1016%2Fj.bmc.2007.10.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives</span></div><div class="casAuthors">Chen, Hua-Sin; Kuo, Sheng-Chu; Teng, Che-Ming; Lee, Fang-Yu; Wang, Jih-Pyang; Lee, Yu-Chun; Kuo, Chiung-Wen; Huang, Ching-Che; Wu, Chin-Chung; Huang, Li-Jiau</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1262-1278</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Previously, Et 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) was identified by us as the first non-peptide protease-activated receptor 4 (PAR4) antagonist.  To continue on our development of novel anti-PAR4 agents, YD-3 was used as a lead compd. and a series of its derivs. were synthesized and evaluated for their selective anti-PAR4 activity.  Through structure-activity relation (SAR) study, we identified the important functional groups contributing to anti-PAR4 activity, and these functional groups were kept intact during subsequent structural modification.  Several new compds. with anti-PAR4 activity comparable to YD-3 were identified.  Among them, Et 4-[1-(3-chlorobenzyl)-1H-indazol-3-yl]benzoate (33) showed the most potent inhibitory effect on PAR4-mediated platelet aggregation, ATP release, and P-selectin expression.  Et 4-(1-phenyl-1H-indazol-3-yl)benzoate (83) exhibited dual inhibitory effects on PAR4 and thromboxane formation from arachidonic acid.  The above findings can be used as guidelines for development of novel antiplatelet drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR0NyhOUpKLbVg90H21EOLACvtfcHk0lilThyVgPbUlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvVWhurc%253D&md5=7007481512b165a350c22e9ff1c81fd2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.10.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.10.070%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BS.%26aulast%3DKuo%26aufirst%3DS.%2BC.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DKuo%26aufirst%3DC.%2BW.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DHuang%26aufirst%3DL.%2BJ.%26atitle%3DSynthesis%2520and%2520antiplatelet%2520activity%2520of%2520ethyl%25204-%25281-benzyl-1H-indazol-3-yl%2529benzoate%2520%2528YD-3%2529%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D1262%26epage%3D1278%26doi%3D10.1016%2Fj.bmc.2007.10.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.ejphar.2006.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=16890935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2006&pages=142-147&author=C.+C.+Wuauthor=C.+M.+Teng&title=Comparison+of+the+effects+of+PAR1+antagonists%2C+PAR4+antagonists%2C+and+their+combinations+on+thrombin-induced+human+platelet+activation&doi=10.1016%2Fj.ejphar.2006.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation</span></div><div class="casAuthors">Wu, Chin-Chung; Teng, Che-Ming</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">142-147</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Thrombin activates human platelets through proteolytic activation of two protease-activated receptors (PARs), PAR1 and PAR4.  In the present study, we show that, RWJ-56110, a potent synthetic PAR1 antagonist, inhibited platelet aggregation caused by a low concn. (0.05 U/mL) of thrombin, but lost its effectiveness when higher concns. of thrombin were used as stimulators.  YD-3, a non-peptide PAR4 antagonist, alone had little or no effect on thrombin-induced platelet aggregation, significantly enhanced the anti-aggregatory activity of PAR1 antagonist.  In addn., we demonstrate for the first time that P-selectin expression in thrombin-stimulated platelets can be synergistically prevented by combined treatment of PAR1 antagonist and PAR4 antagonist.  These results indicate that thrombin-induced platelet activation cannot be effectively inhibited by just blocking either single thrombin receptor pathway, and suggest a rationale for potential combination therapy in arterial thrombosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKcN_YPCaA1LVg90H21EOLACvtfcHk0lilThyVgPbUlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVWqtb0%253D&md5=838cd5155bbfdfac63ba00593fab5123</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520PAR1%2520antagonists%252C%2520PAR4%2520antagonists%252C%2520and%2520their%2520combinations%2520on%2520thrombin-induced%2520human%2520platelet%2520activation%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D546%26spage%3D142%26epage%3D147%26doi%3D10.1016%2Fj.ejphar.2006.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duvernay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gailani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenecker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, H. E.</span></span> <span> </span><span class="NLM_article-title">Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1124/mol.112.083477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1124%2Fmol.112.083477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23307185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVyrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=781-792&author=M.+Duvernayauthor=S.+Youngauthor=D.+Gailaniauthor=J.+Schoeneckerauthor=H.+E.+Hamm&title=Protease-activated+receptor+%28PAR%29+1+and+PAR4+differentially+regulate+factor+V+expression+from+human+platelets&doi=10.1124%2Fmol.112.083477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets</span></div><div class="casAuthors">Duvernay, Matthew; Young, Summer; Gailani, David; Schoenecker, Jonathan; Hamm, Heidi E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">781-792</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">With the recent interest of protease-activated receptors (PAR) 1 and PAR4 as possible targets for the treatment of thrombotic disorders, we compared the efficacy of protease-activated receptor (PAR)1 and PAR4 in the generation of procoagulant phenotypes on platelet membranes.  PAR4-activating peptide (AP)-stimulated platelets promoted thrombin generation in blood plasma ≤ 5 min earlier than PAR1-AP-stimulated platelets.  PAR4-AP-mediated factor V (FV) assocn. with the platelet surface was 1.6-fold greater than for PAR1-AP.  Moreover, PAR4 stimulation resulted in a 3-fold greater release of microparticles, compared with PAR1 stimulation.  More robust FV secretion and microparticle generation with PAR4-AP was attributable to stronger and more sustained phosphorylation of myosin light chain at serine 19 and threonine 18.  Inhibition of Rho-kinase reduced PAR4-AP-mediated FV secretion and microparticle generation to PAR1-AP-mediated levels.  Thrombin generation assays measuring prothrombinase complex activity demonstrated 1.5-fold higher peak thrombin levels on PAR4-AP-stimulated platelets, compared with PAR1-AP-stimulated platelets.  Rho-kinase inhibition reduced PAR4-AP-mediated peak thrombin generation by 25% but had no significant effect on PAR1-AP-mediated thrombin generation.  In conclusion, stimulation of PAR4 on platelets leads to faster and more robust thrombin generation, compared with PAR1 stimulation.  The greater procoagulant potential is related to more efficient FV release from intracellular stores and microparticle prodn. driven by stronger and more sustained myosin light chain phosphorylation.  These data have implications about the role of PAR4 during hemostasis and are clin. relevant in light of recent efforts to develop PAR antagonists to treat thrombotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ_MPN_hPiMbVg90H21EOLACvtfcHk0lilThyVgPbUlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVyrt74%253D&md5=f761c0b9bd433134454d9d765e3b392f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.083477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.083477%26sid%3Dliteratum%253Aachs%26aulast%3DDuvernay%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DGailani%26aufirst%3DD.%26aulast%3DSchoenecker%26aufirst%3DJ.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26atitle%3DProtease-activated%2520receptor%2520%2528PAR%2529%25201%2520and%2520PAR4%2520differentially%2520regulate%2520factor%2520V%2520expression%2520from%2520human%2520platelets%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D781%26epage%3D792%26doi%3D10.1124%2Fmol.112.083477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvernay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nance, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locuson, C. W.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span> <span> </span><span class="NLM_article-title">Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4708</span>– <span class="NLM_lpage">4713</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.bmcl.2014.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=25176330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlymu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4708-4713&author=W.+Wenauthor=S.+E.+Youngauthor=M.+T.+Duvernayauthor=M.+L.+Schulteauthor=K.+D.+Nanceauthor=B.+J.+Melanconauthor=J.+Engersauthor=C.+W.+Locusonauthor=M.+R.+Woodauthor=J.+S.+Danielsauthor=W.+Wuauthor=C.+W.+Lindsleyauthor=H.+E.+Hammauthor=S.+R.+Stauffer&title=Substituted+indoles+as+selective+protease+activated+receptor+4+%28PAR-4%29+antagonists%3A+Discovery+and+SAR+of+ML354&doi=10.1016%2Fj.bmcl.2014.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354</span></div><div class="casAuthors">Wen, Wandong; Young, Summer E.; Duvernay, Matthew T.; Schulte, Michael L.; Nance, Kellie D.; Melancon, Bruce J.; Engers, Julie; Locuson, Charles W.; Wood, Michael R.; Daniels, J. Scott; Wu, Wenjun; Lindsley, Craig W.; Hamm, Heidi E.; Stauffer, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4708-4713</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the authors report the discovery and SAR of an indole-based protease activated receptor-4 (PAR-4) antagonist scaffold derived from a similarity search of the Vanderbilt HTS collection, leading to MLPCN probe ML354 I (VU0099704).  Using a novel PAC-1 fluorescent αIIbβ3 activation assay this probe mol. antagonist was found to have an IC50 of 140 nM for PAR-4 with 71-fold selectivity vs. PAR-1 (IC50 = 10 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC3tSlcXaqorVg90H21EOLACvtfcHk0liAJpVvc4gHAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlymu7%252FM&md5=807c84160b474e255aa771989b24a73c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DS.%2BE.%26aulast%3DDuvernay%26aufirst%3DM.%2BT.%26aulast%3DSchulte%26aufirst%3DM.%2BL.%26aulast%3DNance%26aufirst%3DK.%2BD.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DEngers%26aufirst%3DJ.%26aulast%3DLocuson%26aufirst%3DC.%2BW.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26atitle%3DSubstituted%2520indoles%2520as%2520selective%2520protease%2520activated%2520receptor%25204%2520%2528PAR-4%2529%2520antagonists%253A%2520Discovery%2520and%2520SAR%2520of%2520ML354%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4708%26epage%3D4713%26doi%3D10.1016%2Fj.bmcl.2014.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temple, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvernay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blobaum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Development of a series of (1-benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanol as selective protease activated receptor 4 (PAR4) antagonists with in vivo utility and activity against γ-thrombin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7690</span>– <span class="NLM_lpage">7695</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00928</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KktLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7690-7695&author=K.+J.+Templeauthor=M.+T.+Duvernayauthor=S.+E.+Youngauthor=W.+Wenauthor=W.+Wuauthor=J.+G.+Maengauthor=A.+L.+Blobaumauthor=S.+R.+Staufferauthor=H.+E.+Hammauthor=C.+W.+Lindsley&title=Development+of+a+series+of+%281-benzyl-3-%286-methoxypyrimidin-3-yl%29-5-%28trifluoromethoxy%29-1H-indol-2-yl%29methanol+as+selective+protease+activated+receptor+4+%28PAR4%29+antagonists+with+in+vivo+utility+and+activity+against+%CE%B3-thrombin&doi=10.1021%2Facs.jmedchem.6b00928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin</span></div><div class="casAuthors">Temple, Kayla J.; Duvernay, Matthew T.; Young, Summer E.; Wen, Wandong; Wu, Wenjun; Maeng, Jae G.; Blobaum, Anna L.; Stauffer, Shaun R.; Hamm, Heidi E.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7690-7695</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we describe the development of a series of highly selective PAR4 antagonists with nanomolar potency and selectivity vs. PAR1, derived from the indole-based 3.  Of these, 9j (PAR4 IC50 = 445 nM, PAR1 response IC50 > 30 μM) and 10h (PAR4 IC50 = 179 nM, PAR1 response IC50 > 30 μM) maintained an overall favorable in vitro DMPK profile, encouraging rat/mouse in vivo pharmacokinetics (PK) and activity against γ-thrombin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfEoZDK2gsHbVg90H21EOLACvtfcHk0liAJpVvc4gHAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KktLrL&md5=ac0ecd5f66a8fb15c3c54a3099897856</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00928%26sid%3Dliteratum%253Aachs%26aulast%3DTemple%26aufirst%3DK.%2BJ.%26aulast%3DDuvernay%26aufirst%3DM.%2BT.%26aulast%3DYoung%26aufirst%3DS.%2BE.%26aulast%3DWen%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DMaeng%26aufirst%3DJ.%2BG.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDevelopment%2520of%2520a%2520series%2520of%2520%25281-benzyl-3-%25286-methoxypyrimidin-3-yl%2529-5-%2528trifluoromethoxy%2529-1H-indol-2-yl%2529methanol%2520as%2520selective%2520protease%2520activated%2520receptor%25204%2520%2528PAR4%2529%2520antagonists%2520with%2520in%2520vivo%2520utility%2520and%2520activity%2520against%2520%25CE%25B3-thrombin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7690%26epage%3D7695%26doi%3D10.1021%2Facs.jmedchem.6b00928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temple, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvernay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blobaum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5481</span>– <span class="NLM_lpage">5486</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.bmcl.2016.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=27777004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGitrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5481-5486&author=K.+J.+Templeauthor=M.+T.+Duvernayauthor=J.+G.+Maengauthor=A.+L.+Blobaumauthor=S.+R.+Staufferauthor=H.+E.+Hammauthor=C.+W.+Lindsley&title=Identification+of+the+minimum+PAR4+inhibitor+pharmacophore+and+optimization+of+a+series+of+2-methoxy-6-arylimidazo%5B2%2C1-b%5D%5B1%2C3%2C4%5Dthiadiazoles&doi=10.1016%2Fj.bmcl.2016.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles</span></div><div class="casAuthors">Temple, Kayla J.; Duvernay, Matthew T.; Maeng, Jae G.; Blobaum, Anna L.; Stauffer, Shaun R.; Hamm, Heidi E.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5481-5486</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This letter describes the further deconstruction of the known PAR4 inhibitor chemotypes (MWs 490-525 and with high plasma protein binding) to identify a min. PAR4 pharmacophore devoid of metabolic liabilities and improved properties.  This exercise identified a greatly simplified 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazole scaffold that afforded nanomolar inhibition of both activating peptide and γ-thrombin mediated PAR4 stimulation, while reducing both mol. wt. and the no. of hydrogen bond donors/acceptors by ∼50%.  This min. PAR4 pharmacophore, with competitive inhibition, vs. noncompetitive of the larger chemotypes, allows an ideal starting point to incorporate desired functional groups to engender optimal DMPK properties towards a preclin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-20ZEdJW3Z7Vg90H21EOLACvtfcHk0liP8N0xKW96fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGitrbO&md5=4e7987f4e906c1db0c912e7b157f181a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DTemple%26aufirst%3DK.%2BJ.%26aulast%3DDuvernay%26aufirst%3DM.%2BT.%26aulast%3DMaeng%26aufirst%3DJ.%2BG.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DIdentification%2520of%2520the%2520minimum%2520PAR4%2520inhibitor%2520pharmacophore%2520and%2520optimization%2520of%2520a%2520series%2520of%25202-methoxy-6-arylimidazo%255B2%252C1-b%255D%255B1%252C3%252C4%255Dthiadiazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5481%26epage%3D5486%26doi%3D10.1016%2Fj.bmcl.2016.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stables, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattheakis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, S.</span></span> <span> </span><span class="NLM_article-title">Recombinant aequorin as reporter of changes in intracellular calcium in mammalian cells</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1016/s0076-6879(00)27296-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fs0076-6879%2800%2927296-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=11045003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosFSjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2000&pages=456-471&author=J.+Stablesauthor=L.+C.+Mattheakisauthor=R.+Changauthor=S.+Rees&title=Recombinant+aequorin+as+reporter+of+changes+in+intracellular+calcium+in+mammalian+cells&doi=10.1016%2Fs0076-6879%2800%2927296-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Recombinant aequorin as reporter of changes in intracellular calcium in mammalian cells</span></div><div class="casAuthors">Stables, Jenny; Mattheakis, Larry C.; Chang, Ray; Rees, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">Applications of Chimeric Genes and Hybrid Proteins, Pt. B</span>),
    <span class="NLM_cas:pages">456-471</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The use of recombinant aequorin to detect changes in intracellular calcium concn. in mammalian cells after agonist activation of Gαq/11-coupled G protein-coupled receptors and after calcium entry through P2X family ion channels, is described.  In contrast to the use of single-tube luminometer for the detection of aequorin luminescence, the detection of aequorin luminescence in a 96-well microplate format, using either and injector luminometer or the fluorescence imaging plate reader, is described.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr7EZrdK0ScbVg90H21EOLACvtfcHk0liP8N0xKW96fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosFSjurs%253D&md5=198c54c9e5a1e9d4cfa089c9cec8c22b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fs0076-6879%2800%2927296-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0076-6879%252800%252927296-0%26sid%3Dliteratum%253Aachs%26aulast%3DStables%26aufirst%3DJ.%26aulast%3DMattheakis%26aufirst%3DL.%2BC.%26aulast%3DChang%26aufirst%3DR.%26aulast%3DRees%26aufirst%3DS.%26atitle%3DRecombinant%2520aequorin%2520as%2520reporter%2520of%2520changes%2520in%2520intracellular%2520calcium%2520in%2520mammalian%2520cells%26jtitle%3DMethods%2520Enzymol.%26date%3D2000%26volume%3D327%26spage%3D456%26epage%3D471%26doi%3D10.1016%2Fs0076-6879%2800%2927296-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soslau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Class, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jameson, B.</span></span> <span> </span><span class="NLM_article-title">Differential activation and inhibition of human platelet thrombin receptors by structurally distinct alpha-, beta- and gamma-thrombin</span>. <i>Platelets</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1080/0953710042000199848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1080%2F0953710042000199848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=15203717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=155-166&author=G.+Soslauauthor=S.+J.+Goldenbergauthor=R.+Classauthor=B.+Jameson&title=Differential+activation+and+inhibition+of+human+platelet+thrombin+receptors+by+structurally+distinct+alpha-%2C+beta-+and+gamma-thrombin&doi=10.1080%2F0953710042000199848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Differential activation and inhibition of human platelet thrombin receptors by structurally distinct α-, β- and γ-thrombin</span></div><div class="casAuthors">Soslau, Gerald; Goldenberg, Seth J.; Class, Reiner; Jameson, Bradford</div><div class="citationInfo"><span class="NLM_cas:title">Platelets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-166</span>CODEN:
                <span class="NLM_cas:coden">PLTEEF</span>;
        ISSN:<span class="NLM_cas:issn">0953-7104</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The development of drugs to neutralize the action of thrombin has to date focused on the α form of the protease.  It is generally agreed that inactive prothrombin is proteolytically converted to active α-thrombin which may be further hydrolyzed to β- and γ-thrombin.  While all three forms of the enzyme retain catalytic activities, only α-thrombin is presumed to be physiol. important.  The β- and γ-thrombin are presumed to be degrdn. products of no physiol. significance.  Our demonstration that β- and γ-thrombin selectively activate PAR-4 in this and a previous report (J. Biol. Chem. 276, 21173-21183, 2001) necessitates a reevaluation of how we view their physiol. roles and how we approach the pharmacol. regulation of their actions. β-Thrombin, like γ-thrombin, at nM levels selectively activates PAR-4.  This was demonstrated by full retention of aggregation activity with platelets whose PAR-1 and GP Ib receptors were inactivated.  Furthermore, the β-thrombin response was abrogated by desensitizing platelets with suboptimal levels of the thrombin receptor activating peptide for PAR-4 (TRAP-4).  For β-thrombin and γ-thrombin to have a physiol. role, it is necessary to show they can be generated under physiol. conditions.  We demonstrate, for the first time, that α-thrombin is hydrolyzed in less than 1 min by activated factor X at physiol. pH, in vitro.  This implies that α-thrombin may be rapidly converted to β-thrombin and/or γ-thrombin in vivo in the proper microenvironment.  The differential activation of the three platelet thrombin receptors by α-, β- and γ-thrombin implies selective structural variations between these thrombin species.  Structural differences are likely to account for the marked differential responses obsd. with the antithrombotic, hirudin, which inhibits α-thrombin, is a slightly weaker inhibitor of β- thrombin and a very weak inhibitor of γ-thrombin-induced platelet aggregations.  The converse order of inhibition is obsd. with the physiol. protease inhibitor, α1-antitrypsin.  Finally, a non-traditional inhibitor, histone-1, selectively inhibits only β- and γ-thrombin, primarily at the receptor level of PAR-4 rather than on the thrombin mol.  Trypsin, like β- and γ-thrombin, activates PAR-4 and is also inactive with TRAP-4 desensitized platelets.  Therefore, it was reasoned that trypsin would be more structurally similar to γ-thrombin than to α-thrombin.  The anal. of the cryst. structures of α-, γ-thrombin and trypsin from the databases confirm that this is the case. These findings should help to elucidate structure-function relationships of the different thrombins and may aid in the development of new anti-thrombotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxpHY2K-jlmrVg90H21EOLACvtfcHk0liP8N0xKW96fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFaqtb8%253D&md5=ecedd7128fccfadab6144131ac5bf651</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F0953710042000199848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F0953710042000199848%26sid%3Dliteratum%253Aachs%26aulast%3DSoslau%26aufirst%3DG.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DClass%26aufirst%3DR.%26aulast%3DJameson%26aufirst%3DB.%26atitle%3DDifferential%2520activation%2520and%2520inhibition%2520of%2520human%2520platelet%2520thrombin%2520receptors%2520by%2520structurally%2520distinct%2520alpha-%252C%2520beta-%2520and%2520gamma-thrombin%26jtitle%3DPlatelets%26date%3D2004%26volume%3D15%26spage%3D155%26epage%3D166%26doi%3D10.1080%2F0953710042000199848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamisuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizushina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanashima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramochi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, F.</span></span> <span> </span><span class="NLM_article-title">Total synthesis of dehydroaltenusin</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5695</span>– <span class="NLM_lpage">5700</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2004.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.tet.2004.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksl2ltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=5695-5700&author=S.+Kamisukiauthor=S.+Takahashiauthor=Y.+Mizushinaauthor=S.+Hanashimaauthor=K.+Kuramochiauthor=S.+Kobayashiauthor=K.+Sakaguchiauthor=T.+Nakataauthor=F.+Sugawara&title=Total+synthesis+of+dehydroaltenusin&doi=10.1016%2Fj.tet.2004.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of dehydroaltenusin</span></div><div class="casAuthors">Kamisuki, Shinji; Takahashi, Shunya; Mizushina, Yoshiyuki; Hanashima, Shinya; Kuramochi, Kouji; Kobayashi, Susumu; Sakaguchi, Kengo; Nakata, Tadashi; Sugawara, Fumio</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">5695-5700</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The first total synthesis of dehydroaltenusin (I), a natural enzyme inhibitor, is described.  The key step involves Suzuki-coupling reaction of an aryl triflate prepd. from 2,4,6-trihydroxybenzoic acid with a catechol-derived boronic acid or boronic ester.  The synthetic product was evaluated as a potent inhibitor against eukaryotic DNA polymerase α and other DNA polymerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjzEm062ZePbVg90H21EOLACvtfcHk0lg9T1qfDnc_HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksl2ltrk%253D&md5=8a3f4a9bc6da6c45db263eab6a799c53</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2004.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2004.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DKamisuki%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DMizushina%26aufirst%3DY.%26aulast%3DHanashima%26aufirst%3DS.%26aulast%3DKuramochi%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DSakaguchi%26aufirst%3DK.%26aulast%3DNakata%26aufirst%3DT.%26aulast%3DSugawara%26aufirst%3DF.%26atitle%3DTotal%2520synthesis%2520of%2520dehydroaltenusin%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26spage%3D5695%26epage%3D5700%26doi%3D10.1016%2Fj.tet.2004.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokuyama, H.</span></span> <span> </span><span class="NLM_article-title">Mild debenzylation of aryl benzyl ether with BCl<sub>3</sub> in the presence of pentamethylbenzene as a non-Lewis-basic cation scavenger</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_fpage">1977</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1077980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1055%2Fs-2008-1077980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvVOltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=1977-1980&author=K.+Okanoauthor=K.-i.+Okuyamaauthor=T.+Fukuyamaauthor=H.+Tokuyama&title=Mild+debenzylation+of+aryl+benzyl+ether+with+BCl3+in+the+presence+of+pentamethylbenzene+as+a+non-Lewis-basic+cation+scavenger&doi=10.1055%2Fs-2008-1077980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mild debenzylation of aryl benzyl ether with BCl3 in the presence of pentamethylbenzene as a non-Lewis-basic cation scavenger</span></div><div class="casAuthors">Okano, Kentaro; Okuyama, Kei-ichiro; Fukuyama, Tohru; Tokuyama, Hidetoshi</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1977-1980</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Scope and limitations of the debenzylation conditions for aryl benzyl ether, which was developed during our synthetic studies on yatakemycin, were investigated.  The chemoselective debenzylation proceeds at low temp. with a combination of BCl3 and pentamethylbenzene as a cation scavenger in the presence of various functional groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_5T9R_PvPQLVg90H21EOLACvtfcHk0lg9T1qfDnc_HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvVOltbk%253D&md5=18474e18d054ddd5d8c9a8b4b79a8703</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1077980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1077980%26sid%3Dliteratum%253Aachs%26aulast%3DOkano%26aufirst%3DK.%26aulast%3DOkuyama%26aufirst%3DK.-i.%26aulast%3DFukuyama%26aufirst%3DT.%26aulast%3DTokuyama%26aufirst%3DH.%26atitle%3DMild%2520debenzylation%2520of%2520aryl%2520benzyl%2520ether%2520with%2520BCl3%2520in%2520the%2520presence%2520of%2520pentamethylbenzene%2520as%2520a%2520non-Lewis-basic%2520cation%2520scavenger%26jtitle%3DSynlett%26date%3D2008%26spage%3D1977%26epage%3D1980%26doi%3D10.1055%2Fs-2008-1077980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crain, E. J.</span></span> <span> </span><span class="NLM_article-title">The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1007/s11239-015-1302-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1007%2Fs11239-015-1302-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=26660522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKjtr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=514-521&author=P.+C.+Wongauthor=C.+Watsonauthor=E.+J.+Crain&title=The+P2Y1+receptor+antagonist+MRS2500+prevents+carotid+artery+thrombosis+in+cynomolgus+monkeys&doi=10.1007%2Fs11239-015-1302-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys</span></div><div class="casAuthors">Wong, Pancras C.; Watson, Carol; Crain, Earl J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-521</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">ADP directly induces platelet aggregation via the G-protein coupled P2Y1 and P2Y12 receptors.  P2Y12, but not P2Y1, receptor antagonists are available in the clinic.  The relevance of the P2Y1 receptor as an antiplatelet target has been studied in rodents, but not in higher species.  We therefore examd. effects of the pharmacol. blockade of the P2Y1 receptor with its selective antagonist MRS2500 in monkey models of electrolytic-mediated arterial thrombosis (ECAT) and kidney bleeding time (KBT).  Abciximab, a GPIIb-IIIa antagonist, and cangrelor, a P2Y12 antagonist, were utilized to validate these monkey models.  Compds. were given IV at 15-60 min before thrombosis initiation in anesthetized monkeys.  SEM showed the luminal surface of thrombotic artery covered with platelet aggregates and fibrin network.  Administration of abciximab at 0.25 and 0.7 mg/kg IV significantly reduced thrombus wt. by 71 ± 1 and 100 ± 0 %, and increased KBT by 10.0 ± 0.1- and 10.1 ± 0-fold, resp. (n = 3/dose).  Likewise, cangrelor at 0.6 and 2 mg/kg/h IV significantly reduced thrombus wt. significantly by 72 ± 9 % and 100 ± 0 % and increased KBT by 2.1 ± 0.1- and 9.8 ± 0.2-fold, resp. (n = 3/dose).  MRS2500 [mg/kg + mg/kg/h IV] at 0.09 + 0.14 and 0.45 + 0.68 significantly reduced thrombus wt. by 57 ± 1 % and 88 ± 1 % and increased KBT by 2.1 ± 0.3- and 4.9 ± 0.6-fold, resp. (n = 4/dose).  In summary, MRS2500 prevented occlusive arterial thrombosis at a dose that moderately prolonged KBT, indicating a role of P2Y1 receptors in arterial thrombosis and hemostasis in monkeys.  Thus P2Y1 receptor antagonism provides a suitable target for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVE4lLaam5ebVg90H21EOLACvtfcHk0lg9T1qfDnc_HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKjtr7F&md5=9d498e412a43b8e2e3f20745ca6052bd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs11239-015-1302-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-015-1302-7%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DCrain%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520P2Y1%2520receptor%2520antagonist%2520MRS2500%2520prevents%2520carotid%2520artery%2520thrombosis%2520in%2520cynomolgus%2520monkeys%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2016%26volume%3D41%26spage%3D514%26epage%3D521%26doi%3D10.1007%2Fs11239-015-1302-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilchrist, M. A.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, D. G.</span></span> <span> </span><span class="NLM_article-title">Characterization of the 5-HT2b receptor in evaluation of aequorin detection of calcium mobilization for miniaturized GPCR high-throughput screening</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1177/1087057108319212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1177%2F1087057108319212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=18566482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1eitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=486-493&author=M.+A.+Gilchristauthor=A.+Cacaceauthor=D.+G.+Harden&title=Characterization+of+the+5-HT2b+receptor+in+evaluation+of+aequorin+detection+of+calcium+mobilization+for+miniaturized+GPCR+high-throughput+screening&doi=10.1177%2F1087057108319212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the 5-HT2b receptor in evaluation of aequorin detection of calcium mobilization for miniaturized GPCR high-throughput screening</span></div><div class="casAuthors">Gilchrist, Mark A., II; Cacace, Angela; Harden, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">486-493</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Fluorescent detection of calcium mobilization has been used successfully to identify modulators of G-protein-coupled receptors (GPCRs); however, inherent issues with fluorescence may limit its potential for high-throughput screening miniaturization.  The data presented here demonstrate that the calcium-sensitive photoprotein aequorin (AequoScreen), when compared with FLUO-4 in the same cellular background, allows for miniaturization of functional kinetic calcium flux assays, in which the rank order of potency and efficacy was maintained for a series of diverse small-mol. modulators.  Small-vol. (<10 μL) 384- and 1536-well aequorin assays were implemented by integration of acoustic dispensing (Echo 550) and kinetic flash luminometry (CyBi Lumax).  The enhanced high signal-to-background ratios obsd. relative to fluorescence were readily manipulated by altering per-well cell densities and yielded acceptable screening statistics in miniaturized format for both agonist and antagonist screening scenarios.  In addn., the authors demonstrate the feasibility of using agonist concns. less than EC50 in a miniaturized antagonist assay.  These features, coupled with improved sample handling, should enhance sensitivity and provide the benefits of miniaturization including cost redn. and throughput gains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHrqWdxyoUGLVg90H21EOLACvtfcHk0lg9T1qfDnc_HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1eitbY%253D&md5=9d691f835b35b74e06ec14b671671d12</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1177%2F1087057108319212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057108319212%26sid%3Dliteratum%253Aachs%26aulast%3DGilchrist%26aufirst%3DM.%2BA.%26aulast%3DCacace%26aufirst%3DA.%26aulast%3DHarden%26aufirst%3DD.%2BG.%26atitle%3DCharacterization%2520of%2520the%25205-HT2b%2520receptor%2520in%2520evaluation%2520of%2520aequorin%2520detection%2520of%2520calcium%2520mobilization%2520for%2520miniaturized%2520GPCR%2520high-throughput%2520screening%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2008%26volume%3D13%26spage%3D486%26epage%3D493%26doi%3D10.1177%2F1087057108319212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seiler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsueda, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernatowicz, M. S.</span></span> <span> </span><span class="NLM_article-title">Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=8569706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK28Xns1WntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1996&pages=190-197&author=S.+M.+Seilerauthor=M.+Pelusoauthor=J.+G.+Tuttleauthor=K.+Pryorauthor=C.+Klimasauthor=G.+R.+Matsuedaauthor=M.+S.+Bernatowicz&title=Thrombin+receptor+activation+by+thrombin+and+receptor-derived+peptides+in+platelet+and+CHRF-288+cell+membranes%3A+receptor-stimulated+GTPase+and+evaluation+of+agonists+and+partial+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists</span></div><div class="casAuthors">Seiler, Steven M.; Peluso, Marianne; Tuttle, Jeffrey G.; Pryor, Kelly; Klimas, Clifford; Matsueda, Gary R.; Bernatowicz, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">190-7</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Thrombin receptor activation, by thrombin or SFLLR-contg. peptides, stimulates GTPase activity in platelet and CHRF-288 membranes.  Polyclonal antibodies to peptides derived from the thrombin receptor (anti-TR52-69 and anti-TR36-49), which block many of thrombin's actions on platelets and endothelial cells, also block thrombin activation of membrane GTPase (as does thrombin active site and anion-binding exosite inhibitors).  Most of the receptor-activated GTPase, stimulated by both thrombin and SFLLRNP in platelet membranes, was inhibited by prior treatment with pertussis toxin or N-ethylmaleimide, suggesting that under these conditions much of the thrombin receptor-stimulated GTPase in platelet membranes is a member of the pertussis toxin-sensitive Gαi family.  In platelet membrane prepns., the peptide agonists stimulated approx. twice as much GTPase activity as did α-thrombin.  Stimulation of the platelet membrane GTPase by a variety of different peptide agonists correlated with their ability to stimulate platelet aggregation.  Several peptide-based agonists were more potent than the wild-type sequence.  The most potent was Ser-(p-fluoro-Phe)-(2-naphthyl-Ala)-Leu-Arg-NH2, which stimulated platelet aggregation (EC50 = 80 nM) and GTPase activity (EC50 = 110 nM).  The peptide YFLLRN stimulated GTPase activity but only to ∼40% of the activity obsd. with optimal concns. of other receptor agonists.  YFLLRN also limited the stimulation obsd. with SFLLRNP in a competitive fashion, indicating that YFLLRN is a competitive partial agonist at the thrombin receptor.  These studies show that the tethered-ligand receptor mediates the GTPase activation by thrombin in platelet and CHRF-288 cell membranes, and this provides a specific, reliable, and convenient cell-free assay system with which one can evaluate agonists and partial agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUbezt8DejTrVg90H21EOLACvtfcHk0lhziHctiTejjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xns1WntQ%253D%253D&md5=08d431584ffe35488b05b93910df14c0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26aulast%3DPeluso%26aufirst%3DM.%26aulast%3DTuttle%26aufirst%3DJ.%2BG.%26aulast%3DPryor%26aufirst%3DK.%26aulast%3DKlimas%26aufirst%3DC.%26aulast%3DMatsueda%26aufirst%3DG.%2BR.%26aulast%3DBernatowicz%26aufirst%3DM.%2BS.%26atitle%3DThrombin%2520receptor%2520activation%2520by%2520thrombin%2520and%2520receptor-derived%2520peptides%2520in%2520platelet%2520and%2520CHRF-288%2520cell%2520membranes%253A%2520receptor-stimulated%2520GTPase%2520and%2520evaluation%2520of%2520agonists%2520and%2520partial%2520agonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D49%26spage%3D190%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riexinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiler, S. M.</span></span> <span> </span><span class="NLM_article-title">‘Tethered ligand’ derived pentapeptide agonists of thrombin receptor: a study of side chain requirements for human platelet activation and GTPase stimulation</span>. <i>Int. J. Pept. Protein Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.1995.tb01033.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1111%2Fj.1399-3011.1995.tb01033.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=7782162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK2MXktV2murk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1995&pages=145-151&author=S.+Natarajanauthor=D.+Riexingerauthor=M.+Pelusoauthor=S.+M.+Seiler&title=%E2%80%98Tethered+ligand%E2%80%99+derived+pentapeptide+agonists+of+thrombin+receptor%3A+a+study+of+side+chain+requirements+for+human+platelet+activation+and+GTPase+stimulation&doi=10.1111%2Fj.1399-3011.1995.tb01033.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">'Tethered ligand' derived pentapeptide agonists of thrombin receptor: a study of side chain requirements for human platelet activation and GTPase stimulation</span></div><div class="casAuthors">Natarajan, Sesha; Riexinger, Douglas; Peluso, Marianne; Seiler, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-51</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">Proteolytic action of α-thrombin on human thrombin receptor results in cleavage of a portion of the N-terminus, thereby generating a 'tethered ligand' at the newly exposed N-terminus, which then activates the receptor in an intramol. fashion.  Agonist peptides incorporating the amino acid sequence of the newly exposed N-terminal portion of the cleaved receptor cause receptor activation without requiring prior cleavage of the receptor by thrombin.  The pentapeptide amide Ser-Phe-Leu-Leu-Arg-NH2, which retains the N-terminal sequence of the 'tethered ligand' of the receptor, has been shown to be the min. sequence to cause receptor activation.  To understand the importance of the side chains of various residues within the pentapeptide amide, we carried out an extensive structure-activity study of the ability of peptides to stimulate gel-filtered platelet aggregation.  In this study 106 pentapeptide amides were synthesized, utilizing naturally occurring L-amino acids, unnatural amino acids, D-amino acids and N-Me amino acids for replacements.  At position-1, charged residues (acidic or basic) were not tolerated, and the size and shape of the residue were important.  Position-2 tolerated only arom. residues.  Position-3 accommodated various residues.  A significant finding of this study was that two very different residues, [3-(2-naphthyl)]-L-alanine and L-arginine, when substituted for leucine residue at position-3, resulted in more active agonists.  At position-4 arom. and aliph. residues were well tolerated, whereas basic and acidic residues were less tolerated.  Position-5 mimicked position-3 in its ability to tolerate a wide range of residues.  In general, an acidic residue was not preferred in any position.  In all positions a -Phe-residue was tolerated.  Positions 1 and 3 tolerated -Pro-residue, whereas positions 2, 4 and 5 did not.  D-Amino acid substitution was not tolerated in any position.  While N-methylation of residues at positions-3 and -4 led to poor agonists, at position-2 it resulted in an inactive analog.  These studies define the side chain requirements for the 'tethered ligand' derived pentapeptide agonists of thrombin receptor for human platelet activation.  Selected peptides were tested for ability to stimulate platelet membrane GTPase.  A good correlation was obsd. between peptides that stimulate GTPase and those that stimulate platelet aggregation, with the general finding that 3-10-fold higher concns. were required to half maximally activate GTPase when compared with the concns. needed for activation of platelet aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMgB7y3ZNdDLVg90H21EOLACvtfcHk0lhziHctiTejjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktV2murk%253D&md5=a07b93e433213e32d7837490f4fb210e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1995.tb01033.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1995.tb01033.x%26sid%3Dliteratum%253Aachs%26aulast%3DNatarajan%26aufirst%3DS.%26aulast%3DRiexinger%26aufirst%3DD.%26aulast%3DPeluso%26aufirst%3DM.%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26atitle%3D%25E2%2580%2598Tethered%2520ligand%25E2%2580%2599%2520derived%2520pentapeptide%2520agonists%2520of%2520thrombin%2520receptor%253A%2520a%2520study%2520of%2520side%2520chain%2520requirements%2520for%2520human%2520platelet%2520activation%2520and%2520GTPase%2520stimulation%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1995%26volume%3D45%26spage%3D145%26epage%3D151%26doi%3D10.1111%2Fj.1399-3011.1995.tb01033.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shangde  Liu</span>, <span class="hlFld-ContribAuthor ">Shanshan  Li</span>, <span class="hlFld-ContribAuthor ">Duo  Yuan</span>, <span class="hlFld-ContribAuthor ">Enmao  Wang</span>, <span class="hlFld-ContribAuthor ">Roujie  Xie</span>, <span class="hlFld-ContribAuthor ">Weiqi  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi  Kong</span>, <span class="hlFld-ContribAuthor ">Xiong  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112893. <a href="https://doi.org/10.1016/j.ejmech.2020.112893" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112893</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112893%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProtease%252Bactivated%252Breceptor%252B4%252B%252528PAR4%252529%252Bantagonists%25253A%252BResearch%252Bprogress%252Bon%252Bsmall%252Bmolecules%252Bin%252Bthe%252Bfield%252Bof%252Bantiplatelet%252Bagents%26aulast%3DLiu%26aufirst%3DShangde%26date%3D2021%26volume%3D209%26spage%3D112893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mengna  Fan</span>, <span class="hlFld-ContribAuthor ">Min  Han</span>, <span class="hlFld-ContribAuthor ">Yan  Xia</span>, <span class="hlFld-ContribAuthor ">Yingbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yang  Chu</span>, <span class="hlFld-ContribAuthor ">Guirong  Bai</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Ju  Li</span>, <span class="hlFld-ContribAuthor ">Lihui  Zhao</span>, <span class="hlFld-ContribAuthor ">Yi  He</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Ma</span>, <span class="hlFld-ContribAuthor ">Zhongyu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of potent PAR-1 antagonists based on vorapaxar. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (8)
                                     , 127046. <a href="https://doi.org/10.1016/j.bmcl.2020.127046" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127046%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bpotent%252BPAR-1%252Bantagonists%252Bbased%252Bon%252Bvorapaxar%26aulast%3DFan%26aufirst%3DMengna%26date%3D2020%26volume%3D30%26issue%3D8%26spage%3D127046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre E.  Thibeault</span>, <span class="hlFld-ContribAuthor ">Jordan C.  LeSarge</span>, <span class="hlFld-ContribAuthor ">D'Arcy  Arends</span>, <span class="hlFld-ContribAuthor ">Michaela  Fernandes</span>, <span class="hlFld-ContribAuthor ">Peter  Chidiac</span>, <span class="hlFld-ContribAuthor ">Peter B.  Stathopulos</span>, <span class="hlFld-ContribAuthor ">Leonard G.  Luyt</span>, <span class="hlFld-ContribAuthor ">Rithwik  Ramachandran</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular basis for activation and biased signaling at the thrombin-activated GPCR proteinase activated receptor-4 (PAR4). </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2020,</strong> <em>295 </em>
                                    (8)
                                     , 2520-2540. <a href="https://doi.org/10.1074/jbc.RA119.011461" title="DOI URL">https://doi.org/10.1074/jbc.RA119.011461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.011461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.011461%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DMolecular%252Bbasis%252Bfor%252Bactivation%252Band%252Bbiased%252Bsignaling%252Bat%252Bthe%252Bthrombin-activated%252BGPCR%252Bproteinase%252Bactivated%252Breceptor-4%252B%252528PAR4%252529%26aulast%3DThibeault%26aufirst%3DPierre%2BE.%26date%3D2020%26volume%3D295%26issue%3D8%26spage%3D2520%26epage%3D2540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tom N.  Durrant</span>, <span class="hlFld-ContribAuthor ">Ingeborg  Hers</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K inhibitors in thrombosis and cardiovascular disease. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Medicine</span><span> <strong>2020,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s40169-020-0261-6" title="DOI URL">https://doi.org/10.1186/s40169-020-0261-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s40169-020-0261-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs40169-020-0261-6%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Medicine%26atitle%3DPI3K%252Binhibitors%252Bin%252Bthrombosis%252Band%252Bcardiovascular%252Bdisease%26aulast%3DDurrant%26aufirst%3DTom%2BN.%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of PAR1 and PAR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structure of the PAR4 antagonist HTS hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route for Imidazothiadiazoles with 2-Position Modifications<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH, microwave (μwave): 150 °C, 5 min; (b) <i>m</i>-CPBA, tetrahydrofuran (THF); (c) XSH, MeOH, 70 °C; (d) CH<sub>3</sub>NH<sub>2</sub>, dimethylformamide (DMF), μwave: 70 °C, 10 min; (e) NaOMe, MeOH, room temperature (rt) or XOH, K<sub>2</sub>CO<sub>3</sub>, DMF, rt.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Route for the Preparation of Benzofuranyl Imidazothiadiazoles with Benzofuran Modifications<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Cs<sub>2</sub>CO<sub>3</sub>, DMF, 22 °C, 18 h; (b) <i>p</i>-TsOH, 0.1 equiv, THF, rt, 1 h; (c) lithium bis(trimethylsilyl)amide (LiHMDS), trimethylsilyl chloride, THF, −78 °C; (d) <i>N</i>-bromosuccinimide (NBS), −25 to 0 °C, 1.5 h; (e) isopropyl alcohol (IPA), 88 °C, 19 h; (f) 150 °C, 30 min, μwave; (g) NaOMe, MeOH, dichloromethane (DCM), rt, 1 h; (h) diisopropyl azodicarboxylate (DIAD), Ph<sub>3</sub>P, MeOH, THF, rt; (i) BnBr, K<sub>2</sub>CO<sub>3</sub>, DMF; (j) diisobutylaluminum hydride (DIBAL), −78 °C, CH<sub>2</sub>Cl<sub>2</sub>; (k) MeOH, HCl; (l) BCl<sub>3</sub>, pentamethylbenzene, −78 °C, DCM; (m) ArCH<sub>2</sub>Br, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (n) ArCH<sub>2</sub>OH, Bu<sub>3</sub>P, 1,1’-(azodicarbonyl)dipiperidine, THF, rt.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antithrombotic efficacy of <b>UDM-001651</b> in the monkey ECAT model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Profile of <b>UDM-001651</b> in the monkey kidney bleeding time model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route for General Synthetic Method B toward 2-Methoxy-imidazothiadiazoles</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/medium/jm-2019-001867_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Initial Synthetic Route for Benzofuranyl Imidazothiadiazoles with Substituent Variation on the Benzofuran<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00186/20190815/images/large/jm-2019-001867_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00186&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EtOH, μwave: 150 °C, 5 min; (b) <i>m</i>-CPBA, THF; (c) NaOMe, MeOH, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60053" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60053" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mozaffarian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozaffarian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnett, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaha, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ferranti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Després, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isasi, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissela, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisabeth, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magid, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohler, E. R.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muntner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolino, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumar, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaniappan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosamond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorlie, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towfighi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turan, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virani, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, M. B.</span></span>; <span class="NLM_contrib-group">on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee</span> <span> </span><span class="NLM_article-title">Heart disease and stroke statistics—2016 update: a report from the American Heart Association</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">e38</span>– <span class="NLM_lpage">e360</span>, <span class="refDoi"> DOI: 10.1161/cir.0000000000000350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1161%2Fcir.0000000000000350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=26673558" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2016&pages=e38-e360&author=D.+Mozaffarianauthor=D.+Mozaffarianauthor=A.+S.+Goauthor=D.+K.+Arnettauthor=M.+J.+Blahaauthor=M.+Cushmanauthor=S.+R.+Dasauthor=S.+de+Ferrantiauthor=J.-P.+Despr%C3%A9sauthor=H.+J.+Fullertonauthor=V.+J.+Howardauthor=M.+D.+Huffmanauthor=C.+R.+Isasiauthor=M.+C.+Jimenezauthor=S.+E.+Juddauthor=B.+M.+Kisselaauthor=J.+H.+Lichtmanauthor=L.+D.+Lisabethauthor=S.+Liuauthor=R.+H.+Mackayauthor=D.+J.+Magidauthor=D.+K.+McGuireauthor=E.+R.+Mohlerauthor=C.+S.+Moyauthor=P.+Muntnerauthor=M.+E.+Mussolinoauthor=K.+Nasirauthor=R.+W.+Neumarauthor=G.+Nicholauthor=L.+Palaniappanauthor=D.+K.+Pandeyauthor=M.+J.+Reevesauthor=C.+J.+Rodriguezauthor=W.+Rosamondauthor=P.+D.+Sorlieauthor=J.+Steinauthor=A.+Towfighiauthor=T.+N.+Turanauthor=S.+S.+Viraniauthor=D.+Wooauthor=R.+W.+Yehauthor=M.+B.+Turnerauthor=on+behalf+of+the+American+Heart+Association+Statistics+Committee+and+Stroke+Statistics+Subcommittee&title=Heart+disease+and+stroke+statistics%E2%80%942016+update%3A+a+report+from+the+American+Heart+Association&doi=10.1161%2Fcir.0000000000000350"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1161%2Fcir.0000000000000350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fcir.0000000000000350%26sid%3Dliteratum%253Aachs%26aulast%3DMozaffarian%26aufirst%3DD.%26aulast%3DMozaffarian%26aufirst%3DD.%26aulast%3DGo%26aufirst%3DA.%2BS.%26aulast%3DArnett%26aufirst%3DD.%2BK.%26aulast%3DBlaha%26aufirst%3DM.%2BJ.%26aulast%3DCushman%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DS.%2BR.%26aulast%3Dde%2BFerranti%26aufirst%3DS.%26aulast%3DDespr%25C3%25A9s%26aufirst%3DJ.-P.%26aulast%3DFullerton%26aufirst%3DH.%2BJ.%26aulast%3DHoward%26aufirst%3DV.%2BJ.%26aulast%3DHuffman%26aufirst%3DM.%2BD.%26aulast%3DIsasi%26aufirst%3DC.%2BR.%26aulast%3DJimenez%26aufirst%3DM.%2BC.%26aulast%3DJudd%26aufirst%3DS.%2BE.%26aulast%3DKissela%26aufirst%3DB.%2BM.%26aulast%3DLichtman%26aufirst%3DJ.%2BH.%26aulast%3DLisabeth%26aufirst%3DL.%2BD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMackay%26aufirst%3DR.%2BH.%26aulast%3DMagid%26aufirst%3DD.%2BJ.%26aulast%3DMcGuire%26aufirst%3DD.%2BK.%26aulast%3DMohler%26aufirst%3DE.%2BR.%26aulast%3DMoy%26aufirst%3DC.%2BS.%26aulast%3DMuntner%26aufirst%3DP.%26aulast%3DMussolino%26aufirst%3DM.%2BE.%26aulast%3DNasir%26aufirst%3DK.%26aulast%3DNeumar%26aufirst%3DR.%2BW.%26aulast%3DNichol%26aufirst%3DG.%26aulast%3DPalaniappan%26aufirst%3DL.%26aulast%3DPandey%26aufirst%3DD.%2BK.%26aulast%3DReeves%26aufirst%3DM.%2BJ.%26aulast%3DRodriguez%26aufirst%3DC.%2BJ.%26aulast%3DRosamond%26aufirst%3DW.%26aulast%3DSorlie%26aufirst%3DP.%2BD.%26aulast%3DStein%26aufirst%3DJ.%26aulast%3DTowfighi%26aufirst%3DA.%26aulast%3DTuran%26aufirst%3DT.%2BN.%26aulast%3DVirani%26aufirst%3DS.%2BS.%26aulast%3DWoo%26aufirst%3DD.%26aulast%3DYeh%26aufirst%3DR.%2BW.%26aulast%3DTurner%26aufirst%3DM.%2BB.%26aulast%3D%26atitle%3DHeart%2520disease%2520and%2520stroke%2520statistics%25E2%2580%25942016%2520update%253A%2520a%2520report%2520from%2520the%2520American%2520Heart%2520Association%26jtitle%3DCirculation%26date%3D2016%26volume%3D133%26spage%3De38%26epage%3De360%26doi%3D10.1161%2Fcir.0000000000000350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eikelboom, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weitz, J. I.</span></span> <span> </span><span class="NLM_article-title">Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">e89S</span>– <span class="NLM_lpage">e119S</span>, <span class="refDoi"> DOI: 10.1378/chest.11-2293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1378%2Fchest.11-2293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=22315278" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2012&pages=e89S-e119S&author=J.+W.+Eikelboomauthor=J.+Hirshauthor=F.+A.+Spencerauthor=T.+P.+Baglinauthor=J.+I.+Weitz&title=Antiplatelet+drugs%3A+antithrombotic+therapy+and+prevention+of+thrombosis%2C+9th+ed%3A+American+College+of+Chest+Physicians+evidence-based+clinical+practice+guidelines&doi=10.1378%2Fchest.11-2293"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1378%2Fchest.11-2293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.11-2293%26sid%3Dliteratum%253Aachs%26aulast%3DEikelboom%26aufirst%3DJ.%2BW.%26aulast%3DHirsh%26aufirst%3DJ.%26aulast%3DSpencer%26aufirst%3DF.%2BA.%26aulast%3DBaglin%26aufirst%3DT.%2BP.%26aulast%3DWeitz%26aufirst%3DJ.%2BI.%26atitle%3DAntiplatelet%2520drugs%253A%2520antithrombotic%2520therapy%2520and%2520prevention%2520of%2520thrombosis%252C%25209th%2520ed%253A%2520American%2520College%2520of%2520Chest%2520Physicians%2520evidence-based%2520clinical%2520practice%2520guidelines%26jtitle%3DChest%26date%3D2012%26volume%3D141%26spage%3De89S%26epage%3De119S%26doi%3D10.1378%2Fchest.11-2293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dridi, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmvang, L.</span></span> <span> </span><span class="NLM_article-title">Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology</span>. <i>Cardiovasc. Drugs Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1007/s10557-013-6444-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1007%2Fs10557-013-6444-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23380983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12rsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=239-245&author=P.+Clemmensenauthor=N.+P.+Dridiauthor=L.+Holmvang&title=Dual+antiplatelet+therapy+with+prasugrel+or+ticagrelor+versus+clopidogrel+in+interventional+cardiology&doi=10.1007%2Fs10557-013-6444-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Antiplatelet Therapy with Prasugrel or Ticagrelor Versus Clopidogrel in Interventional Cardiology</span></div><div class="casAuthors">Clemmensen, Peter; Dridi, Nadia Paarup; Holmvang, Lene</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drugs and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-245</span>CODEN:
                <span class="NLM_cas:coden">CDTHET</span>;
        ISSN:<span class="NLM_cas:issn">0920-3206</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  For several years, clopidogrel plus aspirin has been the dual antiplatelet therapy (DAPT) of choice for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation.  More recently, prasugrel and ticagrelor have demonstrated greater efficacy than clopidogrel.  In TRITON-TIMI 38, the risk of TIMI major bleeding unrelated to coronary artery bypass graft (CABG) surgery was similar for prasugrel and clopidogrel after excluding subgroups with increased bleeding risk (previous stroke or transient ischemic event; age ≥75 years; wt. <60 kg).  In the PLATO trial, rates of TIMI major bleeding were similar for ticagrelor and clopidogrel, but ticagrelor was assocd. with a significantly higher rate of non-CABG-related TIMI major bleeding.  Current evidence suggests that prasugrel or ticagrelor plus aspirin should be the DAPT of choice in patients with ACS undergoing PCI unless they are at particularly high risk of bleeding.  No studies have yet compared prasugrel and ticagrelor in ACS patients, however prasugrel and ticagrelor have different side effect profiles, and the choice of agent should be made either as a default choice and/or on an individual patient basis.  Ongoing trials in ACS patients will increase the evidence base for new P2Y12 receptor inhibitors and help to establish the most effective DAPT regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3f27ZiuBAp7Vg90H21EOLACvtfcHk0lhTUSsZDaWN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12rsrw%253D&md5=d519560540e6e74a84bb5423cd2d9558</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs10557-013-6444-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10557-013-6444-2%26sid%3Dliteratum%253Aachs%26aulast%3DClemmensen%26aufirst%3DP.%26aulast%3DDridi%26aufirst%3DN.%2BP.%26aulast%3DHolmvang%26aufirst%3DL.%26atitle%3DDual%2520antiplatelet%2520therapy%2520with%2520prasugrel%2520or%2520ticagrelor%2520versus%2520clopidogrel%2520in%2520interventional%2520cardiology%26jtitle%3DCardiovasc.%2520Drugs%2520Ther.%26date%3D2013%26volume%3D27%26spage%3D239%26epage%3D245%26doi%3D10.1007%2Fs10557-013-6444-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurbel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlinge, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neely, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neely, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakaran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantry, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. T.</span></span>; <span class="NLM_contrib-group">TRILOGY ACS Platelet Function Substudy Investigators</span> <span> </span><span class="NLM_article-title">Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1785</span>– <span class="NLM_lpage">1794</span>, <span class="refDoi"> DOI: 10.1001/jama.2012.17312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1001%2Fjama.2012.17312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23117779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKisL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=1785-1794&author=P.+A.+Gurbelauthor=D.+Erlingeauthor=E.+M.+Ohmanauthor=B.+Neelyauthor=M.+Neelyauthor=S.+G.+Goodmanauthor=K.+Huberauthor=M.+Y.+Chanauthor=J.+H.+Cornelauthor=E.+Brownauthor=C.+Zhouauthor=J.+A.+Jakubowskiauthor=H.+D.+Whiteauthor=K.+A.+Foxauthor=D.+Prabhakaranauthor=P.+W.+Armstrongauthor=U.+S.+Tantryauthor=M.+T.+Roeauthor=TRILOGY+ACS+Platelet+Function+Substudy+Investigators&title=Platelet+function+during+extended+prasugrel+and+clopidogrel+therapy+for+patients+with+ACS+treated+without+revascularization%3A+the+TRILOGY+ACS+platelet+function+substudy&doi=10.1001%2Fjama.2012.17312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization. The TRILOGY ACS platelet function substudy</span></div><div class="casAuthors">Gurbel, Paul A.; Erlinge, David; Ohman, E. Magnus; Neely, Benjamin; Neely, Megan; Goodman, Shaun G.; Huber, Kurt; Chan, Mark Y.; Cornel, Jan H.; Brown, Eileen; Zhou, Chunmei; Jakubowski, Joseph A.; White, Harvey D.; Fox, Keith A. A.; Prabhakaran, Dorairaj; Armstrong, Paul W.; Tantry, Udaya S.; Roe, Matthew T.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1785-1794</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context. The relationship of platelet function testing measurements with outcomes in patients with acute coronary syndromes (ACS) initially managed medically without revascularization is unknown.  Objective. To characterize the differences and evaluate clin. outcomes assocd. with platelet reactivity among patients with ACS treated with clopidogrel or prasugrel.  Design, Setting, and Patients. Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel.  Of 9326 participants, 27.5% were included in a platelet function substudy: 1286 treated with prasugrel and 1278 treated with clopidogrel.  Interventions. Aspirin with either prasugrel (10 or 5 mg/d) or clopidogrel (75 mg/d); those 75 years or older and younger than 75 years but who weighed less than 60 kg received a 5-mg prasugrel maintenance dose.  Main Outcome Measures. Platelet reactivity, measured in P2Y12 reaction units (PRUs), was performed at baseline, at 2 h, and at 1, 3, 6, 12, 18, 24, and 30 mo after randomization.  The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke through 30 mo.  Results. Among participants younger than 75 years and weighing 60 kg or more, the median PRU values at 30 days were 64 (interquartile range [IQR], 33-128) in the prasugrel group vs 200 (IQR, 141-260) in the clopidogrel group (P < .001), a difference that persisted through all subsequent time points.  For participants younger than 75 years and weighing less than 60 kg, the median 30-day PRU values were 139 (IQR, 86-203) for the prasugrel group vs 209 (IQR, 148-283) for the clopidogrel group (P < .001), and for participants 75 years or older, the median PRU values were 164 (IQR, 105-216) for the prasugrel group vs 222 (IQR, 148-268) for the clopidogrel group (P < .001).  At 30 mo the rate of the primary efficacy end point was 17.2% (160 events) in the prasugrel group vs 18.9% (180 events) in the clopidogrel group (P = .29).  There were no significant differences in the continuous distributions of 30-day PRU values for participants with a primary efficacy end point event after 30 days (n = 214) compared with participants without an event (n = 1794; P = .07) and no significant relationship between the occurrence of the primary efficacy end point and continuous PRU values (adjusted hazard ratio [HR] for increase of 60 PRUs, 1.03; 95% CI, 0.96-1.11; P = .44).  Similar findings were obsd. with 30-day PRU cut points used to define high on-treatment platelet reactivity - PRU more than 208 (adjusted HR, 1.16; 95% CI, 0.89-1.52, P = .28) and PRU more than 230 (adjusted HR, 1.20; 95% CI, 0.90-1.61; P = .21).  Conclusions. Among patients with ACS without ST-segment elevation and initially managed without revascularization, prasugrel was assocd. with lower platelet reactivity than clopidogrel, irresp. of age, wt., and dose.  Among those in the platelet substudy, no significant differences existed between prasugrel vs clopidogrel in the occurrence of the primary efficacy end point through 30 mo and no significant assocn. existed between platelet reactivity and occurrence of ischemic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdFeyZN3FOLVg90H21EOLACvtfcHk0ljk9IrdvVf9GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKisL3O&md5=b2a3a3dae92830c1da6526366ced1587</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Fjama.2012.17312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2012.17312%26sid%3Dliteratum%253Aachs%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26aulast%3DErlinge%26aufirst%3DD.%26aulast%3DOhman%26aufirst%3DE.%2BM.%26aulast%3DNeely%26aufirst%3DB.%26aulast%3DNeely%26aufirst%3DM.%26aulast%3DGoodman%26aufirst%3DS.%2BG.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DM.%2BY.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DH.%2BD.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DPrabhakaran%26aufirst%3DD.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DTantry%26aufirst%3DU.%2BS.%26aulast%3DRoe%26aufirst%3DM.%2BT.%26aulast%3D%26atitle%3DPlatelet%2520function%2520during%2520extended%2520prasugrel%2520and%2520clopidogrel%2520therapy%2520for%2520patients%2520with%2520ACS%2520treated%2520without%2520revascularization%253A%2520the%2520TRILOGY%2520ACS%2520platelet%2520function%2520substudy%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D1785%26epage%3D1794%26doi%3D10.1001%2Fjama.2012.17312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, M. J.</span></span> <span> </span><span class="NLM_article-title">Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1806</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1001/jama.2012.34011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1001%2Fjama.2012.34011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23117783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKisLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=1806-1808&author=M.+J.+Price&title=Measured+drug+effect+and+cardiovascular+outcomes+in+patients+receiving+platelet+P2Y12+receptor+antagonists%3A+clarifying+the+time+and+place+for+intensive+inhibition&doi=10.1001%2Fjama.2012.34011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition</span></div><div class="casAuthors">Price, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1806-1808</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfOCV5PV4gJrVg90H21EOLACvtfcHk0ljk9IrdvVf9GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKisLjJ&md5=6b1b5e1a555d6dcb2bd2e1cf273570b8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.2012.34011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2012.34011%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DM.%2BJ.%26atitle%3DMeasured%2520drug%2520effect%2520and%2520cardiovascular%2520outcomes%2520in%2520patients%2520receiving%2520platelet%2520P2Y12%2520receptor%2520antagonists%253A%2520clarifying%2520the%2520time%2520and%2520place%2520for%2520intensive%2520inhibition%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D1806%26epage%3D1808%26doi%3D10.1001%2Fjama.2012.34011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakaran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardissino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boden, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzyllo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiva-Pons, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhomenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topacio, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlides, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudev, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkely, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbalan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinteza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLendon, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokhnygina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylward, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohman, E. M.</span></span>; <span class="NLM_contrib-group">TRILOGY ACS Investigators</span> <span> </span><span class="NLM_article-title">Prasugrel versus clopidogrel for acute coronary syndromes without revascularization</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1297</span>– <span class="NLM_lpage">1309</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1205512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1056%2FNEJMoa1205512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=22920930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFWksL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1297-1309&author=M.+T.+Roeauthor=P.+W.+Armstrongauthor=K.+A.+Foxauthor=H.+D.+Whiteauthor=D.+Prabhakaranauthor=S.+G.+Goodmanauthor=J.+H.+Cornelauthor=D.+L.+Bhattauthor=P.+Clemmensenauthor=F.+Martinezauthor=D.+Ardissinoauthor=J.+C.+Nicolauauthor=W.+E.+Bodenauthor=P.+A.+Gurbelauthor=W.+Ruzylloauthor=A.+J.+Dalbyauthor=D.+K.+McGuireauthor=J.+L.+Leiva-Ponsauthor=A.+Parkhomenkoauthor=S.+Gottliebauthor=G.+O.+Topacioauthor=C.+Hammauthor=G.+Pavlidesauthor=A.+R.+Goudevauthor=A.+Otoauthor=C.+D.+Tsengauthor=B.+Merkelyauthor=V.+Gasparovicauthor=R.+Corbalanauthor=M.+Cintezaauthor=R.+C.+McLendonauthor=K.+J.+Wintersauthor=E.+B.+Brownauthor=Y.+Lokhnyginaauthor=P.+E.+Aylwardauthor=K.+Huberauthor=J.+S.+Hochmanauthor=E.+M.+Ohmanauthor=TRILOGY+ACS+Investigators&title=Prasugrel+versus+clopidogrel+for+acute+coronary+syndromes+without+revascularization&doi=10.1056%2FNEJMoa1205512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel versus clopidogrel for acute coronary syndromes without revascularization</span></div><div class="casAuthors">Roe, Matthew T.; Armstrong, Paul W.; Fox, Keith A. A.; White, Harvey D.; Prabhakaran, Dorairaj; Goodman, Shaun G.; Cornel, Jan H.; Bhatt, Deepak L.; Clemmensen, Peter; Martinez, Felipe; Ardissino, Diego; Nicolau, Jose C.; Boden, William E.; Gurbel, Paul A.; Ruzyllo, Witold; Dalby, Anthony J.; McGuire, Darren K.; Leiva-Pons, Jose L.; Parkhomenko, Alexander; Gottlieb, Shmuel; Topacio, Gracita O.; Hamm, Christian; Pavlides, Gregory; Goudev, Assen R.; Oto, Ali; Tseng, Chuen-Den; Merkely, Bela; Gasparovic, Vladimir; Corbalan, Ramon; Cinteza, Mircea; McLendon, R. Craig; Winters, Kenneth J.; Brown, Eileen B.; Lokhnygina, Yuliya; Aylward, Philip E.; Huber, Kurt; Hochman, Judith S.; Ohman, E. Magnus</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1297-1309</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated.  Methods: In this double-blind, randomized trial, in a primary anal. involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 mo of treatment with prasugrel (10 mg daily) vs. clopidogrel (75 mg daily).  In a secondary anal. involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel vs. 75 mg of clopidogrel.  Results: At a median follow-up of 17 mo, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P = 0.21).  Similar results were obsd. in the overall population.  The prespecified anal. of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P = 0.04).  Rates of severe and intracranial bleeding were similar in the two groups in all age groups.  There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group.  Conclusions: Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSPwjePprYy7Vg90H21EOLACvtfcHk0ljdo2byfCaqSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFWksL3K&md5=a6634ae5efa951bc11b56019ff980c5f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1205512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1205512%26sid%3Dliteratum%253Aachs%26aulast%3DRoe%26aufirst%3DM.%2BT.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DWhite%26aufirst%3DH.%2BD.%26aulast%3DPrabhakaran%26aufirst%3DD.%26aulast%3DGoodman%26aufirst%3DS.%2BG.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26aulast%3DBhatt%26aufirst%3DD.%2BL.%26aulast%3DClemmensen%26aufirst%3DP.%26aulast%3DMartinez%26aufirst%3DF.%26aulast%3DArdissino%26aufirst%3DD.%26aulast%3DNicolau%26aufirst%3DJ.%2BC.%26aulast%3DBoden%26aufirst%3DW.%2BE.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26aulast%3DRuzyllo%26aufirst%3DW.%26aulast%3DDalby%26aufirst%3DA.%2BJ.%26aulast%3DMcGuire%26aufirst%3DD.%2BK.%26aulast%3DLeiva-Pons%26aufirst%3DJ.%2BL.%26aulast%3DParkhomenko%26aufirst%3DA.%26aulast%3DGottlieb%26aufirst%3DS.%26aulast%3DTopacio%26aufirst%3DG.%2BO.%26aulast%3DHamm%26aufirst%3DC.%26aulast%3DPavlides%26aufirst%3DG.%26aulast%3DGoudev%26aufirst%3DA.%2BR.%26aulast%3DOto%26aufirst%3DA.%26aulast%3DTseng%26aufirst%3DC.%2BD.%26aulast%3DMerkely%26aufirst%3DB.%26aulast%3DGasparovic%26aufirst%3DV.%26aulast%3DCorbalan%26aufirst%3DR.%26aulast%3DCinteza%26aufirst%3DM.%26aulast%3DMcLendon%26aufirst%3DR.%2BC.%26aulast%3DWinters%26aufirst%3DK.%2BJ.%26aulast%3DBrown%26aufirst%3DE.%2BB.%26aulast%3DLokhnygina%26aufirst%3DY.%26aulast%3DAylward%26aufirst%3DP.%2BE.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DHochman%26aufirst%3DJ.%2BS.%26aulast%3DOhman%26aufirst%3DE.%2BM.%26aulast%3D%26atitle%3DPrasugrel%2520versus%2520clopidogrel%2520for%2520acute%2520coronary%2520syndromes%2520without%2520revascularization%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1297%26epage%3D1309%26doi%3D10.1056%2FNEJMoa1205512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collet, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuisset, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangé, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elhadad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouillot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motreff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrié, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boueri, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Belle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monségu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabouret, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abtan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerneis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Etienne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthélémy, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beygui, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicaut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalescot, G.</span></span>; <span class="NLM_contrib-group">ARCTIC Investigators</span> <span> </span><span class="NLM_article-title">Bedside monitoring to adjust antiplatelet therapy for coronary stenting</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">2100</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1209979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1056%2FNEJMoa1209979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23121439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyltrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2100-2109&author=J.-P.+Colletauthor=T.+Cuissetauthor=G.+Rang%C3%A9author=G.+Caylaauthor=S.+Elhadadauthor=C.+Pouillotauthor=P.+Henryauthor=P.+Motreffauthor=D.+Carri%C3%A9author=Z.+Boueriauthor=L.+Belleauthor=E.+Van+Belleauthor=H.+Rousseauauthor=P.+Aubryauthor=J.+Mons%C3%A9guauthor=P.+Sabouretauthor=S.+A.+O%E2%80%99Connorauthor=J.+Abtanauthor=M.+Kerneisauthor=C.+Saint-Etienneauthor=O.+Barth%C3%A9l%C3%A9myauthor=F.+Beyguiauthor=J.+Silvainauthor=E.+Vicautauthor=G.+Montalescotauthor=ARCTIC+Investigators&title=Bedside+monitoring+to+adjust+antiplatelet+therapy+for+coronary+stenting&doi=10.1056%2FNEJMoa1209979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Bedside monitoring to adjust antiplatelet therapy for coronary stenting</span></div><div class="casAuthors">Collet, Jean-Philippe; Cuisset, Thomas; Range, Gregoire; Cayla, Guillaume; Elhadad, Simon; Pouillot, Christophe; Henry, Patrick; Motreff, Pascal; Carrie, Didier; Boueri, Ziad; Belle, Loic; Van Belle, Eric; Rousseau, Helene; Aubry, Pierre; Monsegu, Jacques; Sabouret, Pierre; O'Connor, Stephen A.; Abtan, Jeremie; Kerneis, Mathieu; Saint-Etienne, Christophe; Barthelemy, Olivier; Beygui, Farzin; Silvain, Johanne; Vicaut, Eric; Montalescot, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2100-2109</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Patients' responses to oral antiplatelet therapy are subject to variation.  Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy.  METHODS We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment in patients who had a poor response to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment.  The primary end point was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 yr after stent implantation.  For patients in the monitoring group, the VerifyNow P2Y12 and aspirin point-of-care assays were used in the catheterization lab. before stent implantation and in the outpatient clinic 2 to 4 wk later.  RESULTS In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an addnl. bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure.  The primary end point occurred in 34.6% of the patients in the monitoring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval [CI], 0.98 to 1.29; P = 0.10).  The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional-treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P = 0.77).  The rate of major bleeding events did not differ significantly between groups.  CONCLUSIONS This study showed no significant improvements in clin. outcomes with platelet-function monitoring and treatment adjustment for coronary stenting, as compared with std. antiplatelet therapy without monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJgxC6EfcYPrVg90H21EOLACvtfcHk0ljwrzfjCgyIQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyltrvL&md5=7f75c29e6d4c25cef68fc44212af7d2f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209979%26sid%3Dliteratum%253Aachs%26aulast%3DCollet%26aufirst%3DJ.-P.%26aulast%3DCuisset%26aufirst%3DT.%26aulast%3DRang%25C3%25A9%26aufirst%3DG.%26aulast%3DCayla%26aufirst%3DG.%26aulast%3DElhadad%26aufirst%3DS.%26aulast%3DPouillot%26aufirst%3DC.%26aulast%3DHenry%26aufirst%3DP.%26aulast%3DMotreff%26aufirst%3DP.%26aulast%3DCarri%25C3%25A9%26aufirst%3DD.%26aulast%3DBoueri%26aufirst%3DZ.%26aulast%3DBelle%26aufirst%3DL.%26aulast%3DVan%2BBelle%26aufirst%3DE.%26aulast%3DRousseau%26aufirst%3DH.%26aulast%3DAubry%26aufirst%3DP.%26aulast%3DMons%25C3%25A9gu%26aufirst%3DJ.%26aulast%3DSabouret%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DS.%2BA.%26aulast%3DAbtan%26aufirst%3DJ.%26aulast%3DKerneis%26aufirst%3DM.%26aulast%3DSaint-Etienne%26aufirst%3DC.%26aulast%3DBarth%25C3%25A9l%25C3%25A9my%26aufirst%3DO.%26aulast%3DBeygui%26aufirst%3DF.%26aulast%3DSilvain%26aufirst%3DJ.%26aulast%3DVicaut%26aufirst%3DE.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3D%26atitle%3DBedside%2520monitoring%2520to%2520adjust%2520antiplatelet%2520therapy%2520for%2520coronary%2520stenting%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2100%26epage%3D2109%26doi%3D10.1056%2FNEJMoa1209979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brass, L. F.</span></span> <span> </span><span class="NLM_article-title">Thrombin and platelet activation</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">18S</span>– <span class="NLM_lpage">25S</span>, <span class="refDoi"> DOI: 10.1378/chest.124.3_suppl.18S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1378%2Fchest.124.3_suppl.18S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=12970120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVensLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2003&pages=18S-25S&author=L.+F.+Brass&title=Thrombin+and+platelet+activation&doi=10.1378%2Fchest.124.3_suppl.18S"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Thrombin and platelet activation</span></div><div class="casAuthors">Brass, Lawrence F.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3, Suppl.</span>),
    <span class="NLM_cas:pages">18S-25S</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">A review.  The accumulation of thrombin at sites of vascular injury provides 1 of the chief means for recruiting platelets into a growing hemostatic plug.  Studies completed over the past 10 yr show that platelet responses to thrombin are mediated by a subset of G protein-coupled receptors known as protease-activated receptors.  These receptors are activated on cleavage by thrombin, initiating the intracellular signaling events needed to transform mobile, non-adhesive platelets into cells that can participate in the growth of an immobile hemostatic plug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDuAPi0r-_GbVg90H21EOLACvtfcHk0ljwrzfjCgyIQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVensLs%253D&md5=67ced0996920b2d26ada7ea7bf5b6791</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1378%2Fchest.124.3_suppl.18S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.124.3_suppl.18S%26sid%3Dliteratum%253Aachs%26aulast%3DBrass%26aufirst%3DL.%2BF.%26atitle%3DThrombin%2520and%2520platelet%2520activation%26jtitle%3DChest%26date%3D2003%26volume%3D124%26spage%3D18S%26epage%3D25S%26doi%3D10.1378%2Fchest.124.3_suppl.18S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toschi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lettino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertz, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ortiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesebro, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badimon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemerson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuster, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badimon, J. J.</span></span> <span> </span><span class="NLM_article-title">Tissue factor modulates the thrombogenicity of human atherosclerotic plaques</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.95.3.594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1161%2F01.CIR.95.3.594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=9024145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVCisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1997&pages=594-599&author=V.+Toschiauthor=R.+Galloauthor=M.+Lettinoauthor=J.+T.+Fallonauthor=S.+D.+Gertzauthor=A.+Fernandez-Ortizauthor=J.+H.+Chesebroauthor=L.+Badimonauthor=Y.+Nemersonauthor=V.+Fusterauthor=J.+J.+Badimon&title=Tissue+factor+modulates+the+thrombogenicity+of+human+atherosclerotic+plaques&doi=10.1161%2F01.CIR.95.3.594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue factor modulates the thrombogenicity of human atherosclerotic plaques</span></div><div class="casAuthors">Toschi, Vincenzo; Gallo, Richard; Lettino, Maddalena; Fallon, John T.; Gertz, S. David; Fernandez-Ortiz, Antonio; Chesebro, James H.; Badimon, Lina; Nemerson, Yale; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">594-599</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">American Heart Association</span>)
        </div><div class="casAbstract">The thrombogenicity of a disrupted atherosclerotic lesion is dependent on the nature and extent of the plaque components exposed to flowing blood together with local rheol. and a variety of systemic factors.  The authors previously reported on the different thrombogenicity of the various types of human atherosclerotic lesions when exposed to flowing blood in a well-characterized perfusion system.  This study examines the role of tissue factor in the thrombogenicity of different types of atherosclerotic plaques and their components.  Fifty human arterial segments (5 foam cell-rich, 9 collagen-rich, and 10 lipid-rich atherosclerotic lesions and 26 normal, nonatherosclerotic segments) were exposed to heparinized blood at high shear rate conditions in the Badimon perfusion chamber.  The thrombogenicity of the arterial specimens was assessed by IIIIn-labeled platelets.  After perfusion, specimens were stained for tissue factor by use of an in situ binding assay for factor VIIa.  Tissue factor in specimens was semiquant. assessed on a scale of 0 to 3.  Platelet deposition on the lipid-rich atheromatous core was significantly higher than on all other substrates.  The lipid-rich core also exhibited the most intense tissue factor staining (3±0.1 arbitrary units) compared with other arterial components.  Comparison of all specimens showed a pos. correlation between quant. platelet deposition and tissue factor staining score (r=.35).  The results show that tissue factor is present in lipid-rich human atherosclerotic plaques and suggest that it is an important determinant of the thrombogenicity of human atherosclerotic lesions after spontaneous or mech. plaque disruption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfE7kYFCOU2bVg90H21EOLACvtfcHk0ljwrzfjCgyIQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVCisL4%253D&md5=387140d483b5b6143142cd889e6857eb</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.95.3.594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.95.3.594%26sid%3Dliteratum%253Aachs%26aulast%3DToschi%26aufirst%3DV.%26aulast%3DGallo%26aufirst%3DR.%26aulast%3DLettino%26aufirst%3DM.%26aulast%3DFallon%26aufirst%3DJ.%2BT.%26aulast%3DGertz%26aufirst%3DS.%2BD.%26aulast%3DFernandez-Ortiz%26aufirst%3DA.%26aulast%3DChesebro%26aufirst%3DJ.%2BH.%26aulast%3DBadimon%26aufirst%3DL.%26aulast%3DNemerson%26aufirst%3DY.%26aulast%3DFuster%26aufirst%3DV.%26aulast%3DBadimon%26aufirst%3DJ.%2BJ.%26atitle%3DTissue%2520factor%2520modulates%2520the%2520thrombogenicity%2520of%2520human%2520atherosclerotic%2520plaques%26jtitle%3DCirculation%26date%3D1997%26volume%3D95%26spage%3D594%26epage%3D599%26doi%3D10.1161%2F01.CIR.95.3.594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Thrombin signalling and protease-activated receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/35025229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1038%2F35025229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=11001069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVSls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=258-264&author=S.+R.+Coughlin&title=Thrombin+signalling+and+protease-activated+receptors&doi=10.1038%2F35025229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Thrombin signalling and protease-activated receptors</span></div><div class="casAuthors">Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6801</span>),
    <span class="NLM_cas:pages">258-264</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 64 refs.  How does the coagulation protease thrombin regulate cellular behavior.  The protease-activated receptors (PARs) provide one answer.  In concert with the coagulation cascade, these receptors provide an elegant mechanism linking mech. information in the form of tissue injury or vascular leakage to cellular responses.  Roles for PARs are beginning to emerge in hemostasis and thrombosis, inflammation, and perhaps even blood vessel development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry0F_6k5PRO7Vg90H21EOLACvtfcHk0ljjDfOH0ctAgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVSls7w%253D&md5=6fe64606d9f20fdc0688d5e76672f2b6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2F35025229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35025229%26sid%3Dliteratum%253Aachs%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DThrombin%2520signalling%2520and%2520protease-activated%2520receptors%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D258%26epage%3D264%26doi%3D10.1038%2F35025229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faruqi, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">19728</span>– <span class="NLM_lpage">19734</span>, <span class="refDoi"> DOI: 10.1074/jbc.M909960199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1074%2Fjbc.M909960199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10779527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkslaht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=19728-19734&author=T.+R.+Faruqiauthor=E.+J.+Weissauthor=M.+J.+Shapiroauthor=W.+Huangauthor=S.+R.+Coughlin&title=Structure-function+analysis+of+protease-activated+receptor+4+tethered+ligand+peptides.+Determinants+of+specificity+and+utility+in+assays+of+receptor+function&doi=10.1074%2Fjbc.M909960199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function</span></div><div class="casAuthors">Faruqi, Tatjana R.; Weiss, Ethan J.; Shapiro, Michael J.; Huang, Wei; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">19728-19734</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Thrombin activates protease-activated receptors (PARs) by specific cleavage of their amino-terminal exodomains to unmask a tethered ligand that binds intramolecularly to the body of the receptor to effect transmembrane signaling.  Peptides that mimic such ligands are valuable as agonists for probing PAR function, but the tethered ligand peptide for PAR4, GYPGKF, lacks potency and is of limited utility.  In a structure-activity anal. of PAR4 peptides, AYPGKF was ∼10-fold more potent than GYPGKF and, unlike GYPGKF, elicited PAR4-mediated responses comparable in magnitude to those elicited by thrombin.  AYPGKF was relatively specific for PAR4 in part due to the tyrosine at position 2; substitution of phenylalanine or p-fluorophenylalanine at this position produced peptides that activated both PAR1 and PAR4.  Because human platelets express both PAR1 and PAR4, it might be desirable to inhibit both receptors.  Identifying a single agonist for both receptors raises the possibility that a single antagonist for both receptors might be developed.  The AYPGKF peptide is a useful new tool for probing PAR4 function.  For example, AYPGKF activated and desensitized PAR4 in platelets and, like thrombin, triggered phosphoinositide hydrolysis but not inhibition of adenylyl cyclase in PAR4-expressing cells.  The latter shows that, unlike PAR1, PAR4 couples to Gq and not Gi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJqqbRQv7g7Vg90H21EOLACvtfcHk0ljjDfOH0ctAgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkslaht70%253D&md5=219d9a016b747a408bea922e7192155f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M909960199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M909960199%26sid%3Dliteratum%253Aachs%26aulast%3DFaruqi%26aufirst%3DT.%2BR.%26aulast%3DWeiss%26aufirst%3DE.%2BJ.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DStructure-function%2520analysis%2520of%2520protease-activated%2520receptor%25204%2520tethered%2520ligand%2520peptides.%2520Determinants%2520of%2520specificity%2520and%2520utility%2520in%2520assays%2520of%2520receptor%2520function%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D19728%26epage%3D19734%26doi%3D10.1074%2Fjbc.M909960199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammes, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: evidence for a novel mechanism for preventing or terminating signaling by PAR1’s tethered ligand</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2486</span>– <span class="NLM_lpage">2493</span>, <span class="refDoi"> DOI: 10.1021/bi982527i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi982527i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK1MXnsF2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1999&pages=2486-2493&author=S.+R.+Hammesauthor=S.+R.+Coughlin&title=Protease-activated+receptor-1+can+mediate+responses+to+SFLLRN+in+thrombin-desensitized+cells%3A+evidence+for+a+novel+mechanism+for+preventing+or+terminating+signaling+by+PAR1%E2%80%99s+tethered+ligand&doi=10.1021%2Fbi982527i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Protease-Activated Receptor-1 Can Mediate Responses to SFLLRN in Thrombin-Desensitized Cells: Evidence for a Novel Mechanism for Preventing or Terminating Signaling by PAR1's Tethered Ligand</span></div><div class="casAuthors">Hammes, Stephen R.; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2486-2493</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The thrombin receptor PAR1 is activated when thrombin cleaves the receptor's amino-terminal exodomain to reveal the new N-terminal sequence SFLLRN which then acts as a tethered peptide ligand.  Free SFLLRN activates PAR1 independent of receptor cleavage and has been used to probe PAR1 function in various cells and tissues.  PAR1-expressing cells desensitized to thrombin retain responsiveness to SFLLRN.  Toward detg. the mechanism of such responses, we utilized fibroblasts derived from a PAR1-deficient mouse.  These cells were unresponsive to thrombin and SFLLRN and became sensitive to both ligands after transfection with human PAR1 cDNA.  Moreover, PAR1-transfected cells responded to SFLLRN after thrombin-desensitization, indicating that signaling of thrombin-desensitized cells to SFLLRN was mediated by PAR1 itself.  SFLLRN caused signaling in thrombin-desensitized cells when no uncleaved PAR1 was detectable on the cell surface; however, cleaved PAR1 was present.  To det. whether the cleaved receptors could still signal, fibroblasts were transfected with a PAR1 mutant contg. a trypsin site/SFLLRN sequence carboxyl terminal to the native thrombin site.  These cells retained responsiveness to trypsin after thrombin-desensitization.  Conversely, fibroblasts expressing a PAR1 mutant with the trypsin site/SFLLRN sequence amino terminal to the native thrombin site retained responsiveness to thrombin after trypsin-desensitization.  This suggests that a population of thrombin-cleaved PAR1 can respond both to exogenous SFLLRN and to a second tethered ligand.  In this population, the tethered ligand unmasked by thrombin cleavage must not be functional, suggesting the possibility of a novel mechanism of receptor shutoff involving sequestration or modification of the tethered ligand to prevent or terminate its function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7IY_MeOPstLVg90H21EOLACvtfcHk0lg8p6VI9A2ftw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnsF2lsg%253D%253D&md5=430d9497d7ff88fc24eac18c4a06656c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fbi982527i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi982527i%26sid%3Dliteratum%253Aachs%26aulast%3DHammes%26aufirst%3DS.%2BR.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DProtease-activated%2520receptor-1%2520can%2520mediate%2520responses%2520to%2520SFLLRN%2520in%2520thrombin-desensitized%2520cells%253A%2520evidence%2520for%2520a%2520novel%2520mechanism%2520for%2520preventing%2520or%2520terminating%2520signaling%2520by%2520PAR1%25E2%2580%2599s%2520tethered%2520ligand%26jtitle%3DBiochemistry%26date%3D1999%26volume%3D38%26spage%3D2486%26epage%3D2493%26doi%3D10.1021%2Fbi982527i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tricoci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moliterno, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Werf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylward, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallentin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokhnygina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorick, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilian, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cequier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jukema, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoff, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalescot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfisterer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzyllo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinnaeve, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valgimigli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whellan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widimsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahaffey, K. W.</span></span> <span> </span><span class="NLM_article-title">Thrombin-receptor antagonist vorapaxar in acute coronary syndromes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1109719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1056%2FNEJMoa1109719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=22077816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=20-33&author=P.+Tricociauthor=Z.+Huangauthor=C.+Heldauthor=D.+J.+Moliternoauthor=P.+W.+Armstrongauthor=F.+Van+de+Werfauthor=H.+D.+Whiteauthor=P.+E.+Aylwardauthor=L.+Wallentinauthor=E.+Chenauthor=Y.+Lokhnyginaauthor=J.+Peiauthor=S.+Leonardiauthor=T.+L.+Rorickauthor=A.+M.+Kilianauthor=L.+H.+Jenningsauthor=G.+Ambrosioauthor=C.+Bodeauthor=A.+Cequierauthor=J.+H.+Cornelauthor=R.+Diazauthor=A.+Erkanauthor=K.+Huberauthor=M.+P.+Hudsonauthor=L.+Jiangauthor=J.+W.+Jukemaauthor=B.+S.+Lewisauthor=A.+M.+Lincoffauthor=G.+Montalescotauthor=J.+C.+Nicolauauthor=H.+Ogawaauthor=M.+Pfistererauthor=J.+C.+Prietoauthor=W.+Ruzylloauthor=P.+R.+Sinnaeveauthor=R.+F.+Storeyauthor=M.+Valgimigliauthor=D.+J.+Whellanauthor=P.+Widimskyauthor=J.+Stronyauthor=R.+A.+Harringtonauthor=K.+W.+Mahaffey&title=Thrombin-receptor+antagonist+vorapaxar+in+acute+coronary+syndromes&doi=10.1056%2FNEJMoa1109719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Thrombin-receptor antagonist vorapaxar in acute coronary syndromes</span></div><div class="casAuthors">Tricoci, Pierluigi; Huang, Zhen; Held, Claes; Moliterno, David J.; Armstrong, Paul W.; Van de Werf, Frans; White, Harvey D.; Aylward, Philip E.; Wallentin, Lars; Chen, Edmond; Lokhnygina, Yuliya; Pei, Jinglan; Leonardi, Sergio; Rorick, Tyrus L.; Kilian, Ann M.; Jennings, Lisa H. K.; Ambrosio, Giuseppe; Bode, Christoph; Cequier, Angel; Cornel, Jan H.; Diaz, Rafael; Erkan, Aycan; Huber, Kurt; Hudson, Michael P.; Jiang, Lixin; Jukema, J. Wouter; Lewis, Basil S.; Lincoff, A. Michael; Montalescot, Gilles; Nicolau, Jose Carlos; Ogawa, Hisao; Pfisterer, Matthias; Prieto, Juan Carlos; Ruzyllo, Witold; Sinnaeve, Peter R.; Storey, Robert F.; Valgimigli, Marco; Whellan, David J.; Widimsky, Petr; Strony, John; Harrington, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-33</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.  In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation.  The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization.  Follow-up in the trial was terminated early after a safety review.  After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar vs. 1102 of 6471 patients receiving placebo (Kaplan-Meier 2-yr rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P = 0.07).  A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients. in the vorapaxar group vs. 910 in the placebo group (14.7% and 16.4%, resp.; hazard ratio, 0.89; 95% CI, 0.81 to 0.98; P = 0.02).  Rates of moderate and severe bleeding were 7.2% in the vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; P < 0.001).  Intracranial hemorrhage rates were 1.1% and 0.2%, resp. (hazard ratio, 3.39; 95% CI, 1.78 to 6.45; P < 0.001).  Rates of nonhemorrhagic adverse events were similar in the two groups.  In patients with acute coronary syndromes, the addn. of vorapaxar to std. therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3g6zpddY-rLVg90H21EOLACvtfcHk0lgwmpMfgWXFCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKit7c%253D&md5=8d75130f9c31dab2ee272c401da53aa8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1109719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1109719%26sid%3Dliteratum%253Aachs%26aulast%3DTricoci%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DHeld%26aufirst%3DC.%26aulast%3DMoliterno%26aufirst%3DD.%2BJ.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DVan%2Bde%2BWerf%26aufirst%3DF.%26aulast%3DWhite%26aufirst%3DH.%2BD.%26aulast%3DAylward%26aufirst%3DP.%2BE.%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DLokhnygina%26aufirst%3DY.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLeonardi%26aufirst%3DS.%26aulast%3DRorick%26aufirst%3DT.%2BL.%26aulast%3DKilian%26aufirst%3DA.%2BM.%26aulast%3DJennings%26aufirst%3DL.%2BH.%26aulast%3DAmbrosio%26aufirst%3DG.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DCequier%26aufirst%3DA.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DErkan%26aufirst%3DA.%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DHudson%26aufirst%3DM.%2BP.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DJukema%26aufirst%3DJ.%2BW.%26aulast%3DLewis%26aufirst%3DB.%2BS.%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DNicolau%26aufirst%3DJ.%2BC.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DPfisterer%26aufirst%3DM.%26aulast%3DPrieto%26aufirst%3DJ.%2BC.%26aulast%3DRuzyllo%26aufirst%3DW.%26aulast%3DSinnaeve%26aufirst%3DP.%2BR.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DValgimigli%26aufirst%3DM.%26aulast%3DWhellan%26aufirst%3DD.%2BJ.%26aulast%3DWidimsky%26aufirst%3DP.%26aulast%3DStrony%26aufirst%3DJ.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26aulast%3DMahaffey%26aufirst%3DK.%2BW.%26atitle%3DThrombin-receptor%2520antagonist%2520vorapaxar%2520in%2520acute%2520coronary%2520syndromes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D20%26epage%3D33%26doi%3D10.1056%2FNEJMoa1109719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunwald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaca, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ameriso, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipka, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolau, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ophuis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolasso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scirica, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiviott, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. A.</span></span> <span> </span><span class="NLM_article-title">Vorapaxar in the secondary prevention of atherothrombotic events</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1200933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1056%2FNEJMoa1200933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=22443427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=1404-1413&author=D.+A.+Morrowauthor=E.+Braunwaldauthor=M.+P.+Bonacaauthor=S.+F.+Amerisoauthor=A.+J.+Dalbyauthor=M.+P.+Fishauthor=K.+A.+Foxauthor=L.+J.+Lipkaauthor=X.+Liuauthor=J.+C.+Nicolauauthor=A.+J.+Ophuisauthor=E.+Paolassoauthor=B.+M.+Sciricaauthor=J.+Spinarauthor=P.+Therouxauthor=S.+D.+Wiviottauthor=J.+Stronyauthor=S.+A.+Murphy&title=Vorapaxar+in+the+secondary+prevention+of+atherothrombotic+events&doi=10.1056%2FNEJMoa1200933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Vorapaxar in the secondary prevention of atherothrombotic events</span></div><div class="casAuthors">Morrow, David A.; Braunwald, Eugene; Bonaca, Marc P.; Ameriso, Sebastian F.; Dalby, Anthony J.; Fish, Mary Polly; Fox, Keith A. A.; Lipka, Leslie J.; Liu, Xuan; Nicolau, Jose Carlos; Oude Ophuis, A. J.; Paolasso, Ernesto; Scirica, Benjamin M.; Spinar, Jindrich; Theroux, Pierre; Wiviott, Stephen D.; Strony, John; Murphy, Sabina A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1404-1413</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Thrombin potently activates platelets through the protease-activated receptor PAR-1.  Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1.  We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 mo.  The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke.  After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage.  At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001).  Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P = 0.001).  Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001).  There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001).  Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving std. therapy.  However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvIsD7zdTXXbVg90H21EOLACvtfcHk0lgwxdWDRhy4Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOrsLk%253D&md5=11e0c03c44b88b5e74583748a4f97a7c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200933%26sid%3Dliteratum%253Aachs%26aulast%3DMorrow%26aufirst%3DD.%2BA.%26aulast%3DBraunwald%26aufirst%3DE.%26aulast%3DBonaca%26aufirst%3DM.%2BP.%26aulast%3DAmeriso%26aufirst%3DS.%2BF.%26aulast%3DDalby%26aufirst%3DA.%2BJ.%26aulast%3DFish%26aufirst%3DM.%2BP.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DLipka%26aufirst%3DL.%2BJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DNicolau%26aufirst%3DJ.%2BC.%26aulast%3DOphuis%26aufirst%3DA.%2BJ.%26aulast%3DPaolasso%26aufirst%3DE.%26aulast%3DScirica%26aufirst%3DB.%2BM.%26aulast%3DSpinar%26aufirst%3DJ.%26aulast%3DTheroux%26aufirst%3DP.%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DStrony%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DS.%2BA.%26atitle%3DVorapaxar%2520in%2520the%2520secondary%2520prevention%2520of%2520atherothrombotic%2520events%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D1404%26epage%3D1413%26doi%3D10.1056%2FNEJMoa1200933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span> <i>Zontivity (Vorapaxar) [Package Insert]</i>; <span class="NLM_publisher-name">Merck Sharp & Dohme Corp.</span>: <span class="NLM_publisher-loc">Whitehouse
Station, NJ</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Zontivity+%28Vorapaxar%29+%5BPackage+Insert%5D%3B+Merck+Sharp+%26+Dohme+Corp.%3A+Whitehouse%0AStation%2C+NJ%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DZontivity%2520%2528Vorapaxar%2529%2520%255BPackage%2520Insert%255D%26pub%3DMerck%2520Sharp%2520%2526%2520Dohme%2520Corp%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiviott, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiolillo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalescot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeymer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylward, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guetta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziecina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contant, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flather, M. D.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1853</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.110.000786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1161%2FCIRCULATIONAHA.110.000786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=21502577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVynsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2011&pages=1843-1853&author=M.+L.+O%E2%80%99Donoghueauthor=D.+L.+Bhattauthor=S.+D.+Wiviottauthor=S.+G.+Goodmanauthor=D.+J.+Fitzgeraldauthor=D.+J.+Angiolilloauthor=S.+Gotoauthor=G.+Montalescotauthor=U.+Zeymerauthor=P.+E.+Aylwardauthor=V.+Guettaauthor=D.+Dudekauthor=R.+Ziecinaauthor=C.+F.+Contantauthor=M.+D.+Flather&title=Safety+and+tolerability+of+atopaxar+in+the+treatment+of+patients+with+acute+coronary+syndromes%3A+the+lessons+from+antagonizing+the+cellular+effects+of+Thrombin-Acute+Coronary+Syndromes+Trial&doi=10.1161%2FCIRCULATIONAHA.110.000786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes: The Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes Trial</span></div><div class="casAuthors">O'Donoghue, Michelle L.; Bhatt, Deepak L.; Wiviott, Stephen D.; Goodman, Shaun G.; Fitzgerald, Desmond J.; Angiolillo, Dominick J.; Goto, Shinya; Montalescot, Gilles; Zeymer, Uwe; Aylward, Philip E.; Guetta, Victor; Dudek, Dariusz; Ziecina, Rafal; Contant, Charles F.; Flather, Marcus D.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1843-1853</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Atopaxar (E5555) is a reversible protease-activated receptor-1 thrombin receptor antagonist that interferes with platelet signaling.  The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT-ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS.  603 Subjects were randomized within 72 h of non-ST-elevation ACS to 1 of 3 doses of atopaxar (400-mg loading dose followed by 50, 100, or 200 mg daily) or matching placebo.  The incidence of Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) major or minor bleeding did not differ significantly between the combined atopaxar and placebo groups (3.08% vs. 2.17%, resp.; P=0.63), and there was no dose-related trend (P=0.80).  The incidence of CURE major bleeding was numerically higher in the atopaxar group compared with the placebo group (1.8% vs. 0%; P=0.12).  The incidence of cardiovascular death, myocardial infarction, stroke, or recurrent ischemia was similar between the atopaxar and placebo arms (8.03% vs. 7.75%; P=0.93).  The incidence of CV death, MI, or stroke was 5.63% in the placebo group and 3.25% in the combined atopaxar group (P=0.20).  Dose-dependent trends for efficacy were not seen.  Atopaxar significantly reduced ischemia on continuous ECG monitoring (Holter) at 48 h compared with placebo (relative risk, 0.67; P=0.02).  Transient dose-dependent transaminase elevation and relative QTc prolongation were obsd. with the highest doses of atopaxar.  In patients after ACS, atopaxar significantly reduced early ischemia on Holter monitoring without a significant increase in major or minor bleeding.  Larger trials are required to fully establish the efficacy and safety of atopaxar.  Clin. TRIAL REGISTRATION-: URL: http://www.ClinicalTrials.gov.  Unique identifier: NCT00548587.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcFv8Lncggy7Vg90H21EOLACvtfcHk0lgwxdWDRhy4Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVynsb8%253D&md5=3e3f75d17c6b78e4f2c19765e629acd3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.110.000786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.110.000786%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DM.%2BL.%26aulast%3DBhatt%26aufirst%3DD.%2BL.%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DGoodman%26aufirst%3DS.%2BG.%26aulast%3DFitzgerald%26aufirst%3DD.%2BJ.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DZeymer%26aufirst%3DU.%26aulast%3DAylward%26aufirst%3DP.%2BE.%26aulast%3DGuetta%26aufirst%3DV.%26aulast%3DDudek%26aufirst%3DD.%26aulast%3DZiecina%26aufirst%3DR.%26aulast%3DContant%26aufirst%3DC.%2BF.%26aulast%3DFlather%26aufirst%3DM.%2BD.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520atopaxar%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520acute%2520coronary%2520syndromes%253A%2520the%2520lessons%2520from%2520antagonizing%2520the%2520cellular%2520effects%2520of%2520Thrombin-Acute%2520Coronary%2520Syndromes%2520Trial%26jtitle%3DCirculation%26date%3D2011%26volume%3D123%26spage%3D1843%26epage%3D1853%26doi%3D10.1161%2FCIRCULATIONAHA.110.000786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiviott, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flather, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aylward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guetta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contant, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiolillo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, D. L.</span></span> <span> </span><span class="NLM_article-title">Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">1854</span>– <span class="NLM_lpage">1863</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.110.001404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1161%2FCIRCULATIONAHA.110.001404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=21502571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVynsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2011&pages=1854-1863&author=S.+D.+Wiviottauthor=M.+D.+Flatherauthor=M.+L.+O%E2%80%99Donoghueauthor=S.+Gotoauthor=D.+J.+Fitzgeraldauthor=F.+Curaauthor=P.+Aylwardauthor=V.+Guettaauthor=D.+Dudekauthor=C.+F.+Contantauthor=D.+J.+Angiolilloauthor=D.+L.+Bhatt&title=Randomized+trial+of+atopaxar+in+the+treatment+of+patients+with+coronary+artery+disease%3A+the+lessons+from+antagonizing+the+cellular+effect+of+Thrombin-Coronary+Artery+Disease+Trial&doi=10.1161%2FCIRCULATIONAHA.110.001404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease: The Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease Trial</span></div><div class="casAuthors">Wiviott, Stephen D.; Flather, Marcus D.; O'Donoghue, Michelle L.; Goto, Shinya; Fitzgerald, Desmond J.; Cura, Fernando; Aylward, Philip; Guetta, Victor; Dudek, Dariusz; Contant, Charles F.; Angiolillo, Dominick J.; Bhatt, Deepak L.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1854-1863</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Thrombin is a key mediator of platelet activation.  Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects.  The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examd. the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD.  Subjects with a qualifying history were randomized in a double-blind fashion to 3 dosing regimens of atopaxar (50, 100, or 200 mg daily) or matching placebo for 24 wk and followed up for an addnl. 4 wk.  The key safety end points were bleeding according to the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Thrombolysis in Myocardial Infarction (TIMI) classifications.  Secondary objectives included platelet aggregation and major adverse cardiac events.  720 Subjects were randomized.  Overall bleeding rates tended to be higher with atopaxar compared with placebo by CURE criteria (placebo, 0.6%; atopaxar, 3.9%; relative risk, 6.82, P=0.03; 50 mg, 3.9%; 100 mg, 1.7%; 200 mg, 5.9%; P for trend=0.01) and TIMI criteria (placebo, 6.8%; atopaxar, 10.3%; relative risk, 1.52, P=0.17; 50 mg, 9.9%; 100 mg, 8.1%; 200 mg, 12.9%; P for trend=0.07).  There was no difference in major bleeding.  Major adverse cardiac events were numerically lower in the atopaxar subjects.  All atopaxar regimens achieved high levels of platelet inhibition.  A transient elevation in liver transaminases and dose-dependent QTc prolongation without apparent complications were obsd. in higher-dose atopaxar treatment groups.  In this dose-ranging study of patients with CAD, treatment with atopaxar resulted in platelet inhibition, more minor bleeding, and numerically but not statistically fewer ischemic events.  Larger-scale trials are needed to det. whether these patterns translate into clin. meaningful effects.  Clin. TRIAL REGISTRATION-: URL: http://www.ClinicalTrials.gov.  Unique identifier: NCT00312052.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9dgWqGgNN8LVg90H21EOLACvtfcHk0lj_tXJrpiMS2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVynsbw%253D&md5=4e7fec4a660ef09121e0f6090cfcf86c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.110.001404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.110.001404%26sid%3Dliteratum%253Aachs%26aulast%3DWiviott%26aufirst%3DS.%2BD.%26aulast%3DFlather%26aufirst%3DM.%2BD.%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DM.%2BL.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DFitzgerald%26aufirst%3DD.%2BJ.%26aulast%3DCura%26aufirst%3DF.%26aulast%3DAylward%26aufirst%3DP.%26aulast%3DGuetta%26aufirst%3DV.%26aulast%3DDudek%26aufirst%3DD.%26aulast%3DContant%26aufirst%3DC.%2BF.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26aulast%3DBhatt%26aufirst%3DD.%2BL.%26atitle%3DRandomized%2520trial%2520of%2520atopaxar%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520coronary%2520artery%2520disease%253A%2520the%2520lessons%2520from%2520antagonizing%2520the%2520cellular%2520effect%2520of%2520Thrombin-Coronary%2520Artery%2520Disease%2520Trial%26jtitle%3DCirculation%26date%3D2011%26volume%3D123%26spage%3D1854%26epage%3D1863%26doi%3D10.1161%2FCIRCULATIONAHA.110.001404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brass, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalker, T. J.</span></span> <span> </span><span class="NLM_article-title">Minding the gaps to promote thrombus growth and stability</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3385</span>– <span class="NLM_lpage">3392</span>, <span class="refDoi"> DOI: 10.1172/JCI26869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1172%2FJCI26869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=16322784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=3385-3392&author=L.+F.+Brassauthor=L.+Zhuauthor=T.+J.+Stalker&title=Minding+the+gaps+to+promote+thrombus+growth+and+stability&doi=10.1172%2FJCI26869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Minding the gaps to promote thrombus growth and stability</span></div><div class="casAuthors">Brass, Lawrence F.; Zhu, Li; Stalker, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3385-3392</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Efforts to understand the role of platelets in hemostasis and thrombosis have largely focused on the earliest events of platelet activation, those that lead to aggregation.  Although much remains to be learned about those early events, this review examines a later series of events: the interactions between platelets that can only occur once aggregation has begun, bringing platelets into close contact with each other, creating a protected environment in the gaps between aggregated platelets, and fostering the continued growth and stability of the hemostatic plug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaZgDGfW0SbLVg90H21EOLACvtfcHk0ljzFD_i0LigyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqtL3I&md5=edec92e6a129c209ae5f1a5130a32711</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1172%2FJCI26869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI26869%26sid%3Dliteratum%253Aachs%26aulast%3DBrass%26aufirst%3DL.%2BF.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DStalker%26aufirst%3DT.%2BJ.%26atitle%3DMinding%2520the%2520gaps%2520to%2520promote%2520thrombus%2520growth%2520and%2520stability%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D3385%26epage%3D3392%26doi%3D10.1172%2FJCI26869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gresele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcinelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momi, S.</span></span> <span> </span><span class="NLM_article-title">Potentiation and priming of platelet activation: a potential target for antiplatelet therapy</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2008.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.tips.2008.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=18539343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVGls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=352-360&author=P.+Greseleauthor=E.+Falcinelliauthor=S.+Momi&title=Potentiation+and+priming+of+platelet+activation%3A+a+potential+target+for+antiplatelet+therapy&doi=10.1016%2Fj.tips.2008.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation and priming of platelet activation: a potential target for antiplatelet therapy</span></div><div class="casAuthors">Gresele, Paolo; Falcinelli, Emanuela; Momi, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">352-360</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Ischemic cardiovascular events represent the leading cause of mortality and morbidity worldwide, and platelet aggregation and thrombus formation are the main effectors of acute arterial ischemic events.  Although antiplatelet therapy is the cornerstone of antithrombotic treatment of ischemic cardiovascular disorders, available antiplatelet agents have less than satisfactory efficacy; thus, the identification of novel potential target candidates for antiplatelet therapy is highly warranted.  Recent evidence suggests that several mols. that amplify the aggregation response of platelets to activating stimuli, which are either released by platelets (potentiating mols.) or present in the milieu before platelets get activated (primers), play a major role in pathol. thrombus formation without being significantly involved in primary haemostasis.  These mols. appear to be a particularly appealing novel potential pharmacol. target for antiplatelet therapy.  Here, we review the present knowledge on some mols. acting as potentiators or primers of platelet activation and discuss their possible pharmacol. modulation for antithrombotic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNl4_XDglcIrVg90H21EOLACvtfcHk0ljzFD_i0LigyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVGls7o%253D&md5=13c32ce51fcd39c88c04540c1fc8ce75</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2008.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2008.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DGresele%26aufirst%3DP.%26aulast%3DFalcinelli%26aufirst%3DE.%26aulast%3DMomi%26aufirst%3DS.%26atitle%3DPotentiation%2520and%2520priming%2520of%2520platelet%2520activation%253A%2520a%2520potential%2520target%2520for%2520antiplatelet%2520therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D352%26epage%3D360%26doi%3D10.1016%2Fj.tips.2008.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi-Matsui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1172/JCI6042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1172%2FJCI6042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10079109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFarsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1999&pages=879-887&author=M.+L.+Kahnauthor=M.+Nakanishi-Matsuiauthor=M.+J.+Shapiroauthor=H.+Ishiharaauthor=S.+R.+Coughlin&title=Protease-activated+receptors+1+and+4+mediate+activation+of+human+platelets+by+thrombin&doi=10.1172%2FJCI6042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin</span></div><div class="casAuthors">Kahn, Mark L.; Nakanishi-Matsui, Mayumi; Shapiro, Michael J.; Ishihara, Hiroaki; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">879-887</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Because of the role of thrombin and platelets in myocardial infarction and other pathol. processes, identifying and blocking the receptors by which thrombin activates platelets has been an important goal.  Three protease-activated receptors (PARs) for thrombin - PAR1, PAR3, and PAR4 - are now known.  PAR1 functions in human platelets, and the recent observation that a PAR4-activating peptide activates human platelets suggests that PAR4 also acts in these cells.  Whether PAR1 and PAR4 account for activation of human platelets by thrombin, or whether PAR3 or still other receptors contribute, is unknown.  The authors have examd. the roles of PAR1, PAR3, and PAR4 in platelets.  PAR1 and PAR4 mRNA and protein were detected in human platelets.  Activation of either receptor was sufficient to trigger platelet secretion and aggregation.  Inhibition of PAR1 alone by antagonist, blocking antibody, or desensitization blocked platelet activation by 1 nM thrombin but only modestly attenuated platelet activation by 30 nM thrombin.  Inhibition of PAR4 alone using a blocking antibody had little effect at either thrombin concn.  Strikingly, simultaneous inhibition of both PAR1 and PAR4 virtually ablated platelet secretion and aggregation, even at 30 nM thrombin.  These observations suggest that PAR1 and PAR4 account for most, if not all, thrombin signaling in platelets and that antagonists that block these receptors might be useful antithrombotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp--YosyMXoerVg90H21EOLACvtfcHk0ljzFD_i0LigyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFarsro%253D&md5=8156b7cef30813aa382918f94b351d25</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI6042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI6042%26sid%3Dliteratum%253Aachs%26aulast%3DKahn%26aufirst%3DM.%2BL.%26aulast%3DNakanishi-Matsui%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DIshihara%26aufirst%3DH.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DProtease-activated%2520receptors%25201%2520and%25204%2520mediate%2520activation%2520of%2520human%2520platelets%2520by%2520thrombin%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D103%26spage%3D879%26epage%3D887%26doi%3D10.1172%2FJCI6042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Covic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresser, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuliopulos, A.</span></span> <span> </span><span class="NLM_article-title">Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">5458</span>– <span class="NLM_lpage">5467</span>, <span class="refDoi"> DOI: 10.1021/bi9927078</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9927078" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3cXit1yjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=5458-5467&author=L.+Covicauthor=A.+L.+Gresserauthor=A.+Kuliopulos&title=Biphasic+kinetics+of+activation+and+signaling+for+PAR1+and+PAR4+thrombin+receptors+in+platelets&doi=10.1021%2Fbi9927078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Biphasic Kinetics of Activation and Signaling for PAR1 and PAR4 Thrombin Receptors in Platelets</span></div><div class="casAuthors">Covic, Lidija; Gresser, Amy L.; Kuliopulos, Athan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5458-5467</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Thrombin activates platelets in an ordered sequence of events that includes shape change, increase in cytoplasmic Ca2+, activation of the αIIbβ3 integrin, granule secretion, aggregation, and formation of a stable hemostatic plug.  Activation of this process has also been implicated in the pathogenesis of atherosclerosis, stroke, and thrombosis.  There are two identified thrombin-activated receptors on the surface of human platelets. PAR1 is a high-affinity thrombin receptor, and PAR4 is a low apparent affinity thrombin receptor of uncertain function.  The goal of these studies is to det. the kinetics of thrombin activation of PAR1 and PAR4 and to relate the individual inputs from each receptor to platelet Ca2+ signaling, secondary autocrine stimulation, and aggregation.  Using a combination of PAR-specific peptide ligands and anti-PAR1 reagents, we sepd. the biphasic thrombin Ca2+ response of platelets into two discrete components-a rapid spike response caused by PAR1, followed by a slower prolonged response from PAR4.  Despite having a 20-70-fold slower rate of activation, PAR4 produces the majority of the integrated Ca2+ signal that is sustained by the continuous presence of catalytically active thrombin. Surprisingly, PAR4 activation is much more effective than PAR1 activation in mounting secondary autocrine Ca2+ signals from secreted ADP.  The strong ADP response due to activated PAR4, however, requires prior activation of PAR1 as would normally occur during treatment of platelets with thrombin. Thus, the late signal generated by activated PAR4 is not redundant with the early signal from PAR1 and instead serves to greatly extend the high intracellular Ca2+ levels that support the late phase of the platelet aggregation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3W8JjBktbX7Vg90H21EOLACvtfcHk0lhXHofe2JCUXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXit1yjsr0%253D&md5=8c79d7882a3052a9738be0a845aedbf5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fbi9927078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9927078%26sid%3Dliteratum%253Aachs%26aulast%3DCovic%26aufirst%3DL.%26aulast%3DGresser%26aufirst%3DA.%2BL.%26aulast%3DKuliopulos%26aufirst%3DA.%26atitle%3DBiphasic%2520kinetics%2520of%2520activation%2520and%2520signaling%2520for%2520PAR1%2520and%2520PAR4%2520thrombin%2520receptors%2520in%2520platelets%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D5458%26epage%3D5467%26doi%3D10.1021%2Fbi9927078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">9780</span>– <span class="NLM_lpage">9786</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=7683662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK3sXktVGlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=9780-9786&author=K.+Ishiiauthor=L.+Heinauthor=B.+Kobilkaauthor=S.+R.+Coughlin&title=Kinetics+of+thrombin+receptor+cleavage+on+intact+cells.+Relation+to+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling</span></div><div class="casAuthors">Ishii, Kenji; Hein, Lutz; Kobilka, Brian; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9780-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Thrombin, a protease generated at sites of vascular injury, signals cellular responses vital for hemostasis and thrombosis.  How thrombin, an enzyme rather than a classical ligand, effects graded and concn.-dependent responses in its target cells has been a long-standing question.  Thrombin activates its receptor by cleaving off an activation peptide to unmask a tethered peptide ligand.  The authors utilized a thrombin receptor with an epitope-tagged activation peptide to directly demonstrate thrombin receptor cleavage and to examine the kinetics of receptor activation on intact cells.  The rate of thrombin receptor cleavage was proportional to thrombin concn. over the physiol. range, but low thrombin concns. ultimately cleaved and activated all receptors.  Cumulative phosphoinositide hydrolysis in response to thrombin correlated precisely with cumulative receptor cleavage.  These data strongly suggest that each cleaved and activated thrombin receptor produces a quantum of phosphatidylinositol hydrolysis, then shuts off.  Surprisingly, this shut off occurred despite the continued presence of cleaved and activated receptors on the cell surface and at a time when the cells were refractory to thrombin but sensitive to agonist peptide, suggesting that a novel shut off mechanism may have evolved to deal with the tethered ligand.  Unlike the case with classical ligands, cells thus cannot detect differences in thrombin concns. as differences in fractional occupancy but rather must sense different rates of receptor activation.  Because each cleaved thrombin receptor generates a quantum of second messenger, the magnitude of the cell's response to thrombin must be detd. by the balance between rates of receptor activation and second messenger clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSs7Qk7D9ktLVg90H21EOLACvtfcHk0lhXHofe2JCUXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVGlu7c%253D&md5=62f20291c541d308cedac61114511032</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DHein%26aufirst%3DL.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DKinetics%2520of%2520thrombin%2520receptor%2520cleavage%2520on%2520intact%2520cells.%2520Relation%2520to%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D9780%26epage%3D9786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span>; <span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Seiffert, D. A.</span>; <span class="NLM_string-name">Posy, S. L.</span>; <span class="NLM_string-name">Wong, P. C.</span>; <span class="NLM_string-name">Banville, J.</span>; <span class="NLM_string-name">Ruediger, E. H.</span>; <span class="NLM_string-name">Deon, D. H.</span>; <span class="NLM_string-name">Martel, A.</span>; <span class="NLM_string-name">Tremblay, F.</span>; <span class="NLM_string-name">Guy, J.</span>; <span class="NLM_string-name">Lavallee, J.-F.</span>; <span class="NLM_string-name">Gagnon, M.</span></span> <span> </span><span class="NLM_article-title">Imidazothiadiazole Derivatives as Protease Activated Receptor 4 (PAR4) Inhibitors</span>. PCT Int. Appl. <span class="NLM_patent">WO2013/163244</span>, Oct 31, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+M.+Lawrence&author=M.+M.+Miller&author=D.+A.+Seiffert&author=S.+L.+Posy&author=P.+C.+Wong&author=J.+Banville&author=E.+H.+Ruediger&author=D.+H.+Deon&author=A.+Martel&author=F.+Tremblay&author=J.+Guy&author=J.-F.+Lavallee&author=M.+Gagnon&title=Imidazothiadiazole+Derivatives+as+Protease+Activated+Receptor+4+%28PAR4%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26atitle%3DImidazothiadiazole%2520Derivatives%2520as%2520Protease%2520Activated%2520Receptor%25204%2520%2528PAR4%2529%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giancarli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banville, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priestley, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">eaaf5294</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaf5294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1126%2Fscitranslmed.aaf5294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=28053157" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&author=P.+C.+Wongauthor=D.+Seiffertauthor=J.+E.+Birdauthor=C.+A.+Watsonauthor=J.+S.+Bostwickauthor=M.+Giancarliauthor=N.+Allegrettoauthor=J.+Huaauthor=D.+Hardenauthor=J.+Guayauthor=M.+Callejoauthor=M.+M.+Millerauthor=R.+M.+Lawrenceauthor=J.+Banvilleauthor=J.+Guyauthor=B.+D.+Maxwellauthor=E.+S.+Priestleyauthor=A.+Marinierauthor=R.+R.+Wexlerauthor=M.+Bouvierauthor=D.+A.+Gordonauthor=W.+A.+Schumacherauthor=J.+Yang&title=Blockade+of+protease-activated+receptor-4+%28PAR4%29+provides+robust+antithrombotic+activity+with+low+bleeding&doi=10.1126%2Fscitranslmed.aaf5294"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaf5294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaf5294%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DSeiffert%26aufirst%3DD.%26aulast%3DBird%26aufirst%3DJ.%2BE.%26aulast%3DWatson%26aufirst%3DC.%2BA.%26aulast%3DBostwick%26aufirst%3DJ.%2BS.%26aulast%3DGiancarli%26aufirst%3DM.%26aulast%3DAllegretto%26aufirst%3DN.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DHarden%26aufirst%3DD.%26aulast%3DGuay%26aufirst%3DJ.%26aulast%3DCallejo%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%2BM.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DBanville%26aufirst%3DJ.%26aulast%3DGuy%26aufirst%3DJ.%26aulast%3DMaxwell%26aufirst%3DB.%2BD.%26aulast%3DPriestley%26aufirst%3DE.%2BS.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DD.%2BA.%26aulast%3DSchumacher%26aufirst%3DW.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DBlockade%2520of%2520protease-activated%2520receptor-4%2520%2528PAR4%2529%2520provides%2520robust%2520antithrombotic%2520activity%2520with%2520low%2520bleeding%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26doi%3D10.1126%2Fscitranslmed.aaf5294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole analogues as novel antiplatelet agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">3746</span>– <span class="NLM_lpage">3749</span>, <span class="refDoi"> DOI: 10.1021/jm010001h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010001h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntVyntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3746-3749&author=F.+Y.+Leeauthor=J.+C.+Lienauthor=L.+J.+Huangauthor=T.+M.+Huangauthor=S.+C.+Tsaiauthor=C.+M.+Tengauthor=C.+C.+Wuauthor=F.+C.+Chengauthor=S.+C.+Kuo&title=Synthesis+of+1-benzyl-3-%285%E2%80%B2-hydroxymethyl-2%E2%80%B2-furyl%29indazole+analogues+as+novel+antiplatelet+agents&doi=10.1021%2Fjm010001h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole Analogues as Novel Antiplatelet Agents</span></div><div class="casAuthors">Lee, Fang-Yu; Lien, Jin-Cherng; Huang, Li-Jiau; Huang, Tsang-Miao; Tsai, Sheng-Chung; Teng, Che-Ming; Wu, Chin-Chung; Cheng, Fong-Chi; Kuo, Sheng-Chu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3746-3749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1-Benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (YC-1) was selected as the lead compd. for systemic structural modification.  After screening for antiplatelet activity, SARs of YC-1 analogs were established.  Several potent active derivs. functioned as potent activators of sGC and inhibitors of PDE5 with potency comparable to that of YC-1.  In addn., the indazole deriv. (I) was found to be a selective and potent inhibitor of protease-activated receptor type 4 (PAR4)-dependent platelet activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvq6NAuBVgbLVg90H21EOLACvtfcHk0ljHjjaaXwRuxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntVyntLs%253D&md5=33c7e6ad37c20ce72b54e12a9fe4ff04</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm010001h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010001h%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLien%26aufirst%3DJ.%2BC.%26aulast%3DHuang%26aufirst%3DL.%2BJ.%26aulast%3DHuang%26aufirst%3DT.%2BM.%26aulast%3DTsai%26aufirst%3DS.%2BC.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DCheng%26aufirst%3DF.%2BC.%26aulast%3DKuo%26aufirst%3DS.%2BC.%26atitle%3DSynthesis%2520of%25201-benzyl-3-%25285%25E2%2580%25B2-hydroxymethyl-2%25E2%2580%25B2-furyl%2529indazole%2520analogues%2520as%2520novel%2520antiplatelet%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3746%26epage%3D3749%26doi%3D10.1021%2Fjm010001h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3</span>. <i>Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1026</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1055/s-0037-1613128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1055%2Fs-0037-1613128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=12083482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVyrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=1026-1033&author=C.+C.+Wuauthor=T.+L.+Hwangauthor=C.+H.+Liaoauthor=S.+C.+Kuoauthor=F.+Y.+Leeauthor=C.+Y.+Leeauthor=C.+M.+Teng&title=Selective+inhibition+of+protease-activated+receptor+4-dependent+platelet+activation+by+YD-3&doi=10.1055%2Fs-0037-1613128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3</span></div><div class="casAuthors">Wu, Chin-Chung; Hwang, Tsong-Long; Liao, Chang-Hui; Kuo, Sheng-Chu; Lee, Fang-Yu; Lee, Chun-Yann; Teng, Che-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1026-1033</span>CODEN:
                <span class="NLM_cas:coden">THHADQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-6245</span>.
    
            (<span class="NLM_cas:orgname">Schattauer GmbH</span>)
        </div><div class="casAbstract">In the present study, the antiplatelet effect and its mechanism of a new synthetic compd. YD-3 [1-benzyl-3-(ethoxycarbonylphenyl)-indazole] were examd.  YD-3 inhibited the aggregation of washed human platelets caused by protease-activated receptor (PAR) 4 agonist peptide GYPGKF (IC50=0.13±0.02 μM), but had no or little effect on that by thrombin, PAR1 agonist peptide SFLLRN, collagen or U46619.  YD-3 produced a parallel, rightward shift of the concn.-response curve for GYPGKF without decreasing of the max. platelet aggregation, indicating a competitive antagonism.  In contrast to human platelets, both thrombin- and GYPGKF-induced mouse platelet shape change and aggregation were completely inhibited by YD-3.  YD-3 also selectively prevented GYPGKF-induced intracellular Ca2+ mobilization in human platelets.  Furthermore, in the PAR1-desensitized human platelets, thrombin induced a relatively slow rise and decay of calcium mobilization that was significantly inhibited by YD-3.  In addn., the synergistic effect of SFLLRN and GYPGKF on platelet activation was prevented by YD-3.  YD-3 also inhibits both fMLP-stimulated neutrophil- and purified cathepsin G-induced platelet aggregation, which has been demonstrated to be PAR4-dependent.  Taken together, the authors' results suggest that YD-3 selectively inhibits PAR4-dependent platelet activation through blockade of PAR4.  To the best of the authors' knowledge, it is the first non-peptide PAR4 antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6z0pKOY8eOLVg90H21EOLACvtfcHk0ljHjjaaXwRuxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVyrur8%253D&md5=70096eac66d29ca5837d09b8179e39b5</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-0037-1613128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0037-1613128%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DHwang%26aufirst%3DT.%2BL.%26aulast%3DLiao%26aufirst%3DC.%2BH.%26aulast%3DKuo%26aufirst%3DS.%2BC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BY.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DSelective%2520inhibition%2520of%2520protease-activated%2520receptor%25204-dependent%2520platelet%2520activation%2520by%2520YD-3%26jtitle%3DThromb.%2520Haemostasis%26date%3D2002%26volume%3D87%26spage%3D1026%26epage%3D1033%26doi%3D10.1055%2Fs-0037-1613128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1278</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.10.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.bmc.2007.10.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=17988878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvVWhurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=1262-1278&author=H.+S.+Chenauthor=S.+C.+Kuoauthor=C.+M.+Tengauthor=F.+Y.+Leeauthor=J.+P.+Wangauthor=Y.+C.+Leeauthor=C.+W.+Kuoauthor=C.+C.+Huangauthor=C.+C.+Wuauthor=L.+J.+Huang&title=Synthesis+and+antiplatelet+activity+of+ethyl+4-%281-benzyl-1H-indazol-3-yl%29benzoate+%28YD-3%29+derivatives&doi=10.1016%2Fj.bmc.2007.10.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives</span></div><div class="casAuthors">Chen, Hua-Sin; Kuo, Sheng-Chu; Teng, Che-Ming; Lee, Fang-Yu; Wang, Jih-Pyang; Lee, Yu-Chun; Kuo, Chiung-Wen; Huang, Ching-Che; Wu, Chin-Chung; Huang, Li-Jiau</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1262-1278</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Previously, Et 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) was identified by us as the first non-peptide protease-activated receptor 4 (PAR4) antagonist.  To continue on our development of novel anti-PAR4 agents, YD-3 was used as a lead compd. and a series of its derivs. were synthesized and evaluated for their selective anti-PAR4 activity.  Through structure-activity relation (SAR) study, we identified the important functional groups contributing to anti-PAR4 activity, and these functional groups were kept intact during subsequent structural modification.  Several new compds. with anti-PAR4 activity comparable to YD-3 were identified.  Among them, Et 4-[1-(3-chlorobenzyl)-1H-indazol-3-yl]benzoate (33) showed the most potent inhibitory effect on PAR4-mediated platelet aggregation, ATP release, and P-selectin expression.  Et 4-(1-phenyl-1H-indazol-3-yl)benzoate (83) exhibited dual inhibitory effects on PAR4 and thromboxane formation from arachidonic acid.  The above findings can be used as guidelines for development of novel antiplatelet drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR0NyhOUpKLbVg90H21EOLACvtfcHk0ljHjjaaXwRuxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvVWhurc%253D&md5=7007481512b165a350c22e9ff1c81fd2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.10.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.10.070%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%2BS.%26aulast%3DKuo%26aufirst%3DS.%2BC.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DKuo%26aufirst%3DC.%2BW.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DHuang%26aufirst%3DL.%2BJ.%26atitle%3DSynthesis%2520and%2520antiplatelet%2520activity%2520of%2520ethyl%25204-%25281-benzyl-1H-indazol-3-yl%2529benzoate%2520%2528YD-3%2529%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D1262%26epage%3D1278%26doi%3D10.1016%2Fj.bmc.2007.10.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.ejphar.2006.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=16890935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVWqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2006&pages=142-147&author=C.+C.+Wuauthor=C.+M.+Teng&title=Comparison+of+the+effects+of+PAR1+antagonists%2C+PAR4+antagonists%2C+and+their+combinations+on+thrombin-induced+human+platelet+activation&doi=10.1016%2Fj.ejphar.2006.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation</span></div><div class="casAuthors">Wu, Chin-Chung; Teng, Che-Ming</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">142-147</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Thrombin activates human platelets through proteolytic activation of two protease-activated receptors (PARs), PAR1 and PAR4.  In the present study, we show that, RWJ-56110, a potent synthetic PAR1 antagonist, inhibited platelet aggregation caused by a low concn. (0.05 U/mL) of thrombin, but lost its effectiveness when higher concns. of thrombin were used as stimulators.  YD-3, a non-peptide PAR4 antagonist, alone had little or no effect on thrombin-induced platelet aggregation, significantly enhanced the anti-aggregatory activity of PAR1 antagonist.  In addn., we demonstrate for the first time that P-selectin expression in thrombin-stimulated platelets can be synergistically prevented by combined treatment of PAR1 antagonist and PAR4 antagonist.  These results indicate that thrombin-induced platelet activation cannot be effectively inhibited by just blocking either single thrombin receptor pathway, and suggest a rationale for potential combination therapy in arterial thrombosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKcN_YPCaA1LVg90H21EOLACvtfcHk0lhTrkKHdgId8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVWqtb0%253D&md5=838cd5155bbfdfac63ba00593fab5123</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520PAR1%2520antagonists%252C%2520PAR4%2520antagonists%252C%2520and%2520their%2520combinations%2520on%2520thrombin-induced%2520human%2520platelet%2520activation%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D546%26spage%3D142%26epage%3D147%26doi%3D10.1016%2Fj.ejphar.2006.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duvernay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gailani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenecker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, H. E.</span></span> <span> </span><span class="NLM_article-title">Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1124/mol.112.083477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1124%2Fmol.112.083477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=23307185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsVyrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2013&pages=781-792&author=M.+Duvernayauthor=S.+Youngauthor=D.+Gailaniauthor=J.+Schoeneckerauthor=H.+E.+Hamm&title=Protease-activated+receptor+%28PAR%29+1+and+PAR4+differentially+regulate+factor+V+expression+from+human+platelets&doi=10.1124%2Fmol.112.083477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets</span></div><div class="casAuthors">Duvernay, Matthew; Young, Summer; Gailani, David; Schoenecker, Jonathan; Hamm, Heidi E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">781-792</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">With the recent interest of protease-activated receptors (PAR) 1 and PAR4 as possible targets for the treatment of thrombotic disorders, we compared the efficacy of protease-activated receptor (PAR)1 and PAR4 in the generation of procoagulant phenotypes on platelet membranes.  PAR4-activating peptide (AP)-stimulated platelets promoted thrombin generation in blood plasma ≤ 5 min earlier than PAR1-AP-stimulated platelets.  PAR4-AP-mediated factor V (FV) assocn. with the platelet surface was 1.6-fold greater than for PAR1-AP.  Moreover, PAR4 stimulation resulted in a 3-fold greater release of microparticles, compared with PAR1 stimulation.  More robust FV secretion and microparticle generation with PAR4-AP was attributable to stronger and more sustained phosphorylation of myosin light chain at serine 19 and threonine 18.  Inhibition of Rho-kinase reduced PAR4-AP-mediated FV secretion and microparticle generation to PAR1-AP-mediated levels.  Thrombin generation assays measuring prothrombinase complex activity demonstrated 1.5-fold higher peak thrombin levels on PAR4-AP-stimulated platelets, compared with PAR1-AP-stimulated platelets.  Rho-kinase inhibition reduced PAR4-AP-mediated peak thrombin generation by 25% but had no significant effect on PAR1-AP-mediated thrombin generation.  In conclusion, stimulation of PAR4 on platelets leads to faster and more robust thrombin generation, compared with PAR1 stimulation.  The greater procoagulant potential is related to more efficient FV release from intracellular stores and microparticle prodn. driven by stronger and more sustained myosin light chain phosphorylation.  These data have implications about the role of PAR4 during hemostasis and are clin. relevant in light of recent efforts to develop PAR antagonists to treat thrombotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ_MPN_hPiMbVg90H21EOLACvtfcHk0lhTrkKHdgId8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsVyrt74%253D&md5=f761c0b9bd433134454d9d765e3b392f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.083477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.083477%26sid%3Dliteratum%253Aachs%26aulast%3DDuvernay%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DGailani%26aufirst%3DD.%26aulast%3DSchoenecker%26aufirst%3DJ.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26atitle%3DProtease-activated%2520receptor%2520%2528PAR%2529%25201%2520and%2520PAR4%2520differentially%2520regulate%2520factor%2520V%2520expression%2520from%2520human%2520platelets%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D83%26spage%3D781%26epage%3D792%26doi%3D10.1124%2Fmol.112.083477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvernay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nance, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locuson, C. W.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span> <span> </span><span class="NLM_article-title">Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4708</span>– <span class="NLM_lpage">4713</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.bmcl.2014.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=25176330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlymu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4708-4713&author=W.+Wenauthor=S.+E.+Youngauthor=M.+T.+Duvernayauthor=M.+L.+Schulteauthor=K.+D.+Nanceauthor=B.+J.+Melanconauthor=J.+Engersauthor=C.+W.+Locusonauthor=M.+R.+Woodauthor=J.+S.+Danielsauthor=W.+Wuauthor=C.+W.+Lindsleyauthor=H.+E.+Hammauthor=S.+R.+Stauffer&title=Substituted+indoles+as+selective+protease+activated+receptor+4+%28PAR-4%29+antagonists%3A+Discovery+and+SAR+of+ML354&doi=10.1016%2Fj.bmcl.2014.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354</span></div><div class="casAuthors">Wen, Wandong; Young, Summer E.; Duvernay, Matthew T.; Schulte, Michael L.; Nance, Kellie D.; Melancon, Bruce J.; Engers, Julie; Locuson, Charles W.; Wood, Michael R.; Daniels, J. Scott; Wu, Wenjun; Lindsley, Craig W.; Hamm, Heidi E.; Stauffer, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4708-4713</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the authors report the discovery and SAR of an indole-based protease activated receptor-4 (PAR-4) antagonist scaffold derived from a similarity search of the Vanderbilt HTS collection, leading to MLPCN probe ML354 I (VU0099704).  Using a novel PAC-1 fluorescent αIIbβ3 activation assay this probe mol. antagonist was found to have an IC50 of 140 nM for PAR-4 with 71-fold selectivity vs. PAR-1 (IC50 = 10 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC3tSlcXaqorVg90H21EOLACvtfcHk0lhTrkKHdgId8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlymu7%252FM&md5=807c84160b474e255aa771989b24a73c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DS.%2BE.%26aulast%3DDuvernay%26aufirst%3DM.%2BT.%26aulast%3DSchulte%26aufirst%3DM.%2BL.%26aulast%3DNance%26aufirst%3DK.%2BD.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DEngers%26aufirst%3DJ.%26aulast%3DLocuson%26aufirst%3DC.%2BW.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26atitle%3DSubstituted%2520indoles%2520as%2520selective%2520protease%2520activated%2520receptor%25204%2520%2528PAR-4%2529%2520antagonists%253A%2520Discovery%2520and%2520SAR%2520of%2520ML354%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4708%26epage%3D4713%26doi%3D10.1016%2Fj.bmcl.2014.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temple, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvernay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blobaum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Development of a series of (1-benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanol as selective protease activated receptor 4 (PAR4) antagonists with in vivo utility and activity against γ-thrombin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7690</span>– <span class="NLM_lpage">7695</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00928</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00928" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KktLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7690-7695&author=K.+J.+Templeauthor=M.+T.+Duvernayauthor=S.+E.+Youngauthor=W.+Wenauthor=W.+Wuauthor=J.+G.+Maengauthor=A.+L.+Blobaumauthor=S.+R.+Staufferauthor=H.+E.+Hammauthor=C.+W.+Lindsley&title=Development+of+a+series+of+%281-benzyl-3-%286-methoxypyrimidin-3-yl%29-5-%28trifluoromethoxy%29-1H-indol-2-yl%29methanol+as+selective+protease+activated+receptor+4+%28PAR4%29+antagonists+with+in+vivo+utility+and+activity+against+%CE%B3-thrombin&doi=10.1021%2Facs.jmedchem.6b00928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin</span></div><div class="casAuthors">Temple, Kayla J.; Duvernay, Matthew T.; Young, Summer E.; Wen, Wandong; Wu, Wenjun; Maeng, Jae G.; Blobaum, Anna L.; Stauffer, Shaun R.; Hamm, Heidi E.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7690-7695</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we describe the development of a series of highly selective PAR4 antagonists with nanomolar potency and selectivity vs. PAR1, derived from the indole-based 3.  Of these, 9j (PAR4 IC50 = 445 nM, PAR1 response IC50 > 30 μM) and 10h (PAR4 IC50 = 179 nM, PAR1 response IC50 > 30 μM) maintained an overall favorable in vitro DMPK profile, encouraging rat/mouse in vivo pharmacokinetics (PK) and activity against γ-thrombin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfEoZDK2gsHbVg90H21EOLACvtfcHk0ljEx6ZVzzMyJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KktLrL&md5=ac0ecd5f66a8fb15c3c54a3099897856</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00928%26sid%3Dliteratum%253Aachs%26aulast%3DTemple%26aufirst%3DK.%2BJ.%26aulast%3DDuvernay%26aufirst%3DM.%2BT.%26aulast%3DYoung%26aufirst%3DS.%2BE.%26aulast%3DWen%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DMaeng%26aufirst%3DJ.%2BG.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DDevelopment%2520of%2520a%2520series%2520of%2520%25281-benzyl-3-%25286-methoxypyrimidin-3-yl%2529-5-%2528trifluoromethoxy%2529-1H-indol-2-yl%2529methanol%2520as%2520selective%2520protease%2520activated%2520receptor%25204%2520%2528PAR4%2529%2520antagonists%2520with%2520in%2520vivo%2520utility%2520and%2520activity%2520against%2520%25CE%25B3-thrombin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7690%26epage%3D7695%26doi%3D10.1021%2Facs.jmedchem.6b00928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temple, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvernay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blobaum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5481</span>– <span class="NLM_lpage">5486</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.bmcl.2016.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=27777004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGitrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5481-5486&author=K.+J.+Templeauthor=M.+T.+Duvernayauthor=J.+G.+Maengauthor=A.+L.+Blobaumauthor=S.+R.+Staufferauthor=H.+E.+Hammauthor=C.+W.+Lindsley&title=Identification+of+the+minimum+PAR4+inhibitor+pharmacophore+and+optimization+of+a+series+of+2-methoxy-6-arylimidazo%5B2%2C1-b%5D%5B1%2C3%2C4%5Dthiadiazoles&doi=10.1016%2Fj.bmcl.2016.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles</span></div><div class="casAuthors">Temple, Kayla J.; Duvernay, Matthew T.; Maeng, Jae G.; Blobaum, Anna L.; Stauffer, Shaun R.; Hamm, Heidi E.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5481-5486</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This letter describes the further deconstruction of the known PAR4 inhibitor chemotypes (MWs 490-525 and with high plasma protein binding) to identify a min. PAR4 pharmacophore devoid of metabolic liabilities and improved properties.  This exercise identified a greatly simplified 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazole scaffold that afforded nanomolar inhibition of both activating peptide and γ-thrombin mediated PAR4 stimulation, while reducing both mol. wt. and the no. of hydrogen bond donors/acceptors by ∼50%.  This min. PAR4 pharmacophore, with competitive inhibition, vs. noncompetitive of the larger chemotypes, allows an ideal starting point to incorporate desired functional groups to engender optimal DMPK properties towards a preclin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-20ZEdJW3Z7Vg90H21EOLACvtfcHk0ljEx6ZVzzMyJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGitrbO&md5=4e7987f4e906c1db0c912e7b157f181a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DTemple%26aufirst%3DK.%2BJ.%26aulast%3DDuvernay%26aufirst%3DM.%2BT.%26aulast%3DMaeng%26aufirst%3DJ.%2BG.%26aulast%3DBlobaum%26aufirst%3DA.%2BL.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DHamm%26aufirst%3DH.%2BE.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DIdentification%2520of%2520the%2520minimum%2520PAR4%2520inhibitor%2520pharmacophore%2520and%2520optimization%2520of%2520a%2520series%2520of%25202-methoxy-6-arylimidazo%255B2%252C1-b%255D%255B1%252C3%252C4%255Dthiadiazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5481%26epage%3D5486%26doi%3D10.1016%2Fj.bmcl.2016.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stables, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattheakis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, S.</span></span> <span> </span><span class="NLM_article-title">Recombinant aequorin as reporter of changes in intracellular calcium in mammalian cells</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1016/s0076-6879(00)27296-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fs0076-6879%2800%2927296-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=11045003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosFSjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2000&pages=456-471&author=J.+Stablesauthor=L.+C.+Mattheakisauthor=R.+Changauthor=S.+Rees&title=Recombinant+aequorin+as+reporter+of+changes+in+intracellular+calcium+in+mammalian+cells&doi=10.1016%2Fs0076-6879%2800%2927296-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Recombinant aequorin as reporter of changes in intracellular calcium in mammalian cells</span></div><div class="casAuthors">Stables, Jenny; Mattheakis, Larry C.; Chang, Ray; Rees, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">Applications of Chimeric Genes and Hybrid Proteins, Pt. B</span>),
    <span class="NLM_cas:pages">456-471</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The use of recombinant aequorin to detect changes in intracellular calcium concn. in mammalian cells after agonist activation of Gαq/11-coupled G protein-coupled receptors and after calcium entry through P2X family ion channels, is described.  In contrast to the use of single-tube luminometer for the detection of aequorin luminescence, the detection of aequorin luminescence in a 96-well microplate format, using either and injector luminometer or the fluorescence imaging plate reader, is described.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr7EZrdK0ScbVg90H21EOLACvtfcHk0ljEx6ZVzzMyJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosFSjurs%253D&md5=198c54c9e5a1e9d4cfa089c9cec8c22b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fs0076-6879%2800%2927296-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0076-6879%252800%252927296-0%26sid%3Dliteratum%253Aachs%26aulast%3DStables%26aufirst%3DJ.%26aulast%3DMattheakis%26aufirst%3DL.%2BC.%26aulast%3DChang%26aufirst%3DR.%26aulast%3DRees%26aufirst%3DS.%26atitle%3DRecombinant%2520aequorin%2520as%2520reporter%2520of%2520changes%2520in%2520intracellular%2520calcium%2520in%2520mammalian%2520cells%26jtitle%3DMethods%2520Enzymol.%26date%3D2000%26volume%3D327%26spage%3D456%26epage%3D471%26doi%3D10.1016%2Fs0076-6879%2800%2927296-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soslau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Class, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jameson, B.</span></span> <span> </span><span class="NLM_article-title">Differential activation and inhibition of human platelet thrombin receptors by structurally distinct alpha-, beta- and gamma-thrombin</span>. <i>Platelets</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1080/0953710042000199848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1080%2F0953710042000199848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=15203717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvFaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=155-166&author=G.+Soslauauthor=S.+J.+Goldenbergauthor=R.+Classauthor=B.+Jameson&title=Differential+activation+and+inhibition+of+human+platelet+thrombin+receptors+by+structurally+distinct+alpha-%2C+beta-+and+gamma-thrombin&doi=10.1080%2F0953710042000199848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Differential activation and inhibition of human platelet thrombin receptors by structurally distinct α-, β- and γ-thrombin</span></div><div class="casAuthors">Soslau, Gerald; Goldenberg, Seth J.; Class, Reiner; Jameson, Bradford</div><div class="citationInfo"><span class="NLM_cas:title">Platelets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-166</span>CODEN:
                <span class="NLM_cas:coden">PLTEEF</span>;
        ISSN:<span class="NLM_cas:issn">0953-7104</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The development of drugs to neutralize the action of thrombin has to date focused on the α form of the protease.  It is generally agreed that inactive prothrombin is proteolytically converted to active α-thrombin which may be further hydrolyzed to β- and γ-thrombin.  While all three forms of the enzyme retain catalytic activities, only α-thrombin is presumed to be physiol. important.  The β- and γ-thrombin are presumed to be degrdn. products of no physiol. significance.  Our demonstration that β- and γ-thrombin selectively activate PAR-4 in this and a previous report (J. Biol. Chem. 276, 21173-21183, 2001) necessitates a reevaluation of how we view their physiol. roles and how we approach the pharmacol. regulation of their actions. β-Thrombin, like γ-thrombin, at nM levels selectively activates PAR-4.  This was demonstrated by full retention of aggregation activity with platelets whose PAR-1 and GP Ib receptors were inactivated.  Furthermore, the β-thrombin response was abrogated by desensitizing platelets with suboptimal levels of the thrombin receptor activating peptide for PAR-4 (TRAP-4).  For β-thrombin and γ-thrombin to have a physiol. role, it is necessary to show they can be generated under physiol. conditions.  We demonstrate, for the first time, that α-thrombin is hydrolyzed in less than 1 min by activated factor X at physiol. pH, in vitro.  This implies that α-thrombin may be rapidly converted to β-thrombin and/or γ-thrombin in vivo in the proper microenvironment.  The differential activation of the three platelet thrombin receptors by α-, β- and γ-thrombin implies selective structural variations between these thrombin species.  Structural differences are likely to account for the marked differential responses obsd. with the antithrombotic, hirudin, which inhibits α-thrombin, is a slightly weaker inhibitor of β- thrombin and a very weak inhibitor of γ-thrombin-induced platelet aggregations.  The converse order of inhibition is obsd. with the physiol. protease inhibitor, α1-antitrypsin.  Finally, a non-traditional inhibitor, histone-1, selectively inhibits only β- and γ-thrombin, primarily at the receptor level of PAR-4 rather than on the thrombin mol.  Trypsin, like β- and γ-thrombin, activates PAR-4 and is also inactive with TRAP-4 desensitized platelets.  Therefore, it was reasoned that trypsin would be more structurally similar to γ-thrombin than to α-thrombin.  The anal. of the cryst. structures of α-, γ-thrombin and trypsin from the databases confirm that this is the case. These findings should help to elucidate structure-function relationships of the different thrombins and may aid in the development of new anti-thrombotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxpHY2K-jlmrVg90H21EOLACvtfcHk0lgwngm4eLmlVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvFaqtb8%253D&md5=ecedd7128fccfadab6144131ac5bf651</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F0953710042000199848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F0953710042000199848%26sid%3Dliteratum%253Aachs%26aulast%3DSoslau%26aufirst%3DG.%26aulast%3DGoldenberg%26aufirst%3DS.%2BJ.%26aulast%3DClass%26aufirst%3DR.%26aulast%3DJameson%26aufirst%3DB.%26atitle%3DDifferential%2520activation%2520and%2520inhibition%2520of%2520human%2520platelet%2520thrombin%2520receptors%2520by%2520structurally%2520distinct%2520alpha-%252C%2520beta-%2520and%2520gamma-thrombin%26jtitle%3DPlatelets%26date%3D2004%26volume%3D15%26spage%3D155%26epage%3D166%26doi%3D10.1080%2F0953710042000199848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamisuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizushina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanashima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuramochi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, F.</span></span> <span> </span><span class="NLM_article-title">Total synthesis of dehydroaltenusin</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5695</span>– <span class="NLM_lpage">5700</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2004.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1016%2Fj.tet.2004.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksl2ltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=5695-5700&author=S.+Kamisukiauthor=S.+Takahashiauthor=Y.+Mizushinaauthor=S.+Hanashimaauthor=K.+Kuramochiauthor=S.+Kobayashiauthor=K.+Sakaguchiauthor=T.+Nakataauthor=F.+Sugawara&title=Total+synthesis+of+dehydroaltenusin&doi=10.1016%2Fj.tet.2004.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of dehydroaltenusin</span></div><div class="casAuthors">Kamisuki, Shinji; Takahashi, Shunya; Mizushina, Yoshiyuki; Hanashima, Shinya; Kuramochi, Kouji; Kobayashi, Susumu; Sakaguchi, Kengo; Nakata, Tadashi; Sugawara, Fumio</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">5695-5700</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The first total synthesis of dehydroaltenusin (I), a natural enzyme inhibitor, is described.  The key step involves Suzuki-coupling reaction of an aryl triflate prepd. from 2,4,6-trihydroxybenzoic acid with a catechol-derived boronic acid or boronic ester.  The synthetic product was evaluated as a potent inhibitor against eukaryotic DNA polymerase α and other DNA polymerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjzEm062ZePbVg90H21EOLACvtfcHk0lgwngm4eLmlVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksl2ltrk%253D&md5=8a3f4a9bc6da6c45db263eab6a799c53</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2004.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2004.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DKamisuki%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DMizushina%26aufirst%3DY.%26aulast%3DHanashima%26aufirst%3DS.%26aulast%3DKuramochi%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DSakaguchi%26aufirst%3DK.%26aulast%3DNakata%26aufirst%3DT.%26aulast%3DSugawara%26aufirst%3DF.%26atitle%3DTotal%2520synthesis%2520of%2520dehydroaltenusin%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26spage%3D5695%26epage%3D5700%26doi%3D10.1016%2Fj.tet.2004.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokuyama, H.</span></span> <span> </span><span class="NLM_article-title">Mild debenzylation of aryl benzyl ether with BCl<sub>3</sub> in the presence of pentamethylbenzene as a non-Lewis-basic cation scavenger</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_fpage">1977</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1077980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1055%2Fs-2008-1077980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvVOltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=1977-1980&author=K.+Okanoauthor=K.-i.+Okuyamaauthor=T.+Fukuyamaauthor=H.+Tokuyama&title=Mild+debenzylation+of+aryl+benzyl+ether+with+BCl3+in+the+presence+of+pentamethylbenzene+as+a+non-Lewis-basic+cation+scavenger&doi=10.1055%2Fs-2008-1077980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mild debenzylation of aryl benzyl ether with BCl3 in the presence of pentamethylbenzene as a non-Lewis-basic cation scavenger</span></div><div class="casAuthors">Okano, Kentaro; Okuyama, Kei-ichiro; Fukuyama, Tohru; Tokuyama, Hidetoshi</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1977-1980</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Scope and limitations of the debenzylation conditions for aryl benzyl ether, which was developed during our synthetic studies on yatakemycin, were investigated.  The chemoselective debenzylation proceeds at low temp. with a combination of BCl3 and pentamethylbenzene as a cation scavenger in the presence of various functional groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_5T9R_PvPQLVg90H21EOLACvtfcHk0lgwngm4eLmlVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvVOltbk%253D&md5=18474e18d054ddd5d8c9a8b4b79a8703</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1077980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1077980%26sid%3Dliteratum%253Aachs%26aulast%3DOkano%26aufirst%3DK.%26aulast%3DOkuyama%26aufirst%3DK.-i.%26aulast%3DFukuyama%26aufirst%3DT.%26aulast%3DTokuyama%26aufirst%3DH.%26atitle%3DMild%2520debenzylation%2520of%2520aryl%2520benzyl%2520ether%2520with%2520BCl3%2520in%2520the%2520presence%2520of%2520pentamethylbenzene%2520as%2520a%2520non-Lewis-basic%2520cation%2520scavenger%26jtitle%3DSynlett%26date%3D2008%26spage%3D1977%26epage%3D1980%26doi%3D10.1055%2Fs-2008-1077980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crain, E. J.</span></span> <span> </span><span class="NLM_article-title">The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1007/s11239-015-1302-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1007%2Fs11239-015-1302-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=26660522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKjtr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=514-521&author=P.+C.+Wongauthor=C.+Watsonauthor=E.+J.+Crain&title=The+P2Y1+receptor+antagonist+MRS2500+prevents+carotid+artery+thrombosis+in+cynomolgus+monkeys&doi=10.1007%2Fs11239-015-1302-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys</span></div><div class="casAuthors">Wong, Pancras C.; Watson, Carol; Crain, Earl J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-521</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">ADP directly induces platelet aggregation via the G-protein coupled P2Y1 and P2Y12 receptors.  P2Y12, but not P2Y1, receptor antagonists are available in the clinic.  The relevance of the P2Y1 receptor as an antiplatelet target has been studied in rodents, but not in higher species.  We therefore examd. effects of the pharmacol. blockade of the P2Y1 receptor with its selective antagonist MRS2500 in monkey models of electrolytic-mediated arterial thrombosis (ECAT) and kidney bleeding time (KBT).  Abciximab, a GPIIb-IIIa antagonist, and cangrelor, a P2Y12 antagonist, were utilized to validate these monkey models.  Compds. were given IV at 15-60 min before thrombosis initiation in anesthetized monkeys.  SEM showed the luminal surface of thrombotic artery covered with platelet aggregates and fibrin network.  Administration of abciximab at 0.25 and 0.7 mg/kg IV significantly reduced thrombus wt. by 71 ± 1 and 100 ± 0 %, and increased KBT by 10.0 ± 0.1- and 10.1 ± 0-fold, resp. (n = 3/dose).  Likewise, cangrelor at 0.6 and 2 mg/kg/h IV significantly reduced thrombus wt. significantly by 72 ± 9 % and 100 ± 0 % and increased KBT by 2.1 ± 0.1- and 9.8 ± 0.2-fold, resp. (n = 3/dose).  MRS2500 [mg/kg + mg/kg/h IV] at 0.09 + 0.14 and 0.45 + 0.68 significantly reduced thrombus wt. by 57 ± 1 % and 88 ± 1 % and increased KBT by 2.1 ± 0.3- and 4.9 ± 0.6-fold, resp. (n = 4/dose).  In summary, MRS2500 prevented occlusive arterial thrombosis at a dose that moderately prolonged KBT, indicating a role of P2Y1 receptors in arterial thrombosis and hemostasis in monkeys.  Thus P2Y1 receptor antagonism provides a suitable target for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVE4lLaam5ebVg90H21EOLACvtfcHk0lgbINPKoDZeLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKjtr7F&md5=9d498e412a43b8e2e3f20745ca6052bd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs11239-015-1302-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-015-1302-7%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DCrain%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520P2Y1%2520receptor%2520antagonist%2520MRS2500%2520prevents%2520carotid%2520artery%2520thrombosis%2520in%2520cynomolgus%2520monkeys%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2016%26volume%3D41%26spage%3D514%26epage%3D521%26doi%3D10.1007%2Fs11239-015-1302-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilchrist, M. A.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, D. G.</span></span> <span> </span><span class="NLM_article-title">Characterization of the 5-HT2b receptor in evaluation of aequorin detection of calcium mobilization for miniaturized GPCR high-throughput screening</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1177/1087057108319212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1177%2F1087057108319212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=18566482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1eitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=486-493&author=M.+A.+Gilchristauthor=A.+Cacaceauthor=D.+G.+Harden&title=Characterization+of+the+5-HT2b+receptor+in+evaluation+of+aequorin+detection+of+calcium+mobilization+for+miniaturized+GPCR+high-throughput+screening&doi=10.1177%2F1087057108319212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the 5-HT2b receptor in evaluation of aequorin detection of calcium mobilization for miniaturized GPCR high-throughput screening</span></div><div class="casAuthors">Gilchrist, Mark A., II; Cacace, Angela; Harden, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">486-493</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Fluorescent detection of calcium mobilization has been used successfully to identify modulators of G-protein-coupled receptors (GPCRs); however, inherent issues with fluorescence may limit its potential for high-throughput screening miniaturization.  The data presented here demonstrate that the calcium-sensitive photoprotein aequorin (AequoScreen), when compared with FLUO-4 in the same cellular background, allows for miniaturization of functional kinetic calcium flux assays, in which the rank order of potency and efficacy was maintained for a series of diverse small-mol. modulators.  Small-vol. (<10 μL) 384- and 1536-well aequorin assays were implemented by integration of acoustic dispensing (Echo 550) and kinetic flash luminometry (CyBi Lumax).  The enhanced high signal-to-background ratios obsd. relative to fluorescence were readily manipulated by altering per-well cell densities and yielded acceptable screening statistics in miniaturized format for both agonist and antagonist screening scenarios.  In addn., the authors demonstrate the feasibility of using agonist concns. less than EC50 in a miniaturized antagonist assay.  These features, coupled with improved sample handling, should enhance sensitivity and provide the benefits of miniaturization including cost redn. and throughput gains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHrqWdxyoUGLVg90H21EOLACvtfcHk0lgbINPKoDZeLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1eitbY%253D&md5=9d691f835b35b74e06ec14b671671d12</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1177%2F1087057108319212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057108319212%26sid%3Dliteratum%253Aachs%26aulast%3DGilchrist%26aufirst%3DM.%2BA.%26aulast%3DCacace%26aufirst%3DA.%26aulast%3DHarden%26aufirst%3DD.%2BG.%26atitle%3DCharacterization%2520of%2520the%25205-HT2b%2520receptor%2520in%2520evaluation%2520of%2520aequorin%2520detection%2520of%2520calcium%2520mobilization%2520for%2520miniaturized%2520GPCR%2520high-throughput%2520screening%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2008%26volume%3D13%26spage%3D486%26epage%3D493%26doi%3D10.1177%2F1087057108319212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seiler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsueda, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernatowicz, M. S.</span></span> <span> </span><span class="NLM_article-title">Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=8569706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK28Xns1WntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1996&pages=190-197&author=S.+M.+Seilerauthor=M.+Pelusoauthor=J.+G.+Tuttleauthor=K.+Pryorauthor=C.+Klimasauthor=G.+R.+Matsuedaauthor=M.+S.+Bernatowicz&title=Thrombin+receptor+activation+by+thrombin+and+receptor-derived+peptides+in+platelet+and+CHRF-288+cell+membranes%3A+receptor-stimulated+GTPase+and+evaluation+of+agonists+and+partial+agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists</span></div><div class="casAuthors">Seiler, Steven M.; Peluso, Marianne; Tuttle, Jeffrey G.; Pryor, Kelly; Klimas, Clifford; Matsueda, Gary R.; Bernatowicz, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">190-7</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Thrombin receptor activation, by thrombin or SFLLR-contg. peptides, stimulates GTPase activity in platelet and CHRF-288 membranes.  Polyclonal antibodies to peptides derived from the thrombin receptor (anti-TR52-69 and anti-TR36-49), which block many of thrombin's actions on platelets and endothelial cells, also block thrombin activation of membrane GTPase (as does thrombin active site and anion-binding exosite inhibitors).  Most of the receptor-activated GTPase, stimulated by both thrombin and SFLLRNP in platelet membranes, was inhibited by prior treatment with pertussis toxin or N-ethylmaleimide, suggesting that under these conditions much of the thrombin receptor-stimulated GTPase in platelet membranes is a member of the pertussis toxin-sensitive Gαi family.  In platelet membrane prepns., the peptide agonists stimulated approx. twice as much GTPase activity as did α-thrombin.  Stimulation of the platelet membrane GTPase by a variety of different peptide agonists correlated with their ability to stimulate platelet aggregation.  Several peptide-based agonists were more potent than the wild-type sequence.  The most potent was Ser-(p-fluoro-Phe)-(2-naphthyl-Ala)-Leu-Arg-NH2, which stimulated platelet aggregation (EC50 = 80 nM) and GTPase activity (EC50 = 110 nM).  The peptide YFLLRN stimulated GTPase activity but only to ∼40% of the activity obsd. with optimal concns. of other receptor agonists.  YFLLRN also limited the stimulation obsd. with SFLLRNP in a competitive fashion, indicating that YFLLRN is a competitive partial agonist at the thrombin receptor.  These studies show that the tethered-ligand receptor mediates the GTPase activation by thrombin in platelet and CHRF-288 cell membranes, and this provides a specific, reliable, and convenient cell-free assay system with which one can evaluate agonists and partial agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUbezt8DejTrVg90H21EOLACvtfcHk0lgbINPKoDZeLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xns1WntQ%253D%253D&md5=08d431584ffe35488b05b93910df14c0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26aulast%3DPeluso%26aufirst%3DM.%26aulast%3DTuttle%26aufirst%3DJ.%2BG.%26aulast%3DPryor%26aufirst%3DK.%26aulast%3DKlimas%26aufirst%3DC.%26aulast%3DMatsueda%26aufirst%3DG.%2BR.%26aulast%3DBernatowicz%26aufirst%3DM.%2BS.%26atitle%3DThrombin%2520receptor%2520activation%2520by%2520thrombin%2520and%2520receptor-derived%2520peptides%2520in%2520platelet%2520and%2520CHRF-288%2520cell%2520membranes%253A%2520receptor-stimulated%2520GTPase%2520and%2520evaluation%2520of%2520agonists%2520and%2520partial%2520agonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D49%26spage%3D190%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riexinger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiler, S. M.</span></span> <span> </span><span class="NLM_article-title">‘Tethered ligand’ derived pentapeptide agonists of thrombin receptor: a study of side chain requirements for human platelet activation and GTPase stimulation</span>. <i>Int. J. Pept. Protein Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.1995.tb01033.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=10.1111%2Fj.1399-3011.1995.tb01033.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=7782162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;key=1%3ACAS%3A528%3ADyaK2MXktV2murk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1995&pages=145-151&author=S.+Natarajanauthor=D.+Riexingerauthor=M.+Pelusoauthor=S.+M.+Seiler&title=%E2%80%98Tethered+ligand%E2%80%99+derived+pentapeptide+agonists+of+thrombin+receptor%3A+a+study+of+side+chain+requirements+for+human+platelet+activation+and+GTPase+stimulation&doi=10.1111%2Fj.1399-3011.1995.tb01033.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">'Tethered ligand' derived pentapeptide agonists of thrombin receptor: a study of side chain requirements for human platelet activation and GTPase stimulation</span></div><div class="casAuthors">Natarajan, Sesha; Riexinger, Douglas; Peluso, Marianne; Seiler, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-51</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">Proteolytic action of α-thrombin on human thrombin receptor results in cleavage of a portion of the N-terminus, thereby generating a 'tethered ligand' at the newly exposed N-terminus, which then activates the receptor in an intramol. fashion.  Agonist peptides incorporating the amino acid sequence of the newly exposed N-terminal portion of the cleaved receptor cause receptor activation without requiring prior cleavage of the receptor by thrombin.  The pentapeptide amide Ser-Phe-Leu-Leu-Arg-NH2, which retains the N-terminal sequence of the 'tethered ligand' of the receptor, has been shown to be the min. sequence to cause receptor activation.  To understand the importance of the side chains of various residues within the pentapeptide amide, we carried out an extensive structure-activity study of the ability of peptides to stimulate gel-filtered platelet aggregation.  In this study 106 pentapeptide amides were synthesized, utilizing naturally occurring L-amino acids, unnatural amino acids, D-amino acids and N-Me amino acids for replacements.  At position-1, charged residues (acidic or basic) were not tolerated, and the size and shape of the residue were important.  Position-2 tolerated only arom. residues.  Position-3 accommodated various residues.  A significant finding of this study was that two very different residues, [3-(2-naphthyl)]-L-alanine and L-arginine, when substituted for leucine residue at position-3, resulted in more active agonists.  At position-4 arom. and aliph. residues were well tolerated, whereas basic and acidic residues were less tolerated.  Position-5 mimicked position-3 in its ability to tolerate a wide range of residues.  In general, an acidic residue was not preferred in any position.  In all positions a -Phe-residue was tolerated.  Positions 1 and 3 tolerated -Pro-residue, whereas positions 2, 4 and 5 did not.  D-Amino acid substitution was not tolerated in any position.  While N-methylation of residues at positions-3 and -4 led to poor agonists, at position-2 it resulted in an inactive analog.  These studies define the side chain requirements for the 'tethered ligand' derived pentapeptide agonists of thrombin receptor for human platelet activation.  Selected peptides were tested for ability to stimulate platelet membrane GTPase.  A good correlation was obsd. between peptides that stimulate GTPase and those that stimulate platelet aggregation, with the general finding that 3-10-fold higher concns. were required to half maximally activate GTPase when compared with the concns. needed for activation of platelet aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMgB7y3ZNdDLVg90H21EOLACvtfcHk0liGBYwpV2vopQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktV2murk%253D&md5=a07b93e433213e32d7837490f4fb210e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1995.tb01033.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1995.tb01033.x%26sid%3Dliteratum%253Aachs%26aulast%3DNatarajan%26aufirst%3DS.%26aulast%3DRiexinger%26aufirst%3DD.%26aulast%3DPeluso%26aufirst%3DM.%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26atitle%3D%25E2%2580%2598Tethered%2520ligand%25E2%2580%2599%2520derived%2520pentapeptide%2520agonists%2520of%2520thrombin%2520receptor%253A%2520a%2520study%2520of%2520side%2520chain%2520requirements%2520for%2520human%2520platelet%2520activation%2520and%2520GTPase%2520stimulation%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1995%26volume%3D45%26spage%3D145%26epage%3D151%26doi%3D10.1111%2Fj.1399-3011.1995.tb01033.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i114"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00186">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_34424"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00186">10.1021/acs.jmedchem.9b00186</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Proton and carbon NMR spectra for compound <b>54</b>; single-crystal X-ray data for compound <b>4</b>; biotransformation studies of compounds <b>4</b> and <b>15</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_001.pdf">jm9b00186_si_001.pdf (406.07 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00186/suppl_file/jm9b00186_si_002.csv">jm9b00186_si_002.csv (3.39 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00186&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00186%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-16%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00186" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993f40fe71d1a7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
